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Abstract
In vitro modelling of cellular processes in OM- BMDM studies in Junbo 
mice reveal defects in HIF and TGF-p signalling
Sulzhan Bali 
PhD
The Open University, 2011 
Chronic otitis media (OM) is a common cause of deafness in children. Two 
novel murine models of chronic OM, Junbo and Jeff, generated by chemical 
mutagenesis with ethyl nitrosurea (ENU), have been developed at MRC 
Harwell. Junbo heterozygote mice (Jbo/+) mice have a mutation in 
transcription factor Evi-1 and Jeff heterozygote mice (Jf/+) mice have a 
mutation in gene for Fbxo protein Fbxoll. Pathologic hypoxia has been 
characterized as a common feature of the inflamed middle ear in both 
models. HIF-VEGF pathways dysregulation has been indicated in both 
models previously. However, the mechanisms involved in pathogenesis of 
OM in these two models are yet to be elucidated.
In this thesis I have described an in-vitro model system to study cellular 
processes in OM to study and identify pathways involved in OM 
pathogenesis. This model system involves culturing BMDM and exposing 
them to various treatments under standard defined conditions.
Results from this thesis reveal that Evi-1 is expressed at comparable levels 
in both WT and Jbo/+ genotypes and that Evi-1 A22^ T mutation is a loss of 
function mutation which results in dysregulated expression of Smad 
responsive and hypoxia responsive genes such as Vegf and Glut-1 under 
prolonged hypoxic conditions. Although Jbo/+ BMDM are hyper- 
responsive to LPS in normoxia, as was indicated by higher Vegf and 11-6
levels, macrophage phagocytic function is potentially attenuated in Jbo/+ 
under hypoxic conditions as was indicated by lower levels of Tnf-a and II- 
ip  in Jbo/+ BMDM in LPS and hypoxia combination treatment. A 
perturbed resolution of 11-6 and Il-lfi in hypoxia was also observed.
Studies performed in this thesis revealed dysregulation in TGF-p pathway in 
both Jbo/+ and Jf/+ BMDM in normoxia which suggests a common role of 
TGF-P signalling in OM pathogenesis. Differential expression of cytokines 
was observed in Jbo/+ BMDM after prolonged treatment with TGF-p and 
hypoxia indicating a pro-angiogenic and pro-inflammatory phenotype. 
Levels of pro-inflammatory cytokines such as II-ip, C5a, 11-17, 11-23, and 
Ccl5 were higher in Jbo/+ BMDM and levels of anti-inflammatory 
cytokines such as II-Ira, 11-10, and 11-4 were lower in Jbo/+ BMDM after 
prolonged hypoxia and TGF-p treatment which further validates the role of 
dysregulated HIF and TGF-p signalling pathways in OM in Jbo/+ mice. The 
differential cytokine expression observed in Jbo/+ BMDM is favourable for 
Thl7 cell differentiation and may indicate a role of cross-talk of innate 
immunity and cell mediated immunity in OM chronicity in hypoxia.
To conclude, HIF signalling and TGF-p signalling in Jbo/+ BMDM is 
dysregulated. Pro-angiogenic function, impaired resolution of inflammation 
and predisposition to Thl7 cell differentiation by Jbo/+ BMDM under 
hypoxia contribute to the prolonged and chronic inflammation in Jbo/+ mice 
and may provide some evidence of pathways that could be affected in OM 
patients.
Keywords- HIF- hypoxia inducible factor; TGF-P- Transforming growth factor P; BMDM- 
Bone marrow derived macrophages, OM (Otitis media), mouse models, hypoxia, 
inflammation.
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2. Introduction
Normal ear anatomy and Otitis media (OM)
Irwin describes the human ear as a “complex series of interlinked 
structures” involved in hearing (Irwin, 2006). These structures are broadly 
divided into external ear, middle ear and inner ear. Sound waves are 
collected by the external ear and pass onto a thin, oval, semi-transparent 
membrane known as the tympanic membrane. The tympanic membrane is 
attached to a chain of three small movable bones (ossicles) that transmit 
sound vibrations to the inner ear (Antonelli, 2004). These three ossicles 
(malleus, incus and stapes), along with the openings of both the Eustachian 
tube (ET) and the Mastoid air cell, are present in the tympanic cavity that 
constitutes the middle ear (Gray, 1918). The tympanic membrane forms the 
outer border of the middle ear, which is connected to the pharynx and the 
back of the nose via the ET and the mastoid antrum via the aditus (Gray, 
1918; Irwin, 2006). Also present in the middle ear are two tiny muscles -  
the Stapedius and Tensor tympani, which protect the ears from noise trauma 
by contracting in response to loud noises (Gray, 1918; Irwin, 2006). The 
tympanic cavity is defined in Gray’s anatomy of the human body as “an 
irregular lateral compressed air-filled space within the temporal bone”. It is 
lined with respiratory mucus epithelium. The temporal brain lies superior to 
the middle ear and jugular vein, and inferior to the carotid artery (Gray, 
1918; Irwin, 2006).
The main function of the middle ear is to transmit sound vibrations from the 
air to the inner ear, and the air inside the tympanic cavity is essential for the 
efficient vibration of the tympanic membrane and ossicles in response to
24
sound (Gray, 1918; Irwin, 2006). When the middle ear is inflamed, the air in 
the tympanic cavity is replaced by fluid, which interferes with sound 
transmission to the inner ear (Antonelli, 2004). This results in conductive 
hearing impairment, which is often associated with middle ear inflammation 
or otitis media.
Malleus
Vestibulocochlear
nervePinna
Cochlea
Tympanic cavity
Eustachian tube
Tympanic membrane
External auditory canal
Figure 2.1 Anatomy of the middle ear
This diagram is a graphical representation o f the human middle ear. In otitis 
media, tympanic cavity is filled with fluid which interferes with effective 
transmission o f sound vibration to the inner ear. (Courtesy Dr. Mahmood 
Bhutta)
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1.1.1- Classification of Otitis Media (OM)
Otitis media (OM) is a multi-factorial disease and the most common cause 
of deafness and surgery in children of developed countries (Clarke & De, 
2005; Kubba et al, 2000). The terminology used to describe OM and its 
sequelae in this thesis is consistent with the current understanding of the 
disease. OM manifests itself in the following forms in humans:
1.1.1.1- Acute Otitis Media (AOM)
Acute otitis media (AOM) is the most common form of OM and presents 
itself as an “acute suppurative inflammation” with fever, ear pain and 
eardrum redness (Kong & Coates, 2009). Bulging of the tympanic 
membrane is also often observed (Kong & Coates, 2009). AOM is 
frequently elicited by bacterial or viral infections. Most children have had 
at least one episode of AOM by the age of three. AOM is the most common 
childhood bacterial infection (Teele et al, 1989a; Teele et al, 1989b). 
Although mostly associated with bacterial infection, AOM has also been 
associated with viral infections (Massa et al, 2009; Patel et al, 2007). 
Respiratory syncytial virus (RSV) and Rhinoviruses are viruses often 
associated with AOM development (Henderson et al, 1982). Streptococcus 
pneumoniae (15- 44% of total AOM cases), Haemophilus influenzae (11- 
15% cases) and Moraxella catarrhalis (8% cases) are the common bacterial 
pathogens recovered from OM fluid culture and nasopharangeal fluids of 
AOM patients (Brook & Gober, 2000). Recurrent AOM (RAOM) episodes 
can occur in some children and is termed RAOM, which is defined as three 
or more episodes of AOM in six months or four or more episodes in 12 
months. More than 80% of children have at least a single AOM episode 
before the age of three (Cripps et al, 2005; Teele et al, 1989a). Six or more
AOM episodes occur in 40% of children by the time they are seven years 
old (Casselbrant et al, 1999). Unsurprisingly, AOM is one of most common 
childhood illnesses and a major reason for antibiotic prescription. A study 
by Paradise et al., shows that AOM is the reason for which children spend a 
mean of 42 d on antibiotics in the first year of life (Paradise et al, 2005).
1.1.1.2- Otitis Media with Effusion (OME)
OM can also manifest as OME in patients. OME usually follows an AOM 
episode and presents itself as middle ear inflammation without the 
symptoms commonly associated with AOM, i.e. ear pain and fever. The 
middle ear gets filled with effusion that is serous in nature and with a low 
cellularity of neutrophil leucocytes (NLs). However, over time the effusion 
can become non-serous or thick and glue-like (hence the name “glue ear”). 
OME is distinct from AOM in that its main symptoms of AOM (ear pain 
and fever) are absent in OME. Otoscopy studies have revealed that the 
tympanic membrane in OME can become retracted (Bluestone, 2004). OME 
can become chronic in some children, which is termed as chronic OME 
(COME), and may or may not lead to the development of chronic 
suppurative OM. OME and COME affected children develop conductive 
hearing loss, which may affect speech development (Bluestone & Klein,
2007).
1.1.1.3- Chronic Suppurative OM (CSOM)
CSOM is one of the most common childhood chronic diseases affecting a
range of demographic sections across the world. CSOM is defined as the
“chronic inflammation of the middle ear and mastoid mucosa with
perforation in the tympanic membrane and presence of otorrhea” (Verhoeff
et al, 2006). World Health Organisation (WHO) defines CSOM as “otorrhea
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through a perforated tympanic membrane present for at least two weeks”. 
Some authors classify as ‘chronic’ cases in which symptoms persist for at 
least 3-6 weeks (Bluestone 1998; Roland 2002). CSOM is different from 
COME in that perforation of the tympanic membrane is observed in CSOM 
along with highly suppurative exudate with a high number of NLs 
(Bluestone, 1998). Cholesteatoma or accumulation of kertanised stratified 
squamous epithelium in the middle ear can sometimes occur in CSOM. 
Such cases are termed CSOM with cholesteatoma.
CSOM can result in conductive hearing loss between a range of 20 to 60 dB 
(Kaplan et al., 1996). Studies have also shown that CSOM can cause 
sensorineural hearing loss due to the loss of hair cells in the cochlea 
(Cureoglu et al, 2004; Huang & Lin, 1991). CSOM-related hearing 
impairment can adversely affect children’s language and psycho-social 
development (Winskel, 2006).
CSOM mostly occurs in the first five years of life in children (Wintermeyer 
and Nahata, 1994). A high prevalence of CSOM has been observed in 
children with craniofacial abnormalities (Bluestone, 1998) and certain racial 
groups such as Aborigines, Inuits and American Indians (Coates, 2002; 
Couzos et al, 2003). Despite the low prevalence of CSOM in the UK and 
U.S. (<1%), it is a significant burden on the healthcare system. The WHO 
has reported that a prevalence of CSOM >4% in a defined population 
indicates a massive public health problem in need of urgent attention 
(WHO, 1998) (Acuin, 2004). Roughly 51,000 deaths occur worldwide each 
year due to CSOM complications such as lateral sinus thrombosis, cerebral 
abscess, otitic meningitis etc. The WHO also estimates that 65 million to 
330 million individuals develop CSOM, with subsequent hearing 
impairment in 60% of affected individuals (Acuin, 2004).
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1.1.2- OM medical management
OM is medically managed with antibiotic and steroidal therapies, which are 
not very effective in OME (Browning et al, 2010; Griffin et al, 2006). While 
the majority of children are able to resolve OM, others suffer from persistent 
inflammation in the form of chronic OM. No effective medical management 
therapies for COME or CSOM currently exist. Chronic OM is treated with 
surgical intervention the most common of which is via the insertion of a 
tympanostomy tube otherwise known as ventilation tube or grommets, to 
ventilate the middle ear (Antonelli, 2004). Approximately 30,000 ventilation 
tube insertions are carried out in the UK each year as a surgical intervention 
treatment for chronic OM (Sood & Waddell, 2007). This surgical 
intervention offers only short-term hearing improvement in OME-effected 
children and can result in secondary complications such as otorrhoea, ear 
infection and loss of hearing in the operated ear (Browning et al.,2010, 
Antonelli, 2004).
Multiple patho-genetic factors might be responsible for the increased 
persistence of middle ear inflammation in some children and the resolution 
of OM in others. OM has a strong genetic component (see below), but the 
underlying genes involved in the development of persistent OM need to be 
explored.
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OM risk factors
OM is a multi-faceted disease with a number of factors contributing to its 
development. Various environmental and host genetic factors have been 
linked to susceptibility to OM.
1.2.1- Socio-environmental factors
Socio-environmental conditions such as poverty, overcrowding, 
malnutrition and exposure to cigarette smoke have all been associated with 
the perpetuation of OM ((Elemraid et al, 2009; Lasisi et al, 2007; Uhari et 
al, 1996). Daycare attendance by children (Waldeb et al.,1989) has been 
shown to increase drastically the susceptibility of children to OM. Short­
term breastfeeding , exposure to pollutants and premature birth have all 
been reported to increase the risk of developing OM (Brauer et al, 2006; 
Engel et al, 1999a; Engel et al, 1999b; Xenellis et al, 2005). The risk of 
developing RAOM and chronic OM increases by up to 66% in the presence 
of passive parental cigarette smoke ((Damoiseaux et al, 2006; Uhari et al, 
1996).
1.2.2- Pathogenic Factors
Risk factors for the development of chronic OM include infection with 
AOM pathogens (Vergison, 2008). AOM is a multi-pathogen disease caused 
by bacteria and viruses. A triad of commensal bacteria -  S. pneumoniae, 
non-typeable H. influenzae (NTHi) and M. catarrhalis -  are associated with 
80% of AOM cases (Vergison, 2008). 20% of AOM cases are attributed to 
viruses alone (Segal et al, 2005). Coronavirus, respiratory syncytial virus 
(RSV) and adenovirus are the viruses most commonly associated with AOM 
(Chonmaitree et al, 2008).
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1.2.3- Biofilms
Biofilms are complex communities of bacteria in matrix-enclosed 
biopolymer bacterial aggregates; these are often associated with chronic 
diseases such as endocarditis, cystic fibrosis, periodontal disease (Donlan & 
Costerton, 2002; Homoe et al, 2009). The common bacteria found in CSOM 
-  Pseudomonas aerugionosa, H. influenzae, Pneumococcus spp. etc. -  are 
known to form biofilms. Biofilms have been found in the middle ear of 
chinchillas with COME (Homoe et al, 2009; Jurcisek et al, 2005; Swords et 
al, 2004). The presence of H. influenzae, S. pneumoniae, and M. catarrhalis 
biofilms has also been demonstrated in mucosal lining from children with 
COME or RAOM (Hall-Stoodley et al, 2006). In a study on a high-risk 
CSOM population in Greenland, morphological evidence of biofilms in 
otorrhea in five of six children with CSOM has been observed (Homoe et al, 
2009). Middle ear biopsies from adults operated for CSOM have also 
demonstrated the presence of biofilms (Homoe et al, 2009). The role of 
biofilms in OM pathogenesis is relatively unknown; whether biofilms are 
the cause or sequelae in middle ear diseases is yet to be established.
1.2.4- Host factors
1.2.4.1- Anatomical defects -Craniofacial disorders and Eustachian tube
Risk factors for OM also include anatomical defects such as craniofacial
defects and Eustachian tube (ET) abnormalities. CSOM is over-represented
in children with Down’s syndrome, cleft palate and craniofacial disorders.
Paradise et al. (1969) first demonstrated the near universality of OM in cleft
palate patients. 98% of cleft palate patients develop OME and hearing loss
by the age of five, according to a recent study performed on 86 cleft palate
patients (Szabo et al, 2010). Cleft palate is a developmental abnormality;
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TGF-P signalling is known to be involved in developmental processes 
including development of palate (Proetzel et al, 1995).
Many authors have also ascribed CSOM development to ET dysfunction 
(Bluestone et al, 2005; Sade & Fuchs, 1997). The ET links the naso-pharynx 
to the middle ear and is involved in pressure regulation, ventilation and the 
removal of secretions and dead cells (Bluestone, 1996). Children with 
craniofacial abnormalities such as cleft palate have a shorter ET and are 
more prone to ET obstruction and OM development. However, it is argued 
that ET obstruction is not the primary cause of OM but is instead a 
secondary event due to formation of mucus after inflammation has initiated 
(Sade & Fuchs, 1997). However, there is insufficient evidence in support of 
ET as the main aetiological cause of OM in both syndromic and non- 
syndromic children, with the claim being based on incomplete evidence 
(Bhutta, 2011; Sade & Ar, 1997).
1.2.4.2- Genetic factors
A number of epidemiological reports over the last few years reveal a 
substantial OM burden worldwide. The Centre for disease control (CDC) 
estimates that OM accounts for over 20 million visits to physicians per 
annum in the U.S. (CDC, 2007). The burden of OM is significantly high, 
with evidence of chronicity in certain populations and races. The prevalence 
of CSOM was found to be 12%, 2.5% and 15% respectively in community- 
based epidemiology studies performed in Bangladesh (Biswas et al, 2005), 
Nigeria (Amusa et al, 2005) and Australia (Morris et al, 2005). The rate of 
OM incidence is unusually high in American Indians, Australian Aborigines 
(84%) and Inuits (81%), according to reported studies (Ayukawa et al, 2004; 
Coates, 2002; Gunasekera et al, 2007). High CSOM rates have also been
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reported in Australian Aborigines and Inuits (25-45%), but with low 
incidence of choleosteatoma (1-3%) (Jassar et al, 2006). Other studies have 
also reported high hearing screen fail rates among 19% of 5-6 year-old 
Inuits (Ayukawa et al, 2004). One third of aboriginal children develop 
unilateral or bilateral hearing loss (Thome et al, 2004). These differences in 
incidence, severity and complication rates of OM and CSOM between 
populations suggest a genetic contribution to OM development. Studies of 
OM in Apache Indians in Arizona have also suggested familial disposition 
(Todd, 1987). Various studies suggest that both RAOM and CSOM are 60- 
70% heritable (Casselbrant et al, 1999; Casselbrant et al, 2009; Kvaemer et 
al, 1996; Kvestad et al, 2004; Rovers & Zielhuis, 2004). Twin and triplet 
studies have reported that genetic traits play a major role in OM 
development and that OM susceptibility is inherited (Kvaemer et al, 1999). 
Substantial heritability of OM has been replicated in a study from Norway 
including more than 9000 twins (Kvestad et al, 2004). A number of 
inflammatory gene polymorphism association studies have identified 
polymorphisms in innate immune system related genes such as IL-6, TNF-a, 
IL-10, TLR-4, IL-lfi are associated with OM development (Daly et al, 2004; 
Emonts et al, 2007a; Patel et al, 2006; Pettigrew et al, 2006; Sale et al, 
2011). However, our knowledge of the genetic susceptibility factors 
involved in the chronic progression of OM is still limited. There is a need to 
explore and further identify the genes that might be involved in OM.
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OM Models
Studies outlined above suggest a strong genetic component in OM 
development. Mice can play a key role in undertaking investigations of the 
genetic and cellular pathways that may be involved in the development of 
OM. Mice have been used as a model organism for a number of other 
diseases due to the physiological comparability with humans. Mouse models 
can be generated relatively quickly and are easily manipulated which is an 
added advantage. There is also over 90% synteny between the mouse 
(Mouse Genome Sequencing Consortium 2002) and human (International 
Human Genome Sequencing Consortium et al. 2001; Venter et al. 2001) 
genomes, which makes mice an excellent choice for modelling diseases. 
Several murine models of OM have been described in the literature. These 
models allow a greater understanding of the relationship between genes and 
disease susceptibility (Parkinson & Brown, 2002) and allow the 
identification of candidate genes. Such candidate genes may also be 
identified in with genome-wide association studies in humans. Mouse 
models also function as a suitable platform for drug discovery and 
development of non-surgical interventions and therapies for the treatment of 
OM in humans.
These OM mouse models can be either pathogen-induced models, allowing 
us to study the inflammatory mechanisms involved in OM that are due to 
host abnormality, which allows for further understanding the pathways 
involved in disease progression.
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1.3.1- Pathogen challenge-induced OM mouse models
Inflammation is mediated by the innate immune system following activation 
of toll-like receptors (TLRs) by bacterial pathogen-associated molecular 
patterns (PAMPs) or immune complexes (Aderem & Ulevitch, 2000; Akira, 
2001; Sabroe et al, 2003). TLRs are expressed primarily on macrophages, 
NLs and vascular endothelial cells of the middle ear (Pugin et al, 1993; 
Shuto et al, 2001). Binding of PAMPs to TLR elicits the activation of 
transcription factors such as nuclear factor-kappa beta (NF-kB), which 
activates a number of pro-inflammatory genes (Medzhitov & Janeway, 
1998; Tak et al, 2001). Many of these genes encode for inflammatory 
cytokines (Ghaheri et al, 2007). Some of these cytokines, such as TNF-a, 
IL-ip and IL-8, have been identified in 77-91%, 67-97% and 92-100% of 
chronic middle ear effusions respectively (Kubba et al., 2000). Hence, the 
link between OM and these inflammatory cytokines is studied extensively 
by means of injecting bacteria or bacterial products in middle ear 
(MacArthur & Trune, 2006; Ryan et al, 2006).
Several induced models of OM have been reported, including chinchilla 
(Giebink, 1999; Gitiban et al, 2005) and rat (Clark et al., 2000). However, 
mice are the animals of choice to study OM, as they have been used in the 
past studies to study inflammation mediators and immune response to key 
OM-causing pathogens, such as non-typeable Haemophilus influenzae 
(NTHi), H. influenzae type b, P. aeruginosa, Streptococcus pneumoniae and 
Moraxella catarrhalis (Cripps et al, 1994; Green et al, 1993; Loeb, 1987; 
Yamamoto et al, 1997). The mouse is the premiere mammalian model 
system used in biomedical research. The most significant advantage in using 
murine OM models over other organisms is the availability of genetically
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inbred mice in comparison to other outbred species along with the ease of 
genetic manipulation and availability of the mouse genome (Parkinson & 
Brown, 2002). Another advantage of using mice is the existence of strains 
with natural or induced mutations that exhibit spontaneous OM due to 
compromised defence of the middle ear. Also, unlike other animal models 
that display a lack of middle ear infection by M. catarrhalis, OM is 
observed in mice after M. catarrhalis inoculation (Melhus & Ryan, 2003). 
The mouse middle ear, just as in humans, changes drastically in response to 
infection and inflammation. These changes include the generation of 
effusion, inflammatory cell infiltration and mucosal cell proliferation 
(Ebmeyer et al, 2005). The limitation of using mice as an OM model is that 
the mouse middle ear small in comparison to other animal models. In fact, 
the mouse middle ear has only a volume of ~ 5-6 pi (Huangfu and Saunders, 
1983) which makes OM assessment difficult. However, this handicap is 
progressively being overcome by more sensitive OM assessment techniques, 
such as oto-endoscopy (Bhutta et al, 2010).
There are various methods of OM induction by pathogens. One is to
challenge the nasal mucosa with OM pathogen or inflammatory substance.
Once the substance/pathogen transits to the ET, it can result in OM (Sabirov
et al, 2001). This method mimics the natural mode of middle ear (ME)
infection, but the OM incidence in this case is sporadic and the dose of
inducing agent to reach the middle ear is uncontrolled (Ryan et al, 2006).
Alternatively, a controlled dosage is achieved via direct injection into the
middle ear via the tympanic membrane (Krekorian et al, 1990). However,
the resulting hole in the tympanic membrane poses a risk of contamination
and fluid drainage. This risk can be circumvented by injection through the
bulla which has reduced contamination and fluid drainage, however; as the
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bulla is next to major vessel extreme care needs to be taken through the 
procedure.
Mice do not normally become infected with human OM bacteria, but human 
OM bacteria are extensively used to study OM in mouse models. It is 
interesting to note that susceptibility to the same bacteria can vary in 
different mice strains (Melhus & Ryan, 2003). For example, BALB/c is 
more susceptible to induced to OM than C57BL/6 mice (Melhus & Ryan,
2003). Non-infectious induced models of OM for understanding OM 
pathogenesis are also quite widely used. OM in such models is induced by 
injection of heat-killed bacteria, LPS or other inflammatory mediators such 
as TNF-a or IL-ip (Catanzaro et al, 1991; Krekorian et al, 1990; Maeda et 
al, 2004). These models may not model infection as closely as pathogen- 
based induced OM models, but they are useful for studying individual 
components of OM.
Although induced models of OM are useful and essential for understanding 
the pathogenesis of OM, their use is limited in addressing the genetic 
component of OM as a disease and the basis for differences in OM 
susceptibility that is observed in different demographic groups in humans. 
However, they are often used in conjunction with genetic models to induce 
chronic OM (Described in section 1.3.2).
1.3.2- Gene-driven mouse models of OM
Independent lines of evidence have indicated the role that host genetics
might play in OM. Racial differences in the incidence of OM and CSOM
suggest a genetic contribution of OM (Casselbrant et al, 1999; Coates et al,
2002; Emonts et al, 2007b; Todd, 1987). OM susceptibility is exhibited in
various congenital and inherited syndromes, such as Achondroplasia, as
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well as in patients with Down’s syndrome, cleft palate or inflammatory gene 
polymorphisms (Casselbrant et al, 1999; Daly et al, 2005; Emonts et al, 
2007a; Patel et al, 2006).
Studying the genetic pathways involved in human diseases is fraught with 
practical difficulties, such as uncontrollable environmental factors and a 
mixed genetic background. In such a scenario, mice can play a key role in 
understanding OM pathogenesis. The functional and anatomical similarity 
between the ears of mice and humans (except for the absence of mastoid air 
cells in rodents), their comparable physiology, and the availability of both 
murine and human genomes ((Lander et al, 2001; Venter et al, 2001; 
Waterston et al, 2002) make mice an excellent model for studying the 
genetics of OM (Brown et al, 2008). The murine genome is easily 
manipulated and mice can be generated to produce litters in 9 wks (Rye et 
al, 2010). The availability of tools to create knockout and transgenic mice 
along with easily inducible large-scale mutagenesis and phenotypic 
assessment of mutant strains has made mice a perfect model organism to 
study OM (MacArthur & Trune, 2006).
In gene-driven OM mouse models, gene-driven approaches such as gene 
traps, knockouts or knock-in mutations are introduced in mouse genomes to 
target specific candidate genes (Brown et al, 2008). This approach can be 
scaled up to target every gene in the genome. Programmes for the 
generation of null and conditional null lines is also underway and will 
further enable a comprehensive understanding of genes involved in OM 
(Auwerx et al, 2004). EUCOMM (European Conditional Mouse 
Mutagenesis program), which began in 2006, and IKMC (International 
Knockout Mouse Consortium) are similar programs to develop conditional
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targeted knockouts for every gene in the mouse genome (Collins et al,
2007).
1.3.2.1- Deletion of E2f4 gene results in OM in mice
E2F transcription factors are key regulators of the cell cycle and control the 
expression of genes required in the Gl/S transition (Helin, 1998). Mutation 
in the E2F gene has been previously associated with adult T cell leukemia in 
humans although no association with OM in humans has yet been 
established (Komatsu et al, 2000). Homologous recombination has been 
used to knock out the E2f4 gene and its DNA binding domains in E2f4'f' 
mice (Humbert et al, 2000). Although most mice die shortly after birth, 
investigations have revealed indications of OM and chronic rhinitis in these 
mutants along with other abnormalities such as craniofacial defects and 
erythroid cell abnormalities. (Humbert et al, 2000). E2f4~f' mutants are 
found to be infected with Pasteurella pneumotropica along with the 
accumulation of purulent fluid due to macrophage and NL infiltration at the 
site of inflammation. 2s2/?'7' also have mild craniofacial abnormalities along 
with atrophic olfactory epithelium and mucus accumulation in the nasal 
passage and a lack of ciliated cells in the postnatal epithelium (Danielian et 
al, 2007). However, ME exudate was still found to be present in the bulla of 
E2f4'1' homozygous mice even under Pasteurella pneumotropica free 
conditions. Inflammatory responses were not found to be affected in E2f4 
deficient mice, which suggest structural changes as the cause behind the 
increased bacterial susceptibility observed in these mutants. The evidence 
outlined above suggests that OM in E2f4'/~ mutants is due to a defect in 
embryonic development of cilia resulting in the production of mucin, which
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accumulates in the middle ear and nasal passage to cause OM and chronic 
rhinitis respectively (Rye et al, 201 la).
1.3.2.2- Mice deficient in transformation-related protein p73 gene 
display AOM symptoms
In this mutant the transformation-related protein 73 (p73) gene, was 
disrupted in embryonic cells (Yang et al, 2000). The P73 gene encodes a 
member of the p53 family of transcription factors and is involved in cellular 
responses to stress, cell differentiation and inflammation (Moll & Slade,
2004). P73 shares sequence homology with the gene for transcription factor 
and tumour suppressor P53, but is not involved in oncogenesis (Fontemaggi 
et al, 2002).
Chronic inflammation and infection have been observed in mice deficient in 
p73 along with other larger defects such as hippocampal dysgenesis, 
congenital hydrocephalus and other growth defects as well as high mortality 
rate (Yang et al, 2000). p73~/~ mice develop purulent OM 2 d post-birth 
(DAB), which continues through adulthood with >80% of adult mutants 
displaying AOM symptoms along with NL accumulation at the site of 
inflammation. Bacteria such as E. coli and Pasteurella aerogenes were 
isolated from the middle ear at 21 DAB but not 2 DAB. Chronic 
inflammation is observed in p73'f' mice while no lymphoid or granulocyte 
deficiencies or any craniofacial abnormalities were found (Yang et al, 
2000). This hints at a defect in other immune system components in p73~/~ 
mice, such as hyper-production of mucus and inflammation of the mucous 
membrane, which might make these mutants susceptible to bacterial 
infection (Rye et al, 2011a). The human orthologue of p73, TP73 has also
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been found to be associated with chronic rhinosinusitis (CRS) and OM in 
humans (Bosse et al, 2009; Toumas et al, 2010).
1.3.2.3- Lpr/lpr mice expressing defective Fas protein display prolonged 
AOM
Lpr/lpr is a homozygous recessive lymphoproliferation mutation model that 
exhibits Lupus-like autoimmune disorder due to a defective apoptosis 
receptor Fas protein (Watanabe-Fukunaga et al, 1992). Mutations in FAS 
gene are associated with diseases such as autoimmune lymphoproliferative 
syndrome and pulmonary fibrosis in humans (Nagata, 1997; Tafani et al,
2002). An insertion of a transposable element in the Fas intron results in 
defective Fas protein (Watanabe-Fukunaga et al, 1992).
Fas is a member of the TNF superfamily and is involved in apoptotic 
signalling (Siegel et al, 2000). The lpr/lpr mutation results in a systemic 
autoimmune mutation on the MRL background and OM induction by 
Salmonella typhi LPS results in a continued mucosal hyperplasia and 
inflammatory cell infiltration in the middle ear even after 14 d, while the 
hyperplasia is observed in control mice only up to 5 d (Rivkin et al, 2005). 
This significant difference in the recovery of OM-affected middle ear 
mucosa suggests a role of Fas in prolonging OM and the repair of mucosa.
1.3.2.4- Toll-like receptor defects and OM
Toll-like receptors (TLR) are key innate immune system regulators and 
crucial for elimination of bacterial pathogens. They are a type of pathogen 
recognition receptors (PRRs) present on immune cells such as macrophages, 
dendritic cells (DC), monocytes and B lymphocytes which recognise 
PAMPs on bacteria to trigger the signalling pathways involved in the
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production of cytokines essential for pathogen clearance (Takeda & Akira, 
2003; Takeda et al, 2003). TLR defects have been shown to be associated 
with OM in mouse models (Rye et al, 201 la).
A single amino acid change causing the mutation in the Tlr4 gene renders 
C3H/HeJ mice susceptible to spontaneous chronic OM, along with 
conductive hearing loss, at around 5-12 months of age (MacArthur et al, 
2006). C3H/HeJ mice have normal craniofacial structure and ET, which 
suggests that the OM observed in these mice is due to the loss of function of 
Tlr4, which results in a defective bacterial clearance in these mutants 
(MacArthur et al, 2006). Despite being a spontaneous OM model, C3H/HeJ 
mice do not develop OM until around 5 months of age, which suggests that 
this model may not be biologically relevant as a model of OM in childhood 
(Rye et al, 2011a). However, injecting NTHi into the tympanic cavity in 
C3H/HeJ and WT control C3H/HeN results in AOM in both genotypes 
(Hirano et al, 2007). However, though WT mice resolve inflammation 
within 24 h, OM in C3H/HeJ persisted past 72 h. This result, along with the 
immune-histochemistry staining of the tympanic membrane, indicated an 
important role of Tlr4 in the resolution of OM caused by bacterial infection 
(Hirano et al, 2007).
Interestingly, TLR4 polymorphism in humans has also been associated with 
RAOM and COME/RAOM in studies (Emonts et al, 2007a; Sale et al, 
2008).
The targeted disruption of the Tlr2 gene also shows a delayed bacterial 
clearance (Leichtle et al, 2009). AOM inducted by NTHi injection into the 
tympanic membrane of Tlr2~f~ mice persisted at least 10 d in comparison to 
WT mice, which resolved the AOM within 2 d. No association between
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TLR2 and RAOM/COME has been observed in human studies (Sale et al,
2008).
1.3.2.5- Myeloid differentiation primary response protein 88 defect 
display chronic AOM on bacterial challenge
The myeloid differentiation primary response protein 88 (MyD88) is an 
adaptor molecule involved in TLR signalling. Targeted disruption of 
MyD88 was performed to generate MyD88'f' knockout mice on C57BL/6J 
background (Hernandez et al, 2008). Induction of AOM by NTHi injection 
into the tympanic membrane of MyD88~f~ mice resulted in chronic AOM, 
which persisted for at least 2 Id in comparison to WT mice, which resolved 
the inflammation in 5 d.
Delayed inflammatory cell recruitment was observed in MyD884 mice. 
Defective and delayed inflammatory cell recruitment predisposes MyD88- 
deficient mice to inflammation due to the defective clearance of bacteria 
(Rye et al, 2011a). In humans, the autosomal recessive mutation in MyD88 
predisposes the affected individuals to certain bacterial populations, 
especially S. pneumoniae, which is a key OM-causing bacterium (von 
Bemuth et al, 2008).
1.3.2.6- Plasminogen deficient mice display fibrin deposition and OM
Spontaneous chronic OM has also been reported in plasminogen knockout
mice (Eriksson et al, 2006). Plasminogen is a serine protease involved in
wound healing, fibrinolysis and inflammatory cell migration (Bugge et al,
1995; Ploplis & Castellino, 2000). It is encoded by the Pig gene. Plg-
deficient mice displayed fibrin deposition in a number of mucosal surfaces
and organs, including the tympanic cavity, along with other inflammatory
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changes such as infiltration of neutrophils and macrophages, and abnormal 
keratin formation (Eriksson et al, 2006). Variable numbers of bacteria were 
also isolated from the tympanic cavity of these mice. Polymorphisms in the 
plasminogen activator inhibitor 1 gene PAI-1 polymorphisms have been 
associated with RAOM in human GWAS studies, which suggests a role of 
the plasminogen pathway in OM pathogenesis (Emonts et al, 2007b).
1.3.2.7- Eyes absent homolog 4 gene deficient mice develop spontaneous 
OME
Eya4 knockout mice v" develop spontaneous OME regardless of genetic 
background (CBA/J, BALB/c, C57BL/6 or Swiss-Webster) (Depreux et al,
2008). The Eydf' mice develop OME by 16 DAB and the retraction of the 
tympanic membrane is evident by 21 DAB. Craniofacial and anatomical 
analyses have suggested that OME development in these mice may be due 
to an abnormal middle ear cavity and ET dysmorphology. However, Eya4 
has also been found to play an important role in apoptosis and innate 
immune system regulation as a transcription factor , providing an alternative 
explanation to the chronic and spontaneous OM observed in these mice 
(Okabe et al, 2009).
1.3.3- Phenotype-driven mouse models of OM
In the phenotype driven approach, randomly mutagenized mice are screened 
for disease phenotypes (Nolan et al. 2000). Usually this mutagenesis is 
performed using is by ENU (N-ethyl-N-nitrosourea) which is a potent 
mutagen that induces random point mutations in spermatogonial stem cells 
(Justice et al, 1999). This method follows a forward genetics approach in 
which a phenotypic screens are performed to identify disease phenotypes of
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interest (Hrabe de Anglelis et al.,2000; Nolan et al.,2000). This way the 
abnormal phenotype of interest is starting point of the investigation. Genetic 
mapping allows positional cloning of the causative mutation.. This method 
does not make prior assumptions about the relationship between the 
phenotype and gene and is useful tool to discover novel genes involved in 
complex diseases such as OM. ENU induces point mutations in individual 
loci to give null, gain or loss of function mutations. Strains bearing separate 
mutations can be crossed to make double mutants and understand multi­
factorial basis of disease (Schachem et al, 2007; Zheng & Johnson, 2001). 
Phenotypic assessment of these mutants is performed using procedures such 
as click box, which measures preyer reflex to loud noise (90dB) in mice 
identifing mutants with conductive hearing loss or sensorineural hearing 
defects ((Hardisty et al, 2003; Nolan et al, 2000). Another more sensitive 
method to measure hearing thresholds in mice is through auditory brainstem 
response (ABR) (Zheng et al.,1999; Hardisty-Hughes et al.,2010). In ABR, 
defined sound frequencies are played into the ear of the mouse and the 
brainstem response to the stimulus is then monitored to determine the 
hearing threshold in decibels (dB). The stimulus range is 90 dB to 5 dB. 
Another diagnostic method for OM assessment is by a medical imaging 
technique for middle ear examination or oto-endoscopy which has a 93% 
accuracy in OM diagnosis in mice (Bhutta et al.,2010). In combination with 
ABR and click-box, mouse oto-endoscopy presents an efficient and reliable 
method of OM assessment in mouse mutants.
Phenotypic screening of ENU generated mutants led to discovery of 2 novel
mouse mutants Jeff and Junbo at MRC Harwell (Nolan et al, 2000). Both
Jeff and Junbo display a conductive deafness phenotype characterised by
middle ear fluid and inflammation and lack of preyer reflex in click box test
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(Hardisty-Hughes et al, 2006; Parkinson et al, 2006). These mouse mutants 
are the first good spontaneous mouse models for chronic OM that mimic the 
phenotype of the human condition.
Table 2.1- Current models of OM in mice
Gene Chromosome Model type OM Phenotype Reference
E2f4 10 KO Spontaneous chronic Humbert et al. 2000
Evi-1 3 SNP Spontaneous chronic Parkinson et al. 2006
Eya4 10 KO Spontaneous chronic Depreux et al. 2008
Fbxoll 17 SNP Spontaneous chronic Hardisty-Hughes et al. 2006
P73 4 KO Spontaneous chronic Yang et al. 2000
Pig 17 KO Spontaneous chronic, fibrin deposition Eriksson et al. 2006
Fas 19 SNP Induced acute Rivkin et al. 2005
MyD88 9 KO Induced acute Hernandez et al. 2008
m 3 KO Induced acute Leichtle et al. 2009
Tlr4 4 SNP Induced acute Hirano etal. 2007
This table describes the various current OM models discussed in this thesis 
along with the affected genes. Adapted from (Rye et al, 2010) KO knockout, 
SNP Single nucleotide polymorphism.
1.3.3.1- Non-syndromic spontaneous chronic OM model- Fbxoll 
mutation in Jeff
Jeff is a dominant mouse mutant displaying OM phenotype similar to 
COME in humans. The Jeff mice carry a point mutation in F box gene 
Fbxoll (Figure 1.2) (Hardisty-Hughes et al, 2006). Jf/+ mice display a 
conductive hearing loss along with a middle ear cavity filled serous fluid 
effusion by 28 dab (Hardisty-Hughes et al, 2006; Hardisty et al, 2003). 
Cellular hypoxia in inflammatory cells in middle in Jf/+ middle ear has 
been observed (Figure 1.3) (Cheeseman et al, 2011). Jf/+ mice do not have 
any obvious immune deficiencies but display an OM and deafness 
phenotype along with mild craniofacial abnormalities, shortened snout and 
narrow bent ET (Hardisty et al, 2003). However, Jf/+ mice on a C57BL/6
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unlike the original C3H/HeH background do not develop craniofacial defect 
but still develop OM.
CASH CASH ZnF
334-470 | 624-753 754-819
Q491L 
Jeff
Hsapiens NAL AGIQIRTNSCP
M  Musculus NAL AGIQIRTNSCP
Jeff F b xo ll NALAGILIRTNSCP
R. norvegicus NAL AGI QIRTNSCP
G. Callus NALAGIQIRTNSCP
D. rerio NAL AGI QIRTNSCP
F. rubripes NALAGIQIRTNSCP
D. Melanogaster NALAGIQIRSQSDP
A. Gambia? NALAGIQIRTTSDP
C Elegatis NAL AGI QIRTNSDP
C intestinahs NAL AGI QIRTNSSP
Figure 2.2- Fbxoll sequence is conserved. Mutation in Fbxoll sequence 
underlying the Jeff mutant phenotype
Adapted from (Hardisty-Hughes et al, 2006)
The Fbxoll mutation in Jeff mutant was mapped to chromosome 17 
(Hardisty et al, 2003). The mutation in Jeff is at a highly conserved portion 
o f the gene at amino acid 491 o f F bxoll gene from glutamine to leucine 
(Hardisty-Hughes et al, 2006). Fbxoll is expressed in bone marrow, tissue 
macrophages, epithelial cells o f middle ear from late embryonic stages as 
well as in liver and kidney after birth (Hardisty-Hughes et al, 2006). F bxoll 
is part o f a large family o f F-box proteins which function as a part o f SKP1-
F-box
75-115
cullin-F-box (SCF) E3 protein ligase complex. These proteins promote 
proteosomal ubiquitination and degradation by recognizing and binding to 
phosphorylated proteins (Jin et al, 2004; Kipreos & Pagano, 2000).
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Figure 2.3- Inflammatory cells in J/7+ middle ear effusion are hypoxic.
Left panel shows PIMO labeling in .7/7+ inflammatory cells in the bulla 
lumen (arrows) arrow S indicates serous fluid. Right panel shows WT 
mucosa where PIMO labeling is negative. Scale bare denotes 50 pm. 
Picture adapted from (Cheeseman et al, 2011).
Jf/Jf homozygotes have been shown to have palatal defects and eyes-open at 
birth (EOB) phenotype (Hardisty-Hughes et al, 2006; Tateossian et al,
2009). TGF-P has been known to be involved in all these processes (Pelton 
et al, 1991; Prime et al, 2004; Zhang et al, 2003). Phosphorylated Smad2 
(pSmad2) is an intracellular signalling protein in the TGF-P pathway and is 
upregulated in epithelia o f Jf/Jf homozygotes in the eyelids, palates and 
lungs. Interaction between Fbxol 1 and Smad2 has also been assessed using 
compound heterozygous Jf/+Smad2/+ mutants which had a phenotype 
similar to Jeff homozygotes. However no biochemical interaction between 
the two proteins has been observed (Tateossian et al, 2009). This suggests 
that F b x o ll might be indirectly interacting with Smad2 protein and be
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involved in TGF-p signalling regulation. Recent literature has revealed that 
Fbxoll protein acts as a Nedd8-ligase to p53 (Abida et al, 2007). siRNA 
knockdown and overexpression experiments have shown that neddylation of 
p53 by Fbxol 1 reduces the transcriptional activity of p53 but does not affect 
its stability (Abida et al, 2007). However, a co-immunoprecipitation study 
performed on Jeff mice failed to reveal any direct interaction between the 
two proteins (Tateossian et al, 2009). Although Jf/Jf homozygotes and Jf/+ 
heterozygotes had markedly reduced and intermediate p53 protein levels 
respectively in comparison to WT. This suggests that Fbxoll maybe 
requisite for stabilization of p53 protein (Tateossian et al, 2009). p53 protein 
functions as a transcription activator and is maintained at low level in 
unstressed cells. In response to hypoxia, oxidative damage or oncogene 
activation, p53 levels and transcriptional activity is enhanced (Vogelstein et 
al, 2000). p53 is also known to directly interact with Smad2 to 
synergistically activate TGF-p target genes (Cordenonsi et al, 2003). p53 
deficient mammalian cells demonstrate an impaired TGF-p response 
(Cordenonsi et al.,2003). It has been proposed that in Jf/Jf loss of Fbxoll 
function may result in p53 destabilisation by an unknown mechanism. p53 
levels are substantially reduced in Jf/Jf homozygotes.
It is plausible that Fbxoll dysregulation in mutant Jeff impacts upon TGF-P 
signalling via Smad2 and p53, identifying TGF-p/SMAD pathway in OM 
susceptibility. This might result in an abnormal innate immune response 
resulting in persistent COME observed in Jf/+ mice. Interestingly, evidence 
of association between human orthologue FBXOll and COME/RAOM has 
also been observed in studies with FBXOll SNPs in human OM families 
confirming a role of FBXOll in OM pathogenesis (Rye et al, 2011b; 
Segade et al, 2006).
49
1.3.3.2- Spontaneous non-syndromic chronic OM model - Evi-1 
mutation in Jutibo
Junbo mutant was identified as a novel OM model in a dominant ENU 
mutagenesis screen with preliminary phenotyping using a click box test 
(Parkinson et al, 2006). Heterozygote Jbo/+ mutants exhibit conductive 
deafness phenotype due to middle ear effusion similar to CSOM observed in 
humans. However, no perforation of the tympanic membrane is observed in 
these mutants. Gross antatomical dysmorphologies are absent in Jbo/+ 
mice. Jbo/+ mutant develop spontaneous OM that transforms into 
persistent OM by 29 DAB, suggesting a predominant genetic susceptibility 
of Jbo/+ mice to OM. These mice develop OM even in germ free conditions 
but the onset is delayed (unpublished data, Michael Cheeseman). This 
suggests that microbial infection is not necessary for initiation of OM but 
may accelerate its progression. Jbo/+ mice have no obvious craniofacial 
abnormalities, overt immune defects or organ pathologies (Parkinson et al,
2006). Chronic middle ear effusions from Jbo/+ were found to contain 
variable numbers of viable and necrotic NLs and foamy macrophages, 
bacterial colonies are observed infrequently. Labelling with the hypoxia 
marker pimonoidazole showed that middle ear in Jbo/+ is hypoxic, with the 
epithelium, stromal cells, inflammatory cells in bulla lining all being 
hypoxic (Figure 1.4) (Cheeseman et al., 2011).
The underlying molecular basis of the Jbo/+ phenotype is a mutation in the 
Ecotropic viral integration site 1 {Evi-1) gene (Figure 1.5). The mutation 
causes an A2288T transversion in the Evi-1 locus, resulting in a non­
conservative Asn763Ile change in the second of the two zinc-finger domains 
of the protein (Parkinson et al, 2006). Evi-l gene was first identified as a
retroviral integration site in mouse myeloid tumour model (Morishita et al,
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1988; Mucenski et al, 1988a; Mucenski et al, 1988b). This gene is mapped 
to human chromosome 3q2q and its overexpression in humans is linked to 
myeloid malignancies such as acute myeloid leukemia (AML), chronic 
myeloid leukemia (CML), myelodysplastic syndrome (MDS) (Alessandrino 
et al, 2001; Mitani et al, 1994; Nucifora & Rowley, 1994; Sunde et al, 2006; 
Vinatzer et al, 2003). Evi-1 expression has been observed in myeloid and 
epithelial cells of middle ears without any genotypic differences between 
WT and Jbo!+ (Parkinson et al, 2006).
Evi-1 is a complex locus on mouse chromosome 3 (Nucifora et al, 2006). It 
encodes for a 145 kD transcriptional regulatory protein, and can act as a 
transcriptional activator as well as a repressor (Matsugi et al, 1990; 
Morishita et al, 1990b). The Evi-1 gene is implicated in leukemia and the 
inhibition of TGF-p signalling (Mitani, 2004). The Evi-1 protein consists of 
2 zinc finger domains with 7 zinc finger motifs in N terminal of zinc finger 
domain 1(ZF1) and 3 zinc finger motifs in zinc finger domain 2 (ZF2), a 
central transcription repression domain between ZF1 and ZF2 along with C 
terminal acidic region (Bartholomew et al, 1997; Morishita et al, 1990b). 
Apart from the full length 145 kD Evi-1 transcript which is the major Evi-1 
form, other alternatively spliced forms of Evi-1 are known to exist in mice 
and humans (Wieser, 2007). Evi-lb is a 727 protein which lacks 324 amino 
acid residues coding for Zinc finger motifs 6 and 7 of ZF1 as well as 
adjacent C-terminal residue. It encodes for 88kD protein (Hirai, 1999; 
Morishita et al, 1990a; Morishita et al, 1990b; Morishita et al, 1988). It is 
also known as the Evi-1 A324 isoform (Goyama & Kurokawa, 2010). This 
isoform of Evi-1 is expressed in low levels in humans and mice (Wieser,
2007). Another Evi-1 mRNA variant (A 105) encodes protein lacking 105
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amino acid residues in C terminal. It is abundant in murine cells but not in 
humans (Alzuherri et al, 2006; Wieser, 2007).
The Rp9 variant is abundant in both humans and mice and the protein 
derived lacks 9 amino acid residues from the repression domain (Alzuherri 
et al, 2006). Apart from alternative splicing of the Evi-1 gene, presence of 
alternative transcriptional initiation sites results in a transcriptional variant 
termed as MDS1/EVI1. This variant has an additional 188 amino acid 
residues derived from MDS1 gene at the N terminal of Evi-1 protein (Fears 
et al, 1996; Wieser, 2007). These amino acids encode a PR domain which 
has been implicated in tumour suppression in humans while PR absent 
forms are considered oncogenic (Goyama & Kurokawa, 2010)
Apart from being implicated in leukemia, a role of Evi-1 in development has 
also been suggested owing to its restricted expression pattern in embryo and 
different organs in mice (Wieser, 2007). Deletion of Evi-1 by the disruption
t f i  /of 6 exon confirms the gene’s role in development. Homozygous Evi-1"  
mice demonstrate perinatal lethality along with hypocellularity, defects in 
limb development and nervous system and circulatory system (Hoyt et al, 
1997; Wieser, 2007). Heterozygote mice did not display OM and were 
phenotypically similar to WT. This may be due to A324 isoform not being 
affected in the KO genotype (Parkinson et al, 2006).
Apart from its role in leukemia and development, one of the main
biochemical functions of Evi-7 is as a transcriptional activator and regulator.
Only few target genes (Gata2, Map3kl4, Fog2) are currently known
(Takahashi & Licht, 2002; Yatsula et al, 2005; Yuasa et al, 2005). Evi-1
exerts these biochemical functions via its DNA binding zinc finger domains.
ZF1 recognizes a consensus sequence of GACAAGATAAGAT (Delwel et
al, 1993; Goyama & Kurokawa, 2010) while ZF2 recognizes consensus
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sequence of GAAGATGAG (Morishita et al, 1995). Evi-1 also interacts 
with transcriptional corepressors such as CtBP and epigenetic transcription 
regulators Histone deacetylases (HDACs) (Chakraborty et al, 2001; Chi et 
al, 2003; Vinatzer et al, 2001) as well as transcriptional co-activators CBP 
and P/CAF (Chakraborty et al, 2001).
ZF1 binds directly to the Gata-2 promoter (Yuasa et al, 2005). ZF1 also 
binds to Smad3 and cJun N-terminal kinase (JNK) (Kurokawa et al, 1998a; 
Kurokawa et al, 1998b; Kurokawa et al, 2000). Evi-1 exerts its repressive 
effect on Smad3 via its CtBP binding consensus motif containing repression 
domain between the 2 zinc finger domains (Izutsu et al, 2001; Kurokawa et 
al, 1998b). This links Evi-1 to the TGF-p signalling pathway through its 
interaction with Smad3, suggesting that the mutation may cause OM 
through its effects on TGF-P signalling.
The ZF2 domain of Evi-1 binds cFos and induces activation of transcription 
factor Activator protein-1 (AP-1) which is either a Fos/Jun heterodimer or 
Jun/Jun homodimer (Tanaka et al, 1994). Evi-1 also stimulates PI3K/AKT 
signalling pathway in intestinal epithelial cells (Liu et al, 2006). AP-1 
functions as a regulator of several cellular processes including 
differentiation, apoptosis and inflammation.
The role of Evi-l in inflammation is not clear yet but both TGF-p and AP-1 
pathways are known to crosstalk with numerous pathways involved in 
inflammation and immune defence, and it remains to be determined how the 
Evi-1A2288T mutation leads to CSOM observed in Jbo/+ mutants. 
Interestingly, the Minnesota COME/RAOM Family Study cohort failed to 
show association of EVI-1 with OM (Rye et al, 2011a; Sale et al, 2008). 
However, no study on association of EVI-1 with alternative OM phenotypes
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such as CSOM has been performed yet and such studies may reveal an 
association (Rye et al, 201 la).
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Figure 2.4- Inflamed middle ear in Jbo/+ mice is hypoxic
Adapted from(Cheeseman et al, 2011). Panel A displays Jbo/+ mice labeled 
with pimonidazole (PIMO), arrows indicating hypoxia in epithelium (ep), 
macrophages (mo), exudate (ex), temporomandibular bone (tm) and 
thickened mucosa (m). Panel B shows thin mucosa and absence o f 
inflammation in Junbo WT mouse. Panel C is an unlabelled Jbo/+ mouse. 
Panel D shows hypoxic foamy macrophages in Jbo/+ ear exudates. Scale is 
50pm.
54
NH2 Repressor domain Acidic domain
L z B l^ 2 |3 |4 l5 l6 l7 l
COOH
M. musculus 
Junbo 
R. norvegicus 
H. sapiens 
D. rerio 
F. rubrides 
D. melanogaster 
C. elegans
CDRSFSISSNLQRHVRNIH 
CDRSFSISSNLQRHVRIIH 
CDRSFSISSNLQRHVRNIH 
CDRSFSISSNLQRHVRNIH 
CDRSFSISSNLQRHIRNIH 
CDRSFSISSNLQRHIRNIH 
CDRAF S IS  SNLQRHVRNIH 
CERSFSISSNLQRHVRNIH
Figure 2,5- Evi-1 mutation in Junbo mice
Adapted from (Parkinson et al, 2006). Picture shows schematic 
representation of Evi-1 peptide with the 2 zinc finger domains separated by 
a repressor domain. Expanded peptide sequence shows the high degree of 
conservation at the region of mutated domain
Hypoxia and Inflammation
All mammalian cells have an intrinsic ability to sense and adapt to tissue
oxygen levels and hypoxia. Hypoxia leads to activation of the hypoxia
inducible factor (HIF) pathway which induces genes involved in restoring
blood supply, nutrients, and energy production to maintain tissue
homeostasis. HIF-1 is a transcription factor and global regulator of oxygen
homeostasis (Semenza & Wang, 1992). Target hypoxia-responsive genes
are involved in various cellular processes such as anaerobic respiration
ascribed to the up-regulation of expression of glucose transporters (GLUT),
angiogenesis by activating expression of pro-angiogenic factors such as
VEGF, cell proliferation and apoptosis amongst others. HIF dependent
hypoxia responsive gene expression also plays a key role in innate immunity
and inflammation due to extensive cross talk between the HIF pathway and
inflammatory pathways via NF-kB (Rius et al, 2008). Hypoxic responses in
inflamed micro-environments is favourable for microbial clearance but can
also exacerbate inflammatory damage depending on degree and duration of
hypoxia. Pathologic hypoxia is found at inflammatory sites including
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inflamed middle ear in Jbo/+ and Jf/+ where it creates a unique 
microenvironment condition affecting the function of cells and delivering 
important inflammatory signals (Cheeseman et al, 2011).
1.4.1- Regulation of HIF-la and its activity
HIF-la is the oxygen sensitive subunit of hetero-dimer HIF which consists 
of unstable HIF-la subunit and ubiquitously expressed stable p aryl 
hydrocarbon translocator subunit HIF-lp (Jaakkola et al, 2001; Wang et al, 
1995).
1.4.1.1- HIF-la regulation by O2 availability
HIF-la is known to activate > 1 0 0  hypoxia-responsive genes which are
involved in various cellular processes (Semenza & Wang, 1992). Gene
expression studies on WT vs Hif-la knockout embryonic tissues have
revealed 234 genes which are affected by loss of Hif-la (Vengellur et al,
2003). Activation of these genes is dependent upon stabilization of oxygen
sensitive HIF-la subunit, making it a master regulator of hypoxic response.
HIF-la is a member of Per-ARNT-Sim domain family (PAS domain
family) (Bracken et al, 2003; Weidemann & Johnson, 2008). It is a basic
helix loop helix transcription factor. Regulation of HIF-la subunit occurs at
both protein and functional level through action of prolyl hydroxylase and
prolyl asparaginyl enzymes (Lando et al, 2002; Masson et al, 2001). Under
normoxic conditions, prolyl residues Pro402 and Pro 564 in the N-terminal
domain of HIF-la are hydroxylated by iron(II) and 2-oxoglutarate
dependent prolyl hydroxylase enzymes (termed PHD1, PHD2, PHD3)
(Epstein et al, 2001; Masson et al, 2001). This enables its binding to von
Hippel-Lindau (VHL) to form VHL-E3-ubiqutin ligase complex, which then
initiates HIF-la ubiquitination and degradation by the proteosome (Ivan et
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al, 2001; Jaakkola et al, 2001; Maxwell et al, 1999). During hypoxia, 
decreased hydroxylase activity leads to HIF-a subunit stabilization and 
nuclear translocation where it forms a complex with HIF-lp and its 
cofactors CREB binding protein (CBP) and p300. Inside the nucleus, the 
complex binds to the HIF-DNA consensus-binding sites or HREs of genes 
to drive an increased transcription of HIF-la target genes (Lando et al, 
2002; Masson et al, 2001).
In addition to the protein abundance, the transcriptional or functional 
activity of H if-la gene is also oxygen regulated (Jiang et al, 1997; Pugh et 
al, 1997). Under normoxia, Proline residue 564 of H if-la is hydroxylated by 
iron(II) and 2-oxoglutarate dependent dioxygenase, Factor Inhibiting HIF 
(FIH) binding to the proximal C-terminal transactivation domain (CAD) of 
HIF (Mahon et al, 2001) (Lando et al, 2002). This prevents the binding of 
HIF-la to p300 which is a co-activator of HIF complex (Lando et al, 2002; 
Mahon et al, 2001), thereby affecting its downstream gene activation (Sang 
et al, 2002).
1.4.1.2- H if-la regulation via PHD regulation
Although oxygen is the main determinant of HIF-la via PHD activity, the 
PHD enzyme is also sensitive to redox balances, iron homeostasis and 
ascorbate (Epstein et al, 2001; Ivan et al, 2002). HIF-la is also known to 
negatively regulate its abundance by upregulating PHD2 and PHDS gene 
transcription in hypoxia (DAngelo et al, 2003b; Metzen et al, 2005). 
Increased PHD abundance may compensate for reduced hydroxylase 
activity and prepare cells to clear HIF-la quickly once they are exposed to 
normoxic conditions again (DAngelo et al, 2003a).
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1.4.1.3- O2 independent H if-la regulation
Hif-la expression can be up-regulated by many growth factor and cytokines
such as TNF-a, IL-1 p. Nitric oxide (NO) produced by activated
macrophages is one such mediator (Thomas et al, 2008). Exogenous
addition of NO in normoxia is known to stabilize HIF-la protein and
transactivate HLF-1 under normoxic conditions. It does that by co-ordinating
ferrous iron and decreasing PHD activity (Brune & Zhou, 2007). TGF-P is
also known to stabilize H if-la via Smad3 inhibition of Phd2 (McMahon et
al, 2006). LPS in the bacterial cell wall also stimulates HIF-la protein
accumulation and mRNA activation of HIF-la  (Blouin et al, 2004; Frede et
al, 2006). LPS can increase HIF-la expression in a time and dose dependent
manner. HIF-la mRNA activation is provoked by LPS activation of p42/44
MAPK and NF-kB (Frede et al, 2006). It induces an active form of HIF-1
because the complex can bind HIF-1 specific DNA sequence and activates
HIF-1 specific reporter under those conditions. LPS is a strong stimulator of
gene expression in macrophages (Sweet & Hume, 1996). LPS has been
shown to increase HIF-la mRNA levels in a macrophage derived cell line
(Blouin et al, 2004). Activation of the PI3K pathway would increase
translation of already elevated mRNA leading to increase HIF-la protein
level in non-hypoxic cells (Laughner et al, 2001; Treins et al, 2002). This is
in contrast with hypoxic induction of HIF-la which relies on stabilization of
Hif-la protein. Also LPS-induced ROS generation is known to promote
HIF-la protein accumulation in macrophages (Mi et al, 2008; Nishi et al,
2008). Early in inflammation, macrophages and NLs produce a reactive
oxygen species (ROS) burst which then proceeds in an uncontrolled manner
and can limit antioxidants such as ascorbate which are essential for PHD
function. ROS burst can therefore result in HIF-la accumulation by limiting
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PHD function (Kaelin & Ratcliffe, 2008). Cytokines such as TNF-a and IL- 
ip released during inflammation can further activate HIF-la (Hellwig- 
Burgel et al, 1999). TNF-a activates HIF-1 by ROS, NO production, PI3K 
and/or NF-kB activation (Brune & Zhou, 2007).
It has been proposed that prolyl hydroxylation of hcBkinase-P and IicBa by 
PHD and FIH increases NF-kB activity in mice (Kaelin & Ratcliffe, 2008). 
NF-kB activity is required for HIF-la protein accumulation and is a 
transcriptional activator of HIF-la as well as a transcriptional factor for 
inflammatory cytokines (Rius et al, 2008).
1.4.2- HIF pathway and its role in inflammation
Inflammation is a complex biological response involving many different 
pathways and there is growing evidence linking it to the HIF activation as 
seen by its crosstalk with LPS and NF-kB in the section above. The 
mechanisms underlying this cross-talk still need to be explored. In an 
inflamed tissue, the oxygen concentration is often low (Sitkovsky & 
Lukashev, 2005) which leads to accumulation of HIF-la protein (Albina et 
al, 2001; Elson et al, 2000; Hollander et al, 2001). Areas of hypoxia are 
present in inflamed tissues due to an infiltration and accumulation of 
inflammatory cells. Hypoxia is also a key feature of OM observed in Jbo/+ 
and Jf/+ middle ear. This is also why hypoxia is a physiological stimulus 
and a micro-environmental feature in a range of chronic inflammatory 
conditions (Oliver et al, 2009). Hypoxia is also a feature of bacterial 
infection in tissues due to increase in oxygen consumption by proliferating 
bacteria at the site. As a result inflammatory cells like the macrophages are 
likely to experience hypoxia at the site of bacterial infection and 
inflammation. This is why macrophages need to operate across a broad
range of oxygen tensions which could be important in modulating their 
behaviour in response to hypoxia. Inflammatory cells respond rapidly to 
hypoxia with altered gene expression, via upregulation of hypoxia inducible 
factors and HIF responsive genes (Burke et al, 2003; Talks et al, 2000).
1.4.3- Hypoxia regulates inflammatory cell functions
Evidence that immune cells respond to hypoxia was illustrated when it was 
shown that hypoxia treated macrophages are more effective at promoting 
angiogenesis (Knighton et al, 1983). Hypoxic macrophages express 
increased levels of pro-angiogenic and HIF responsive genes such as Vegf 
(Harmey et al, 1998; Lewis et al, 2000). Deletion of Hif-la from myeloid 
cells in mice also showed a profound impairment in their inflammatory 
response (Cramer et al, 2003). HIF-1 a protein expression has been seen in 
macrophage from inflamed rheumatoid synovial tissue and absent in healthy 
synovial tissue (Hollander et al, 2001). A number of in vitro studies have 
documented the changes in gene expression of macrophages under hypoxic 
conditions. Many of these genes are required for tissue revascularization, 
macrophage survival, recruitment, fighting infection and activation of 
macrophage and other inflammatory cells (Lewis & Murdoch, 2005). In 
fact, HIF pathways play an important role in macrophage response to 
bacterial infection and as described previously do not necessarily need 
activation by hypoxia. Apart from activating HIF-la responsive genes, 
hypoxia can also activate genes independent of HIF. For example CXCL8 
expression is increased under hypoxia because of increase in intracellular 
H2O2 . H2O2 increases binding of AP-1 to CXCL8 promoter and therefore, 
increases its expression which suggests a role of AP-1 as another hypoxia 
regulated transcriptional factor (Hirani et al, 2001). Hypoxia also
upregulates NF-kB activating transcription factor-4 and Egr-1 in human and 
murine macrophages in vitro (Chandel et al, 2000; Elbarghati et al, 2008; 
Zampetaki et al, 2004).
1.4.4- HIF pathway and innate immunity
HIF-1 activation has been observed during inflammation with upregulation 
of classical hypoxia induced genes such as Vegf and Glutl (Elson et al,
2000). Functional studies using conditional HIF-la'7' knockout in myeloid 
cells have also suggested a close connection between HIF-la pathway and 
immunity (Cramer et al, 2003). Peritoneal macrophages and NLs isolated 
from myeloid HIF-la'7' mice have about 80% reduction in ATP levels and 
diminished expression of glycolytic enzymes such as Glutl protein. LPS 
stimulation is known to decrease cellular ATP in macrophages which 
suggests a high energy demand during macrophage activation (Lall et al, 
2008). H if-la  '7' myeloid cells (monocytes, macrophages and NLs) may 
have a defect in energy production in macrophages and NLs which can 
affect their activation (Cramer et al, 2003). Deletion of H if-la in 
macrophages also attenuates iNOS induction after bacterial stimulation 
(Peyssonnaux et al, 2005) as iNOS promoter which contains inflammation 
related transcription site also contains an HRE site, making it a key hypoxia 
induced gene which links HIF pathway to inflammation (Melillo et al, 
1995). During inflammation HIF-1 is also critically involved in iNOS 
upregulation while reduced NO production in H if-la  cells impairs 
macrophage function and TNF-a production (Peyssonnaux et al, 2005). 
HIF-la reduces Staphylococcus aureus infection in mice (Zinkemagel et al,
2008). Hypoxia has also shown the ability to increase the ability of 
macrophages to phagocytose bacteria (Anand et al, 2007). In vivo and in
vitro studies on mouse macrophages have revealed that HIF-1 a increases 
their phagocytic capacity. This has been associated with increased 
p38MAPK phosphorylation (Anand et al, 2007). NLs display a key role in 
innate immune response with NL recruitment being a key characteristic of 
initial inflammatory phase (Stewart et al, 1981). When NLs requirement is 
higher, apoptosis is delayed, which increases the lifespan of inflammatory 
NLs. Hypoxic exposure has also shown to delay NL apoptosis in vivo 
(Mecklenburgh 2002). Reduced survival was also observed in hypoxic NLs 
from mice with Hif-la  deletion in myeloid cells (Walmsley et al, 2005). 
This survival is dependent on NF-kB and associated with Hif-la  dependent 
increase in NF-kB p65 & IKK-a mRNA levels. This links HIF pathways to 
NF-kB. HIF dependent NF-kB activation in macrophages releases 
inflammatory protein-11-1 p, which protects NLs from apoptosis (Walmsley 
et al, 2005). This can have consequences during inflammation as uptake of 
apoptotic NLs results in alternative activation of macrophages and release of 
anti-inflammatory cytokines such as TGF-p (Mosser & Edwards, 2008). 
Enhanced NL survival would disturb the healing processes triggered by 
TGF-p. The role of H if-la in delaying NLs apoptosis was further supported 
by evidence from a germline mutation in the Von Hippel-Lindau gene (vhl) 
gene. As mentioned above, Vhl plays a key role in degradation of H if-la 
protein in normoxia. A germline mutation in vhl resulted in enhanced NLs 
survival (Walmsley et al, 2006). All this suggests that HIF activation is 
important for delaying NLs apoptosis in hypoxia.
Molecular mechanisms underlying cross talk between HIF and 
inflammatory pathways are complex and partially understood but studies 
have established a link between the two via NF-kB pathway.
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Macrophages & neutrophils -The two edged sword of 
inflammation
Inflammation is a formidable ally in the body’s battle against infection and 
yet a fearsome foe if left unregulated. The initial response to infection or 
injury is orchestrated by the innate immune system and is usually resolved 
within hours and first there is an influx of NLs at the site of inflammation 
followed by monocytes. Other cells such as eosinophils, basophils, natural 
killer (NK) cells are also involved in innate immunity but NLs and 
macrophages are the key regulators of the inflammatory response and the 
main phagocytic cells.
1.5.1- Neutrophils
NLs form the majority of leukocytes and are also known as 
polymorphonuclear leukocytes (PMNs). NLs are granulocytic and actively 
phagocytic cells that produce large quantities of reactive oxygen species and 
proteolytic enzymes which are cytotoxic to microbes and participate in 
inflammatory cell recruitment (Moraes et al, 2006). As they protect against 
bacteria, a sufficient amount of NLs is essential for clearing infection. NLs 
express combined markers of CD l ib  (receptor for the inactivated form of 
complement C3) and Gr-1 antigen; which allows their definitive detection 
by FACS (Goni et al, 2002). This is why these markers in combination were 
used as NLs markers for FACS throughout this thesis.
1.5.2- Macrophages
Macrophages are mononuclear phagocytes which are derived from
circulating precursors of myeloid origin. These precursors are known as
monocytes and are present in blood, bone marrow (BM), spleen, liver etc.
Monocytes are different from macrophages in that monocytes lack
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characteristic phagocytic capacity of macrophages. These circulating 
monocytes migrate to different tissues and receive macrophage 
differentiating cues from NLs or disturbed tissue resulting in their 
differentiation into macrophages (Laskin et al, 2011). Some macrophages 
become fixed macrophages in tissues whereas others are motile and free 
macrophages and travel via ameboid movement through tissues. Monocytes 
and macrophages are highly phagocytic and characterized by large cell size 
(11-14 pm diameter) with indented nuclei and surface expression of CD l ib  
and F4/80(Henkel et al, 1999). Monocytes and macrophages are recruited 
more slowly to the site of inflammation than NLs but are essential drivers of 
inflammation. Chronic inflammation is characterized by prolonged 
persistence of macrophages at the site of inflammation. An inflammatory 
response is typically triggered by activation of resident macrophages by 
pathogen-associated molecular patterns (PAMPs) interaction with TLRs 
leading to release of pro-inflammatory cytokines which further sets off a 
cascade of release of inflammatory cell recruiting cytokines and chemokines 
which drive the inflammation. Acute inflammation commences with NL 
recruitment followed by recruitment of monocytes which differentiate into 
macrophages at the site of inflammation.
1.5.3- Resolution of inflammation
Acute inflammation is characterized by the increased permeability of the 
vascular endothelium, vasodilation and expression of adhesion molecules on 
endothelial cells lining the blood vessels. Vasodilation during an 
inflammatory response aids in recruitment of inflammatory cells to the site 
of inflammation by supplying more blood to the site of inflammation. These 
re-circulating inflammatory cells bind to the leukocyte cell adhesion
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molecules (CAMs) expressed by endothelial cells enabling them to 
extravasate into the inflamed tissues. Resolution of inflammation requires 
termination of inflammatory cell recruitment and removal of recruited cells 
in a controlled manner through programmed cell death or apoptosis 
(Porcheray et al, 2005; Savill, 1997a; Savill et al, 1989; Serhan & Savill,
2005). Failure in removal of apoptotic cells may result in necrosis of those 
cells leading to consequences of inflammatory kind which is characterized 
by persistent inflammation (Fadok et al, 2001).
1.5.3.1- Role of neutrophils in resolution of inflammation
As outlined above, the inflammatory cells initially recruited to inflamed 
tissue are NLs. NL infiltration peaks within the first 6 h of inflammatory 
response, with an increased NLs production in the BM to meet the surging 
need (Rankin, 2010; Summers et al, 2010). Effective elimination of NLs 
present at the inflamed/injured tissue is a perquisite for resolution of 
inflammatory response (Savill, 1997a). NLs are recruited from the 
circulation to the site of injury or infection by acute inflammatory 
chemokines such as CXCL1 (also known as growth related protein a or 
GRO a) and CCL2 (also known as monocyte chemoattractant protein-1 or 
MCP-1). NLs are recruited after resident macrophage activation but they are 
relatively short-lived and their recruitment is followed by recruitment of 
monocytes during the course of an inflammatory response. Activated NLs 
phagocytose bacteria or apoptotic cells at the site of inflammation and 
undergo apoptosis to release inflammatory mediators such as CCL3 also 
known as macrophage inflammatory protein a (MIP-la) (Kasama et al, 
1994; Kasama et al, 1993) and chemokines such as CXCL2 (also known as 
MEP-2) (Bennouna et al, 2003; Chertov et al, 1997) which attract
macrophages to the site of inflammation. NLs also secrete myeloperoxidase
(MPO) (Lefkowitz & Lefkowitz, 2001) which is taken up by macrophages
expressing macrophage mannose receptors (MMRs) (Shepherd & Hoidal,
1990). This interaction leads to the release of macrophage secreted
inflammatory mediators such as reactive oxygen species (ROS), TNF-a, IL-
1, IL-6, and Granulocyte/macrophage colony stimulating factor (GM-CSF)
from macrophages (Lefkowitz et al, 2000; Lefkowitz et al, 1996; Lincoln et
al, 1995). Cytokines produced by macrophages also prolong NLs life span
from 6-12 h to 24-48 h (Hume et al, 2002; Lee et al, 1993; Takano et al,
2009; Yamashiro et al, 2001). Activation of master regulator of
inflammation, transcription factor NF-kB by the release of cytokines such as
TNF-a from macrophages can slow down NLs apoptosis which can result in
chronic inflammation if left unregulated (Ward et al, 1999). However,
release of ‘death cytokines’ such as Fas by macrophages can over ride this
effect and trigger NLs apoptosis in neighboring NLs (Brown & Savill,
1999). Other micro-environmental conditions such as hypoxia have also
been shown to prolong NLs survival (Cramer & Johnson, 2003; Walmsley
et al, 2005). Activation of the macrophages by cytokines released by NLs
sequentially releases more pro-inflammatory mediators and NL and
macrophage attracting chemokines to complete a vicious circle by further
recruiting and activating inflammatory cells. This is why, survival of NLs if
left unregulated, or failure of macrophages to clear apoptotic NLs can
prolong inflammation and result in a chronic inflammatory condition.
Influx of NLs is followed by monocyte recruitment during the course of
inflammation. In inflammation, programmed cell death or apoptosis
especially of NLs which are predisposed to apoptosis prevents cytotoxic
content of NL granules to release in surroundings. Apoptosis involves
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phagocytic removal of damaged or dying cells under controlled conditions. 
Removal of cells from the site of inflammation is mediated via apoptosis 
and rapid phagocytosis after recognition of apoptotic cell associated 
molecular patterns (ACAMP) by phagocytes such as macrophages (Devitt 
& Marshall, 2011). Failure to achieve this step or a dysfunctional apoptosis 
or phagocytosis at the site of inflammation can result in non-resolving 
inflammation.
1.5.3.2- The roles of macrophages in the resolution of inflammation
As outlined above, the apoptosis of NLs causes recognition and clearance 
by macrophages (Savill, 1997a; Savill, 1997b; Serhan & Savill, 2005; 
Zhang & Mosser, 2008). In addition to clearing the necrotic or apoptotic 
NLs, the process of phagocytosis serves dual purpose by initiating the signal 
to macrophages to begin the process of exit from inflamed local tissue site 
to the draining lymphatics (Bellingan et al, 1996; Savill, 2001). Uptake of 
apoptotic cells also stimulates macrophages to release anti-inflammatory 
mediators such as TGF-pl and IL-10 (Fadok et al, 1998a; Fadok et al, 
1998b; Huynh et al, 2002; Lucas et al, 2003; Voll et al, 1997) which inhibit 
inflammatory macrophage activation (Stuart et al, 2002). If apoptotic cells 
are not ingested rapidly, they progress undergo necrosis and the cell debris 
released after necrosis contains macrophage activating proteins such as heat- 
shock proteins (Zhang & Mosser, 2008). These proteins and cytokines have 
a dramatic effect on the physiology of macrophages, facilitating a shift 
towards the production of pro-inflammatory cytokines. This results in 
augmentation of inflammation.
Macrophages also release a plethora of T-cell activators and inflammatory 
mediators as well as act as antigen presenting cells to T lymphocytes
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(Laskin, 2009; Laskin et al, 2011). Additionally, recent publications suggest 
that along with driving inflammatory processes, macrophages also play an 
essential role in suppression of inflammation and wound repair (Laskin, 
2009; Laskin et al, 2011). This suggests macrophages act as quintessential 
double agents- agents of defense and agents of destruction. They can both 
protect the host from pathogens as well as promote destructive chronic 
inflammation (Laskin, 2009; Laskin et al, 2011).
1.5.3.3- Different polarized states of macrophages-Ml & M2
Normally, in a resting state, macrophages are activated by a variety of 
stimuli in the course of an immune response. Microbial PAMPs, LPS, 
cytokines secreted from T helper (Th) cells (IFN-y) and NLs, and 
recognition of apoptotic cell associated molecular patterns (ACAMPS) on 
apoptotic cells can all serve as initial activating inflammatory activation or 
anti-inflammatory activation) stimulus for macrophages. Macrophages are 
phenotypically heterogeneous and engage in activities of almost opposing 
nature: pro-inflammation vs. anti-inflammation (Gordon, 2003; Stout & 
Suttles, 2004). The activities macrophages engage in are dependent on their 
activating signal(s). Macrophages can be classified broadly as classically 
activated (Ml) or alternatively activated (M2) macrophages on the basis of 
their function. Ml polarized macrophage populations up-regulate 
inflammation (Laskin, 2009; Martinez et al, 2008) while M2 polarized 
macrophages activate Th2 responses, down-regulate inflammation and 
initiate wound repair by releasing cytokines such as IL-4, IL-10 and IL-13 
(Gordon, 2003). In the course of an inflammatory response, macrophages 
arrive within 5-6 h after the inflammation begins; these macrophages are 
Ml polarized, classically activated cells recruited by cytokines released by
NLs and resident macrophages. PAMPs like LPS, endogenous danger 
signals such as heat-shock proteins or cytokines like IFN-y or TNF-a act as 
ligands for Toll-like receptors (TLRs), intracellular pattem-recognition 
receptors (PRRs) and interleukin-1 receptor (IL-1R) present on the 
macrophage cell surface (Kono & Rock, 2008). The TLR family in 
particular plays a critical role in PAMP ligand detection and macrophage 
activation (Akira et al, 2006). Many of the afore-mentioned receptors utilize 
adaptor molecule MyD88 to activate NF-kB (Arancibia et al, 2007) (Chen et 
al, 2007). Phagocytosis of apoptotic cells by macrophages triggers 
production of anti-inflammatory mediators such as TGF-P (Arnold et al, 
2007). TGF-p is a potent suppressor of classically activated Ml 
macrophages (Tsunawaki et al, 1988) and a mediator of tissue repair. IL-10 
is another such suppressor of Ml macrophage activation released after 
phagocytosis of apoptotic cells (Mosser & Edwards, 2008). Members of 
scavenger receptor and C-lectin families also play an important role in 
microbial recognition and host inflammatory response regulation (Gordon, 
2002). Scavenger receptors such as SR-A, CD-36 recognize endogenous 
ligands such as ACAMPS and play a key role in phagocytosis of apoptotic 
cells (Savill et al, 2002). These receptors also mediate uptake of oxidized 
lipids and formation of foamy macrophages which are commonly associated 
with chronic inflammatory diseases such as atherosclerosis, chronic kidney 
disease, verruciform xanthema (Glass & Witztum, 2001; Vaziri & Norris, 
2011).
Activation of Ml macrophages triggers a panoply of genes induced by a
combination of transcription factors such as signal transducer and activator
of transcription-1 (STAT-1), NF-kB and mitogen activated protein kinases
(MAPK)(0'Shea & Murray, 2008). Classical activation of macrophages
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induces polarized Thl responses, production of ROS, reactive nitrogen 
species (RNS)and pro-inflammatory cytokines (IL-23, IL-12, IL-lp, TNF-a, 
IL-6) (Laskin et al, 2011; Mantovani et al, 2005; Mantovani et al, 2004). 
Activated Ml macrophages exhibit increased phagocytic activity and 
increased expression of class II MHC molecules. Pro-inflammatory and 
cytotoxic molecules are released by Ml macrophages including cytokines 
such as TNF-a, IL-1 and IL-6 which promote inflammation and induce 
apoptosis of NLs (Laskin et al, 2011). Activated macrophages also release 
chemokines, an important group of cytokines that recruit inflammatory cells 
to the site of injury. C-X-C chemokines promote NL inflammation by 
recruiting and activating NLs and C- C chemokines induce migration and 
activation of monocytes and migration of macrophages that exhibit anti­
inflammatory activity. M l macrophages also release inflammation inducing 
proteolytic enzymes such as matrix metalloproteinases (MMPs) which are 
basically enzymes involved in extracellular matrix degradation and 
angiogenesis (Laskin et al, 2011). ROS and RNS are also generated via 
enzyme catalyzed reactions by enzymes such as NADPH oxidase and NOS- 
2. NOS-2 is a key inflammatory enzyme that produces relatively long-lived 
cytotoxic oxidant peroxynitrite (Roberts et al, 2009). Expression of Nos-2 is 
upregulated in Ml macrophages (Edwards et al, 2006; Laskin, 2009; Zhang 
& Mosser, 2008). When generated in excess quantities, ROS and RNS 
species cause oxidative stress which leads to activation transcription factors 
NF-kB and AP-1 to further augment the inflammatory response (Laskin et 
al, 2011).
The activity of M l macrophages is balanced by M2 macrophages. M2
macrophages are induced by IL-4, IL-13, IL-10 and TGF-p and down
regulate inflammation but also promote Th2 response. Exposure of
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macrophages to TGF-P or the Th2 lymphokine IL-4 prevents polarization of 
macrophages into inflammatory M l phenotype (Duffield, 2003). As 
described previously, inflammatory cells at the site of inflammation may die 
by apoptosis. Macrophages limit inflammation by rapidly taking up 
apoptotic cells. If left uncleared these cells would undergo necrosis to 
induce pro-inflammatory Ml macrophages (Duffield, 2003; Savill, 1997b). 
When macrophages ingest apoptotic cells, they release anti-inflammatory 
mediators such as IL-10, prostaglandin 2 (PGE 2) or TGF-p. M2 
macrophages mediate their anti-inflammatory and angiogenic activities by 
further secreting IL-4, IL-10, IL-13, TGF-P, VEGF (Duffield, 2003; 
Martinez et al, 2006; Martinez et al, 2008). M2 macrophages show 
enhanced capacity of antigen presentation and uptake of cell debris and 
generate anti-inflammatory cytokines (Erwig et al, 1998; Goerdt et al, 1999; 
Stein et al, 1992). Resolution of inflammation involves release of anti­
inflammatory mediators such as TGF-p, IL-10 and clearance of classically 
activated macrophages from site of injury which are brought into effect by 
alternatively activated M2 macrophages. M2 macrophages are therefore 
essential for resolution of inflammation and tissue repair. M2 macrophages 
are further sub-grouped as M2a (activated by IL-4 and IL-13), M2b 
(activated by immune complexes in combination with IL-ip and LPS) while 
M2c (activated by IL-10, TGF-p or glucocorticosteroids) (Laskin et al, 
2011). M2 macrophages are important mediators of angiogenesis as well as 
play key role in regulating Th2 cell functioning (Laskin et al, 2011).
In summary, macrophages responding to tissue injury are activated by 
inflammatory signals in their microenvironment and develop into classically 
activated Ml macrophages which release mediators important in host
defense. Phagocytosis of apoptotic cells and release of TGF-p, IL-10, IL-4
71
induces alternatively activated M2 macrophages which generate products 
that downregulate inflammation. An imbalance in the activity of these 
macrophage populations can lead to excessive production of pro- 
inflammatory mediators or subnormal anti-inflammatory mediator 
production causing inflammation. Differences in gene expression profiles of 
Ml and M2 macrophages are exemplified in gene array studies showing that 
IL-10 repressed 63 and further enhanced 15 of 259 genes induced by LPS in 
macrophages (Lang et al, 2002). Microarray expression studies have also 
indicated phenotypic heterogeneity of macrophages (Williams et al, 2002) 
(Wells et al, 2003). However, it should be noted that classification of 
macrophages Ml and M2 polarized states is an something of an 
oversimplification and macrophage populations can exhibit plasticity, 
heterogeneity and modulate their responses according to changing micro­
environment (Martinez et al, 2008; Porcheray et al, 2005; Stout & Suttles,
2004). The same macrophage may take part in initial pro-inflammatory and 
cytotoxic reactions and then later participate in resolution of inflammation 
and wound healing (Martinez et al, 2008; Mosser & Edwards, 2008; 
Porcheray et al, 2005).
Dysregulation in the function of macrophages can have detrimental effects. 
Hyper-responsive M l macrophages and sub-responsive M2 macrophages 
can cause tissue damage and persistent inflammation while overactive 
activation of M2 macrophages can predispose the host to infection making 
macrophages a double edged sword when it comes to chronic inflammation.
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Table 2.2- Stimuli for classically and alternatively activated 
macrophages
W<f) activation Stimulus
Classical IFN-y plus pro-inflammatory cytokines
Bacterial lipoproteins (TLRs)
Bacterial DNA (TLRs)
Parasitic proteins/carbohydrates (TLRs)
Opsonized particles (FcR, CR)
Hypoxia
Abnormal matrix
Alternative IL-4
IL-10
IL-13
TGF -p
Glucocorticoids
Adapted from (Duffield, 2003). Terms in parentheses represents the stimuli 
through which the receptors act
Macrophages
r
Classical activation 
IFNy.LPS.TNFa
Alternative a ctlvatlon 
IL-4, IL-13, M O , TGFp
Host defense
ROS.RNSJNFd, 
IL-1,IL-12, IL-23, 
chemokines
Cytotoxic 
Pro-inflammatory chemokines 
Killing cells by apoptotsis 
Phagocytosis
AnU-tnflamnrsafory 
W ound repair
IL-10, IL-4, IL-13 
TGFfcVEGF.EGF
Matrix sy nthesis 
Anti-inflammatory chemokines 
Angiogenesis 
Phagocytosis
Figure 2.6- Classically and alternatively activated M l and M2 
macrophages.
Adapted from (Duffield, 2003; Laskin et al, 2011). Abbreviations: IFN- 
y:Interferon-y, IL:Interkeukin, RNSrReactive nitrogen species, 
ROS:Reactive oxygen species, VEGF: Vascular endothelial growth factor
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1.5.4- Foamy macrophages and inflammation
As outlined above, dysregulation of macrophages or their function can have
detrimental effects on inflammatory cascade. Both M l and M2
macrophages are capable of lipid accumulation (Peiser & Gordon, 2001; van
Tits et al, 2011). Such cells are termed as foamy macrophages. Foamy
macrophages are formed by uptake of oxidized low-density lipoporotein
(ox-LDL) and subsequent accumulation of cholestrol esters and oxysterols
which gives these macrophages a characteristic foamy appearance (Brown
et al, 2000; Heinecke et al, 1991). Ox-LDL uptake by macrophages is
known to affect their transcriptional profile (Ghisletti et al, 2007; Janowski
et al, 1999). Foamy macrophages are known to be associated in
pathogenesis of chronic inflammatory diseases such as arthesclerosis and
colitis (Jozefczuk & Wozniewicz, 2011; Steinberg, 1997a; Steinberg,
1997b; Steinberg, 2009). Foamy macrophages are also associated with
Jbo/+ ear exudates (Cheeseman et al, 2011; Parkinson et al, 2006).
LDL particles are composed of cholesterol, triacylglycerides and
phospholipids (Steinberg, 2002). LDL particles can undergo oxidation by
various free radical generating enzymes such as lipid peroxidising enzyme
lipoxygenase (LOX), Myeloperoxidase (MPO) and nitric oxide mechanism
(Yoshida & Kisugi, 2010). ROS and RNS including superoxide anions,
hydrogen peroxide, hydroxyl radicals and nitric oxide are produced in large
quantities by activated macrophages during an acute inflammatory response
and also oxidize LDL particles. Nitric oxide reacts rapidly with superoxide
anion to form another cytotoxic oxidant peroxynitrite which can oxidize
LDL (Roberts et al., 2009). Free radical mediated oxidation of LDL
particles or retained cholesterol leads to formation of ox-LDL and
oxysterols respectively (Roberts et al., 2009). Among oxidative agents
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present in ox-LDL, a class of oxidized lipids, i.e., oxysterols, which are key 
modulators of gene expression in vascular macrophages and endothelial 
cells. Oxysterols are bioactive lipids which act as a regulator of lipid 
metabolism, inflammation and as toxic factors (Shibata & Glass, 2010). 
After the uptake and breakdown of Ox-LDL, most of the phospholipids and 
triacylglycerides are metabolized but retain oxysterols (Galkina & Ley,
2009). Oxidized lipids decompose to generate free aldehydes and ketones 
which can modify proteins, which is why Ox-LDL is scavenged avidly and 
ingested by macrophages via PRRs such as LDL receptors and scavenger 
receptors. LDL is internalised by receptor mediated process through 
pinocytosis and LDL receptors, or in the oxidized form via scavenger 
receptors. Expression of LDL receptors is feedback inhibited by the 
cholesterol, which accumulates inside the cell, via sterol regulatory element 
binding protein (SREBP). However, continued oxidation of LDL can cause 
a loss of recognition by LDL receptor and a shift in recognition by 
scavenger receptors which are further up-regulated by uptake of Ox- 
LDL(Brown & Goldstein, 1990; Yoshida et al, 1998). This increases 
accumulation of Ox-LDL components in macrophages and formation of 
foamy cells. Hypoxia increases uptake of LDL (Hulten & Levin, 2009). 
Hypoxia induced activation of macrophages produces reactive oxygen 
species which causes oxidation of LDL and cholesterol (Rydberg et al, 
2004; Rydberg et al, 2003). Macrophages are oxygen sensitive and 
efficiently adapt to conditions of hypoxia by producing ATP from anaerobic 
glycolysis (Leppanen et al, 2006). Extensive glycolysis also promotes 
lactate accumulation which decreases pH. Acidic pH increases Ox-LDL 
binding to proteoglycans and scavenger receptors which also results in an 
increased uptake of Ox-LDL by macrophages (Leppanen et al, 2006).
75
Exposure to Ox-LDL and Ox-LDL uptake has been shown to alter
macrophage responses. It is generally understood that foamy macrophages
lose ability to elicit an inflammatory response upon stimulation. However,
the literature is in disagreement on this point (Groeneweg et al, 2006;
Robbesyn et al, 2004). Lower Ox-LDL and minimally oxidized LDL
(mmOx-LDL) uptake concentration is thought to enhance inflammatory
response of macrophages while higher concentration can repress the
inflammatory response and induce apoptosis (Hundal et al, 2003; Robbesyn
et al, 2004). Ox-LDL pre-exposure of granulocyte/macrophage colony
stimulating factor (GM-CSF) differentiated BMDM has been shown to
reduce NFxp binding to target genes and decreases TNF-a and IL-lp  mRNA
and protein expression (Ohlsson et al, 1996). Pre-exposure to Ox-LDL also
attenuated expression of most LPS induced genes in Human acute
monocytic leukemia cell line (THP-1) derived macrophages (Mikita et al,
2001). On the other hand, an enhanced pro-inflammatory response to LPS in
Ox-LDL treated BMDM has also been demonstrated (Groeneweg et al.,
2006). Ox-LDL alters gene expression via ligand activated transcription
factors such as Liver X receptors (LXRs). LXRs are oxysterol responsive
proteins which act as nuclear transcriptional regulators. 25-
hydroxycholesterol and other oxysterols bind and activate LXRs (Ghisletti
et al, 2007; Janowski et al, 1999). Macrophage uptake of Ox-LDL results in
increased levels of intracellular oxysterol. Activation of LXRs by oxysterol
induces genes involved in cholesterol efflux such as ATP-binding cassette
transporter 1 (Abcal). LXRs suppress LDL uptake by induction of Inducible
degrader of LDL receptor (Idol) which ubiquitinates LDL receptor (Zelcer
et al, 2009). LXR also forms dimers with Retinoid X receptors (RXRs) to
regulate genes. Macrophages carry out several critical immune functions
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such as ridding body o f dead cells, mobilizing and recruiting other 
inflammatory cells, releasing cytokines that direct, amplify or control 
immune response. Altered control o f these processes in foam cells would 
have profound effect on their ability to clear inflammation or infection.
Free radicals
LDL re cep to r Leukocyte' -
iNOS, lipoxygenases, 
MPO, NADPH oxidase
OxLDL
Macrophage
ABCA1
Lactate
ROS
Foamy
M acrophage
Figure 2.7- Mechanism of LDL oxidation and foamy macrophage 
formation.
Adapted from (Hulten & Levin, 2009; van Tits et al, 2011; Yoshida & 
Kisugi, 2010). LDL is oxidized by enzyme generated free radicals released 
by NLs and macrophages under hypoxic or activated conditions. Oxidized 
LDL is taken up by macrophages through scavenger receptors leading to 
formation o f foamy macrophages. Hypoxia promotes formation o f foam 
cells by decreasing ATP levels and increasing lactate levels to enhance Ox- 
LDL uptake by scavenger receptors. Foamy macrophages can modulate the 
by foamy macrophage under different conditions. (A) Oxysterol component 
o f Ox-LDL inside foamy macrophages can modulate gene expression o f 
transcription factor PPARy which modulates gene expression o f scavenger 
receptors (B) and activates transcription factor LXR (C) to modulate gene 
expression o f some cholestrol efflux protein Abcal (D) which results in 
efflux o f cholesterol (E).
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The TGF-p Pathway
As mentioned above, chronic inflammation can be caused by excessive 
immune reaction or decreased immune suppression. TGF-P is a 25kD 
pleiotropic cytokine released by macrophages, T cells, tumour cells 
(Roberts, 1998) which plays an important role in immune system and 
wound repair (Li & Flavell, 2006; Wan & Flavell, 2007). TGF-p is also 
involved in angiogenesis, development, cell differentiation, cell 
proliferation and regulation of extracellular matrix components (ECM) 
(Chin et al, 1999; Dennler et al, 2002; Jeon et al, 2007; Massague et al, 
1990; Shi & Massague, 2003). Most importantly, TGF-P regulates immune 
system by suppressing Th cell differentiation, converting naive T cells into 
regulatory T cells (Tregs), inhibiting production of inflammatory cytokines, 
suppressing pro-inflammatory genes such as Nos2 and inducing alternative 
activation of anti-inflammatory M2 macrophages (Yoshimura, 2010). The 
importance of TGF-p in immune system regulation and the above outlined 
cellular processes is evident from the fact that T g f - f i l knockout mice 
develop severe autoimmunity that leads to death within 2 wk of birth 
(Kulkami & Karlsson, 1997; Kulkami et al, 2002). 
TGF-p has 3 isoforms of which TGF-pi is predominantly expressed in the 
mammalian immune system (Chang et al, 2002; Yoshimura et al, 2010). 
TGF-p is secreted as an inactive form, or latent TGF-p, which is activated 
by binding of latent TGF-p binding protein (LTBP) and in addition to other 
stimuli such as pH and ROS enable its proteolytic activation (Annes et al, 
2003; Taylor, 2009). TGF-P initiates its cellular actions by binding to TGF- 
P serine/threonine kinase receptors (TGF-pRs). The TGF-pR family consists
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of 2 groups TGF-PRI and TGF-PRII. TGF-P first binds to TGF-pRII on cell 
membrane; TGF-pRII then recruits and phospohrylates TGF-pRI to activate 
its kinase activity (Massague, 1998; Piek et al, 1999; Verrecchia & Mauviel,
2002). After ligand activation, TGF-pRI phosphorylates and activates Smad 
transcription factors (Massague, 2000; Massague & Chen, 2000; Massague 
& Wotton, 2000; Piek et al, 1999).
Smad transcription factors include receptor associated Smads (RSmads)- 
Smad2 and Smad3 which are recruited by TGF-pRI via Smad anchor for 
receptor activation (SARA) (Tsukazaki et al, 1998). These RSmads then 
form a heterodimer with common Smad or Smad4. This RSmad/Smad4 
complex then relocates to the nucleus (Kurisaki et al, 2001; Xiao et al,
2000) where it interacts with other cofactors and acts as a transcriptional 
activator for target genes involved in TGF-P signalling (Massague & Chen, 
2000; Massague & Wotton, 2000). TGF-p modulates expression of target 
genes such as TIMP-1, PAI-1, VEGF, which depend on Smad-interacting 
partners, co-activators or co-repressors (Jeon et al, 2007; Shi et al, 1998; 
Yoshimura, 2010). Smad proteins are essential for development and 
inflammation. Smad2'/' knockouts are embryonically lethal (Nomura & Li,
1998) but Smad3~/~ knockouts have normal embryonic and early post-natal 
development but exhibit chronic inflammation and infection in different 
organs but have accelerated wound healing (Ashcroft et al, 1999; Yang et al,
1999). Smad3 null mice also display increased proliferation and activation 
of T cells along with defects in macrophage and NL chemotaxis (Ashcroft et 
al, 1999; Yang et al, 1999).
In addition to the canonical Smad pathway, TGF-P signal also cross talks
with other pathways such as AP-1, HIF-1 pathway, TAK1-MKK4-JNK,
TAKl/MKK3.6-p38 and PI3K-Akt pathways (Derynck & Zhang, 2003;
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Sanchez-Elsner et al, 2001; Yu et al, 2002; Zhang, 2009). Interestingly, 
there is also extensive cross-talk between HIF-1 pathway and TGF-P via 
Smad3 mediated inhibition of PHD2 as well as Smad3 interaction with Hif- 
la  (McMahon et al, 2006; Sanchez-Elsner et al, 2001).
1.7- Concluding Remarks and Thesis Outline
The association of inflammatory gene polymorphisms with OM and the 
implication of host genetic factors in OM development have been 
demonstrated in various studies (Casselbrant et al., 1999; Kvaemer et 
al.,1999; 2002; Daly et al., 2004; Patel et al., 2006; Pettigrew et al., 2006, 
Wieresome et al., 2006; Sale & Marion 2008) (for details, see Section 
1.1.2). Evidence of chronicity and high OM incidence has also been seen in 
certain racial demographic groups and populations with congenital and 
inherited syndromes. In such a scenario, it is essential to identify OM 
causative genetic susceptibility factors for the development of effective 
therapeutic measures and management of OM, especially chronic OM.
Junbo and Jeff mice were generated at MRC Harwell through a large-scale 
ENU mutagenesis program and were the first spontaneous chronic OM 
models. Junbo and Jeff mice carry point mutations in the genes for Evi-1 
and F bxo ll, respectively. Both Jbo/+ and Jf/+ mice display a conductive 
deafness phenotype (Hardisty et al, 2003; Parkinson et al, 2006). Jbo/+ 
mice even develop OM even in germ-free conditions (unpublished data). 
However, the delay in age of OM onset in SPF facility compared to 
conventional facility in Junbo suggests that microbial load can accelerate 
OM progression (Parkinson et al, 2006). Pathologic hypoxia is a key feature 
of the middle ear in both genotypes (Cheeseman et al, 2011). Hypoxia 
results in the stabilisation of Hif-la protein and activation of the HIF
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signalling pathway which regulates angiogenesis and innate immune 
responses and is in turn regulated by inflammation at both transcriptional 
and translational levels (Blouin et al, 2004; Dehne & Brune, 2009; Rius et 
al, 2008). The mechanisms via which these mutations result in the 
development of spontaneous inflammation are yet to be elucidated and 
understood. The purpose of this thesis is to further understand and identify 
those mechanisms, genes and pathway that underlie chronic OM 
development.
It is plausible that Evi-1A2288T mutation and Fbxol 1AU72T mutation 
dysregulate HIF signalling to modify the expression profile of inflammatory 
genes to predispose the mutants to chronic OM. In addition, both Evi-1 and 
F bxoll may have a role in TGF-P, signalling. (Kurokawa et al, 1998b; 
Tateossian et al, 2009). TGF-P is crucial for cell development, cell 
differentiation, M2 macrophage activation, wound repair and the inhibition 
of inflammatory cytokine production. Moreover, TGF-P'7' and Smad3'A mice 
display chronic inflammation, which further suggests their crucial role in 
autoimmunity and inflammation. TGF-p also interacts with the HIF pathway 
and modulates the expression of target genes such as Timp-1, Pai-1 and 
Vegf, which also depend on Smad interacting partners such as Evi-1 protein 
for expression (Derynck & Zhang, 2003; Sanchez-Elsner et al, 2001; Yu et 
al, 2002; Zhang, 2009). Hence, a hypothesis was formed that the mutations 
in Jbo/+ and Jf/+ may impact TGF-p signalling and result in chronic 
inflammation (Figure 1.8).
Extensive cross-talk exists between TGF-P, HIF pathways and inflammatory
signalling pathways via their interaction with NF-kB and AP-1
transcriptional activators. Nasopharyngeal commensal bacteria also
accelerate OM onset in Jbo/+ mice. PAMPs from bacteria trigger
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inflammatory signalling pathways such as the NF-kB pathway. The 
dysregulated or abrogated HIF or TGF-P pathway can have a profound 
effect on NF-kB. Jbo/+ Evi-1 mutation might also affect its interaction 
with AP-1, as their interaction with the HIF pathway.
The aim of this thesis is to understand how the Evi-1 mutation and 
F bxollAl472T mutation might affect HIF, TGF-p pathways and effect innate 
immune system regulation. The main focus of this thesis is the impact of the 
mutation on HIF signalling and TGF-p signalling in Jbo/+ mice. J//+ mice 
were also studied. However, ./^ s tu d ie s  were limited to key experiments 
examining TGF-p due to time limitations. The principle approach was to 
use an in vitro system that used bone marrow derived macrophages 
(BMDM). NLs and foamy macrophages characterise Jbo/+ ear exudates but 
NLs are difficult to work with, as they have a short life span (~6 h). In vivo 
many of the NLs have undergone apoptosis. In contrast macrophages have a 
longer life span. Macrophages release NL-attracting chemokines and are 
key to initiating and resolving inflammation. The number of macrophages 
recoverable from the middle ear of Jbo/+ is too low to study in isolation. 
This is why an in vivo to in vitro model system was developed using 
BMDM. BMDM provides a large number of defined cell phenotypes, which 
could be challenged or activated by treatments lasting up to 72 h as the 
hypoxia in middle ear must be prevalent over long duration. Both hypoxia 
and TGF-p signalling has been studied extensively using a BMDM in vitro 
model system. The use of BMDM in vitro model has enabled the 
researchers to build up the complexity using a combination of hypoxia, 
TGF-p, LPS and oxysterol challenges to investigate chronic inflammatory 
conditions such as atherosclerosis, In this thesis have used this system to
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model the complex micro-environment o f the inflamed middle ear in Jbo/+ 
and Jf/+ mice.
CYTOPLASM
NUCLEUS
TGF-pRII. I
Sm.i
Hypoxia J l if - la  
Nonnoxia
Hif-la
b xo ll
Figure 2.8- Diagrammatic representation of hypothesis
Evi-1A2288T mutation in Jbo/+ mice dysregulates TGF-p and HIF signalling 
Fbxol 1A[472T mutation in Jf/+ mice dysregulates TGF- p signalling via p53 
and Smad2
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Chapter 2
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3.Materials and methods
2.1- Animal Husbandry
The founder mice carrying the Jbo/+ and Jf/+ mutation were generated in a 
large-scale ENU mutagenesis program at Harwell, United Kingdom 
(Hardisty-Hughes et al, 2006; Hardisty et al, 2003; Parkinson et al, 2006). 
Jbo/+ mice are now congenic on C3H/HeH background. Jeff mice are 
maintained on a mixed C57BL/6J C3H/HeH background. Junbo and Jeff 
mice were maintained in a high-health-status specific pathogen free (SPF) 
unit in which all FELASA-listed pathogens have been excluded. Mice were 
housed in individually ventilated racks (Techniplast UK Ltd.) containing 
grade 6 sawdust bedding with exposure to a 12 hour light/dark cycle at 
21±2°C and 55±10% relative humidity. Mice were supplied with irradiated 
mouse diet (Special Diets Services, UK) and water. All animal procedures 
were conducted according to the appropriate Home Office Project and 
Personal licenses and under the guidance issued by the Medical Research 
Council in ‘Responsibility in the Use of Animals for Medical Research’ 
(July 2003).
2.2- Genotyping
2.2.1-Genotyping using pyrosequencing
Original genotyping in the beginning of this project was carried out from 
DNA extracted from ear clips using Qiagen DNeasy Blood & Tissue Kit as 
per manufacturer’s instructions. Ear clips were incubated at 56° C overnight 
after addition of 180 pi lysis buffer and 20pl proteinase K. Final DNA 
elution was performed using 100 pi elution buffer. PCR (Figure 2.1) was
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performed and SNP based detection of Jbo/+ mutation on exon 9 of Evi-1 
was detected by pyrosequencing. Pyrosequencing reaction involves a 
standard PCR using a biotinylated forward primer, a normal reverse primer 
and DNA extracted from ear clips. The internal sequencing primer, purified 
PCR products and Qiagen pyrosequencing reaction mix were used to run the 
pyrosequencing reaction using Qiagen Biotage PSQ HS 96A 
pyrosequencing machine as per manufacturer’s instructions.
Pyrosequencing primers for Jbo/+ sequencing
5 ’ TTTCCCATAACACCACTGAGG 3 ’ Biomers.net
5 ’ TGTTTGCAACACTGTGTCTGTATT3 ’ Biomers.net
PCR was performed as a 20pl reaction containing Qiagen PCR master mix, 
primers (See appendix Table 8.1) and ultra pure water. 5 ng of DNA was 
used as template; ultra pure water was used as a control. All work was 
performed in ultraviolet cabinets and filtered tips were used throughout the 
PCR procedure.
Pyrosequencing primers for Jbo/+ sequencing 
Revers primer 5 ’ TTTCCCATAACACC ACTGAGG 3 ’ Biomers.net
Forward primer 5 ’ TGTTTGCAACACTGTGTCTGTATT3 ’ Biomers.net
The cycling profile was as follows:
Step 1 95 °C for 5 min
Step 2 95 °C for 15 s (44 cycles)
Step3 52 °C for 30 s (44 cycles)
Reverse
primer
Forward primer
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Step 4 72 °C for 15 s (44 cycles)
Step 5 76 °C for 5 min
W T : T/T (Passed)
1320
1300-
1280 "
126 0 -
1240
G A T  A G C G C AE S
5
Jbo/+\ A/T (Passed)
m
1320
1300
1280 "
1260 -
1240
G A T A G C G C AE S
5
Figure 3.1- Genotyping Result Pattern for Jbo/+ and WT mice in 
Pyrosequencing
Although I performed the initial genotyping; the genotyping service was 
taken over by GEMS core service at MRC using the upgraded lightscanner 
technology (Figure 2.2) as the colony was being managed at a much larger 
scale for a number of projects.
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2.2.2- Jeff and Junbo genotyping using Lightscanner
Genotyping of Jeff and Junbo mice was performed by GEMS core using 
LunaProbes on Lightscanner machine, Idaho technology. PCR was 
performed in the presence of dsDNA binding dye LC green under the 
following conditions:
Junbo sequencing
JunboEvi\ex\IF  5 ’ ACTGTGATAGATCATTCAGCATTTC 3’
JunboEVilexl 1R 5’ CTTCAGGTGTCTGTCAAGATT 3’
JunboPvoboR 5 ’ GCTTCTCCTTGTTGTGGATGATGCG 3 ’
PCR mix
HotShot master mix 5 pi
LCGreen lpl
JunboEwiXoxWY (20ng/pl) 0.5pl
JunboEvilexl 1R (20ng/pl) 0.1 pi
JunboProboR (20ng/pl) 0.5pi
DNA (1/10 dil ABI) 2pl
ddH20 0.9pl
88
/e/T’sequencing
Primers/Probe sets 5’>3’
Fboxl\Jeff-F 5’ ACACTACTAGGTTCTAAACACTGACT 3’
FboxlUeff-R 5’ TAAATCCCACCATGCTGTCCATC 3’
Fboxl IJeff-PR 5’ CTGTTTGTCCTGATCAGAATTCCTGCTA 3’
PCR mix
HotShot master mix 5gl
LCGreen lgl
Fboxl \JefjF (20ng/jil) 0.5gl
Fboxl IJeffR. (20ng/jil) 0.1 jil
Fboxl UeffPrR. (20ng/gl) 0.5gl
DNA (1/10 dil ABI) 2gl
ddH20 0.9gl
PCR program for both the genotypes was as follows:
i) 95°C for 2 min
2) 95 °C for 30 s (PCR cycle)
3) 60 °C for 30 s
4) 72 °C for 30 s
5) Cycle, step 2 to 4 55 times
6) 95 °C for 30 s Hybridization
7) 25 °C for 30 s
8) 15 °C for 30 s
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Figure 3.2- Example of lightscanner output for Junbo genotyping
The red samples with 2 peaks denote Jbo/+ while the grey samples with 
single peak denote WT. The plate in the diagram denotes the layout with all 
the samples. (Image courtesy- GEMS).
2.3- Cell culture
Plastic T25 (25 cm2) and T75 (75 cm2) flasks for cell culture were 
purchased from Greiner. All tissue culture and cell culture work was 
performed in tissue culture room facility in a bio safety cabinet (class II). 
Roswell Park Memorial Institute medium (RPMI) medium and Hank's 
Balanced Salt Solution (HBSS) used in NL isolation were obtained from 
Gibco. All tissue culture experiments used Dulbecco modified eagle 
medium (DMEM) supplemented with 10% fetal calf serum (FCS), G418 or 
Gentamycin antibiotic, 1% Pencillin/Streptomycin and 1% L-Glutamine 
(Sigma Aldrich). DMEM 6046, percoll and brew er’s thioglycollate medium 
was supplied by Sigma Aldrich. All media and phosphate buffered saline
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(PBS) solutions were pre-warmed at 37°C for 10 min in a water bath before 
use. A Beckman centrifuge was used at 160 g  for pelleting cells during cell 
culture. Light microscopy was performed on cells using a Nikon TS 100 F 
microscope (Nikon).
2.3.1- Raw 264.7 cell line
Raw 264.7 cell line is a mouse leukaemic monocyte macrophage cell line 
which was obtained from American Type Culture Collection (ATCC). Raw 
264.7 cells were cultured in DMEM media (containing 10% FCS and 1% L- 
Glutamine/Pencillin/Streptomycin).
2.3.2- Granulocyte and macrophage colony stimulating factor (GM- 
CSF) expressing cell line
The Granulocyte and Macrophage Colony Stimulating Factor (GM-CSF) 
cell line is a plasmacytoma line X63-AG8 transfected with mammalian 
expression vector BCMGSNeo with a mouse gene for GM-CSF 
(Karasuyama et al, 1990; Zal et al, 1994). Frozen cell aliquots were thawed 
and cells were grown in selection medium (G418 at 1 mg/ml). GM-CSF cells 
were grown up in a T175 tissue culture flask up to medium density, 
harvested and washed twice in medium without G418 and then returned to 
culture for 2-3 d in DMEM medium without G418. The cells were grown 
for 7 d until the cells were 65% confluent (Figure 2.3 a). The supernatant 
containing GM-CSF was then harvested after centrifugation at 160 g  for 5 
min twice. GM-CSF was then frozen in aliquots and stored at -80°C. GM- 
CSF was tested for macrophage differentiation by a series of dilutions 
(negative control, 1%, 2.5%, 5%, 10%) using wildtype (WT) BMDM every 
-time before freezing a stock.
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2.3.3-BM derived macrophage (BMDM) Culture
Mice were euthanized by cervical dislocation. Mouse femurs and tibias were 
excised, cleaned and bone marrow (BM) was flushed out using a syringe 
and DMEM media (containing 10% FCS and 10% GM-CSF). Cells were 
counted prior to seeding using haemocytometer. Cell count per flask ranged 
between 1 to 2 x 106 cells/ ml at the time of seeding. The cells were then 
grown in T 75 flasks at 37°C for 3 d. On the third day non-adherent cells 
were washed off and fresh DMEM media containing 10% FCS and 10% 
GM-CSF supernatant was added to the flask (Figure 2.3 b). Media was 
replaced with fresh medium after 6 d to yield mature macrophages from 7 d 
onwards. Macrophages were adherent to the plastic and were checked for 
purity using FACS.
2.3.3.1- BMDM Macrophage purity assay
BMDM cells grown and differentiated for 7 d using 10% GM-CSF were 
analyzed for purity with macrophage cell surface marker CD1 lb and F4/80. 
Cells were washed with FACS buffer at and pelleted at 530 g  prior to use. 
Phycoerythrin Rat anti-mouse CD l ib  and F4/80 were purchased from BD 
Pharmingen and Gr-1 antibody from BD Pharmingen was used for NL 
detection. The purity assay revealed a macrophage purity of 84-87% in 
cultured BMDM cells.
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b)
Figure 3.3 - GM-CSF cell line and Junbo BMDM
Olympus CK2 inverted microscope and Nikon Coolpix 955 were used to 
take images of (a) GM-CSF cell line (Scale-bar denotes 50 pm) and (b) 
BMDM from WT Junbo grown for 7 d (Scale-bar denotes 100 pm).
2.3.5-Isolation and culture of BM derived murine neutrophil leukocytes
6-8 wk old mice of mixed gender were euthanised and BM was flushed 
from the femur and tibia of mice using 5 ml RPMI media. The sample was 
the centrifuged at 160 g  for 6 min at 4°C. The pellet was then resuspended 
in 2ml IX HBSS and placed over a 6ml 52%/64%/72% percoll gradient. 
The discontinuous percoll gradient was prepared using isotonic percoll (9
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parts neat percoll: 1 part 10X PBS) and IX HBSS. The gradient with the 
suspended cells was then centrifuged at 275 g  for 30 min at 4°C and using a 
sterile glass 5 ml pipette purified neutrophil leukocytes (NL) were removed 
from the interface between 64% and 72% fractions (Haslett et al, 1985). The 
purified NLs were then cultured in T25 tissue culture flasks and incubated at 
37°C.
2.3.6-Normoxic treatment
Normoxic control cultures were maintained for all experiments in an 
incubator with an atmosphere of 5% CO2 , and 95% filtered air at 37°C.
2.3.7-Hypoxic treatment
After seven days growth and differentiation under normoxic conditions, 
tissue culture flasks containing BMDM cells were transferred to mini Macs 
Anaerobic workstation (Don Whitley Scientific) which was flushed P/0O2 , 
5% CO2, and 94% N2 at 37°C (gas mixture supplied by BOC). To induce 
hypoxia in cell cultures rapidly, hypoxia conditioned medium (24 h hypoxia 
conditioning in the incubator) was added to the tissue culture flasks after 
decanting the original media.
2.3.8-TGF-p Treatment
TGF-pl (T7039-2 UG) was obtained from Sigma Aldrich. A stock solution 
of 2pg/ml was made by dissolving the TGF-pl in 1 ml medium then 
aliquoted (hereafter referred to as TGF-P). The aliquots were stored at -20 
°C until use. A concentration of 200 pmol was used in tissue culture media. 
The concentration used was optimized after a standard dosage experiment.
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2.3.9-LPS Treatment
Lipopolysacharide (LPS) (L4641, Sigma Aldrich) was used as a standard. 1 
mg/ml stocks were aliquoted and stored at -20 °C. A standard dose of 250 
ng/ml of LPS in tissue culture media was used throughout for the LPS 
studies. The optimum dose was decided after a dosage experiment on WT 
BMDM (0, 10, 100, 250, 500, 1000 ng/ml) (See chapter 4 for details).
2.3.10-Oxysterol Treatment
Oxysterol stock was prepared by dissolving oxysterol C27, H4 0225-0H- 
chol or 25-diol (H1015, Sigma) in 95% ethanol to prepare a 5 mg/ml stock 
solution. Oxysterol used was added at a 5 jag/ml working concentration such 
that the final concentration of ethanol in culture medium was 0.1%. BMDM 
were incubated with oxysterol for 24 h after 7 d of culture in GM-CSF to 
induce foamy macrophage formation. 24 h oxysterol treatment in normoxia 
allowed uptake of oxysterol before hypoxia treatment. This incubation was 
followed by another 12 h with oxysterol under hypoxia or normoxia in cell 
media equilibrated to hypoxia or normoxia respectively. In some 
experiments, oxysterol was washed out for 2 h under hypoxia followed by 
activation with LPS (250 ng/ml). In control cells, only the ethanol vehicle 
was added.
2.3.11-Harvesting cells
Growth media was removed from culture flasks and the flasks were washed 
twice with PBS. Cells were detached using a cell scraper (Coming) into 
fresh PBS before being added to a 15 ml conical tube and centrifuged at 160 
g  for 5 min. PBS was removed and the pellets were frozen on dry ice before 
storage at -80 °C.
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2.4- RNA Extraction
Harvested BMDM pellets were stored at -80 °G and were thawed on wet ice 
before extraction of RNA. RNA was isolated using RNeasy Plus mini kit 
from Qiagen according to manufacturer’s instructions in hypoxia studies 
and TGF-P normoxia studies. As a standard procedure 600 pi of lysis buffer 
RLT plus (RNeasy Plus mini kit, Qiagen) was added to lyse the cells. 
QIAshredder from Qiagen was used to homogenize the lysate. RNA was 
finally eluted in 50 pi of RNase free water. Later on Nucleospin kits were 
adopted for RNA extraction as it allowed for extraction of RNA and protein 
at the same time. Extractions were conducted using a Nucleospin® 
RNA/protein kit (Macherey-Nagel) following manufacturer’s instructions 
for all the other RNA studies (TGF-P hypoxia studies, LPS studies, 
oxysterol study) in this thesis. RNA was eluted in 60 pi RNase-free water 
and concentrations were determined using the Nanodrop 8000 (Thermo 
Scientific) and 1.4% agarose gel. Samples were stored at -20 °C.
2.5-cDNA synthesis
The isolated RNA was reverse transcribed to produce cDNA using High- 
Capacity cDNA Reverse Transcription Kit containing MultiScribe ™ 
Reverse Transcriptase (Applied Biosystems). The Kit uses random primer 
scheme for initiating cDNA synthesis. Reaction volume of 30 pi was used 
for the cDNA synthesis. 15 pi of master mix was used per reaction. An 
equal volume of 1 pg RNA was made up using RNase free water per 
reaction for each sample to be used as a template.
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The following volumes were used per reaction:
Component Volume p 1/Reaction
10X RT Buffer 3 pi
25X dNTP mix (lOOmMol) 1.2 pi
10X Random Primers 3 pi
Multiscribe Reverse Transciptase 1.5 pi
Nuclease free water 6.3 pi
The following programme was used for the cDNA synthesis.
Step 1 Step 2 Step 3 Step 4
Temperature 25°C 37°C 85°C 4°C
Time 10 min 120 min 5 min Hold
cDNA samples were either used immediately in RT-qPCR reactions or 
stored long term at -20°C.
2.6- Pre-amplification PCR
Applied Biosystems TaqMan pre-amplification mastermix kit was used to 
detect low levels of Evi-1 in BMDM. Ppia was used as endogenous control 
and a comparison of standard RT-qPCR and preamplified RT-qPCR was 
performed for Tnf-a, II-lp, 11-6 on LPS treated cells and Phd2 on hypoxic 
cells to remove possibility of amplification bias.
Equal volumes of TaqMan assays were pooled for up to 100 assays and a 
pre-amplification reaction performed in PCR tubes using the following 
volumes.
TaqMan PreAmp Master Mix 25 pi
Pooled assay mix (0.2X, each assay) 12.5 pi
33.33 ng cDNA sample + nuclease 
free water
12.5 pi
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A pre-amplification PCR for 10 cycles was then performed using the 
following conditions:
Step 1 95 °C for 10 min
Step 2 95 °C for 15 s
Step3 60 °C for 4 min
Step 4 54 °C holding time
The pre-amplified cDNA was then diluted 1:5 in Tris-EDTA (TE) buffer 
(pH 8.0). The final diluted pre-amplified cDNA was used as template for 
standard RT-qPCR reactions for Evi-1.
2.7-TaqMan ™  RT-qPCR (Real Time quantitative 
Polymerase Chain Reaction)
Levels of gene expression can be determined by measuring amount of 
cellular RNA. RT-qPCR is a powerful tool to quantify gene expression. The 
quantitative end point of PCR cycle is threshold cycle or Ct which is 
defined as the PCR cycle at which fluorescent signal of reporter dye crosses 
an arbitrarily placed threshold (Schmittgen & Livak, 2008a). Ct is inversely 
proportional to the amount of amplicon in the reaction. So lower the Ct, 
greater the amount of amplicon. CT values are logarithmic and are used
either directly (comparative CT method) or indirectly (interpolation to
standard curves to create linear values) for quantifying relative gene 
expression.
cDNA prepared as a 30 pi volume was diluted 4.5 pi in 115.5 pi in nuclease
free water in Non stick Rnase free 1.5 ml microfuge tubes (Ambion).
TaqMan Fast Universal PCR master mix (2 X) from Applied Biosystems
was used as a mastermix. 20X TaqMan assay corresponding to each gene
was used (Appendix 8.1). Ppia was used as an endogenous control for all
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experiments except the Oxysterol studies. Gapdh was used as the 
endogenous control for Oxysterol studies as Ppia C t Cycle changed by >6 
folds with oxysterol treatment.
Each reaction required 4 pi (5ng) of cDNA; subsequently a master mix was 
prepared as per manufacturer’s instructions with 5ng cDNA per reaction. 
Reaction volume of 16 pi was pipetted carefully using Eppendorf combitips, 
to avoid bubbles, into a 0.1 ml Fast Optical 96 well reaction plate (Applied 
Biosystems) and centrifuged for 1 min at 160 g  before being loaded into the 
ABI 7500 Fast qPCR System (Applied Biosystems). Three technical 
replicates were performed for each sample and each probe along with non 
template control. The plate was sealed with Micro Amp Optical Adhesive 
Film (Applied Biosystems) and loaded into the RT-qPCR machine (Applied 
Biosystems). The assay was run as arelative plate quantification (RQ) 
programme.
Components 1 well/pl
Fast Master Mix 10
20x TaqMan assay 1
cDNA (5ng) 4
water 5
2.7.1-Standard curve
The standard curve (Figure 2.4) method involves constructing a standard 
curve from RNA of a known concentration; which is then used as a 
reference for extrapolating quantitative information of mRNA targets of 
unknown concentrations (Livak & Schmittgen, 2001). This method requires 
the least amount of validation but is only useful for a small number of
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samples and low numbers of gene targets. A standard curve was performed 
to check efficiency of TaqMan probes.
For relative quantification to work the efficiency of PCR reaction must be 
between 90 and 110% efficient. To calculate this, real time PCR was 
performed on a dilution series of cDNA (0.1 ng/pl, 1 ng/pl, 10 ng/pl, 100 
ng/pl) and a standard curve was generated from ACt results (Described in 
next section). Reactions were carried out in triplicate for each concentration 
with a non template control (NTC). Efficiency of probe was calculated by 
10 ('1/x)-l into 100 where x is the slope value efficient. Efficiency of all 
probes was calculated to be between 90-110%. The efficiency of all 
TaqMan probes is claimed to be ~ 100% by the manufacturer.
-9S C 3  &9C3
Log CO
Figure 3.4-A representative standard curve for TaqMan probe for 
assay for Hif-la
The slope was calculated and used to calculate efficiency (For e.g., the 
slope for H if-la standard curve is -3.1999 and the efficiency = 99.1%.
2.7.2- Relative quantification
Another method of presenting RT-qPCR is by comparative C j method 
oralso known as 2'AACt  method. It is a gold standard method for interpreting
RT-qPCR data and widely used for its ease of use. The comparative Ct 
method involves comparing the C j values of the samples of interest with a 
calibrator simple. The Ct values of both the calibrator and the samples of 
interest are normalized to an appropriate endogenous housekeeping 
gene. For the AACt calculation (see below for description) to be valid, the 
amplification efficiencies of the target and the endogenous reference must 
be approximately equal.
Fold change or RQ is obtained from the final form of 2'AACt  equation, the 
derivation of which has been reported in Applied Biosystems User Bulletin 
No 2 (P/N 4303859) and (Schmittgen & Livak, 2008b)
Fold change or RQ = 2'AACt
Where AACt = ACt (target sample) -  ACt (calibrator sample)
This allows for data to be interpreted as expression of gene interest relative 
to the internal endogenous control in target to be compared to calibrator as 
fold change.
Throughout this thesis, RT-qPCR results were normalized to the levels of 
Ppia or Gapdh RNA and relative quantification was calculated using 2'AACt  
as recommended by Applied Biosystems. Relative mRNA expression was 
expressed as fold expression over the calibrator sample, the average gene 
expression corresponding to the appropriate calibrator control group. 
Statistics were then performed on 2'AACT or 2'ACT normalized individual data 
points to further confirm difference in gene expression level between 
genotypes (Schmittgen & Livak, 2008b).
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2.8-Statistics
2.8.1- Statistics for RT-qPCR
Statistics were performed using RQmin-max as recommended by Applied 
Biosystems (ABI 7500 Fast Realtime Software). Data was expressed as bar 
graphs in which error bars display RQmin and RQmax (upper and lower 
limits defining region of expression within which the expression levels fall) 
for graphical representations of basal gene differences between genotypes. 
The data was plotted as bar graph.
A true fold difference for each experiment was calculated using formula
2 (Maximum Ct x -  Minimum Ct x) f o r  ^  g i y e n  e x p e r i m e n t  w h e r e  x  j s  t h e
endogenous gene control. As a general rule a fold difference > 2 fold was 
accepted as a true difference.
For each biological sample, standard deviation of ACt value was calculated. 
RQmin and RQmax were calculated using formula RQmin = 2'[average AACT
+(SEdCT*t)] a n d  R Q m a x  =  2 -[average AACT -(SEACT*t)] w h e r e  g g  {& s ta n £ ja r d  e r r o r
and t is the t value from a student t-test table for a given degree of freedom 
at > 95% confidence. Bar graph values where 95% confidence limit error 
bars did not overlap were deemed significant. P  values of <0.05 were 
considered significant.
2.8.2- Other analysis and statistics
Ingenuity Pathway Analysis Software was used to diagrammatically 
represent genetic interactions (www.ingenuity.com).
Student’s t test was used for analysis of experiments other than RT-qPCR 
(See above). Prism Statistical Analysis Software 5 was used to do statistical 
analysis and graphically represent the data. Standard Error of Mean (SEM)
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was defined by error bars in each experiment. P  values of <0.05 were 
considered significant.
2.9- Protein extraction
For hypoxia studies cytoplasmic and nuclear protein extraction was carried 
out using Paris Kit from Ambion as per manufacturer’s instructions. The 
nuclear and cytoplasmic lysates were then pooled together to make a total 
cell lysate. Protease inhibitor (P8340 from Sigma Aldrich) was added to the 
lysis buffer (1000X) before use.
For the LPS studies, the Nucleospin extraction kit was used to obtain protein 
pellets as per manufacturer’s instructions. Protein precipitation was 
performed by washing the pellet in ice cold acetone then centrifugation at 
13, 201 g  for 5 min. The tubes were then dried at 30 °C. The pellet was then 
re-suspended by pipetting in 50 pi of NP40 lysis buffer (150 mM NaCl, 1% 
NP-40, 50mM Tris ph 8.0, supplemented with protease inhibitors, 
phosphatase inhibitors).
2.10- Protein quantification
Protein concentrations in lysates were determined using the Bradford assay. 
Bio-Rad’s Quick Start Serum Albumin Standard Test was used to generate a 
standard curve in each experiment as per manufacturer’s instructions in the 
250 pi microplate assay format. A BMG Labtech Optima plate reader was 
used to measure the absorbance at 595 nm.
2.11-Western Blotting
2.11.1- Western blotting for Hif-la
Electrophoresis of 35 pg of protein lysates from BMDM was performed
using Bio-rad’s 7.5% Tris HC1 pre-cast gels. The gel was run for 1 h at 110
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V using Mini Protean 3 Cell by Bio-rad. Gel was transferred on 
nitrocellulose membrane using wet transfer method at 100 V for 1 h with ice 
pack. The membrane was blocked with 5% non fat dry milk in Tris buffered 
saline with x% Tween 20 (TBST) for 1 h at room temperature. The blot was 
then incubated either with antibodies against H if-la (NB100-479 by Novus 
Biologies), MPO (AF3667 by R & D Systems) or P-actin (Ab8227 from 
Abeam) overnight at 4 °C. The membrane was then incubated with goat 
polyclonal to rabbit IgG (Abeam, ab7090) for H if-la and p-actin and rabbit 
polyclonal to goat IgG (Abeam, ab6741) for MPO at a concentration of 
1:2000 for 1 h at room temperature. A chemiluminescent signal was 
developed on Kodak XOmat AR Film by using Pierce Supersignal West 
Pico detection system. Hypoxia treated Raw 264.7 cells were used as a 
control.
2.11.2- Western blotting for Evi-1
Samples were run on Invitrogen’s NuPAGE Novex Bis-Tris gels (4-12%) as 
per manufacturer’s instructions. The gel was run in X Cell Sure Lock Mini 
Cell (Invitrogen) for 50 min at 200V using 3-(N-morpholino) 
propanesulfonic acid (MOPS) running buffer.
Mini iBlot dry blotting system by Invitrogen was used for transferring the 
gel onto nitrocellulose membrane using iBlot transfer device. The transfer 
was performed at 20 V for 8 min.
The membrane was then blocked using 2.5% non fat dry milk in 1 X PBS 
with 0.1% Tween 20 detergent for 1 h. Primary antibody for Evi-1 86306 
(supplier) was added at a concentration of 1:1000 or for p- actin (1:1000) in 
blocking buffer to the membrane and incubated overnight. The blot was 
washed three times for 10 min with PBS 0.1% Tween. Anti-rabbit antibody
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was added at a concentration of 1: 10,000. The blot was washed again three 
times for 5 min each in PBS with 0.1% Tween.
Amersham ECL advance western blotting detection kit was used for signal 
detection on Amersham X Ray film. Thermo Restore™ Western Blot 
Stripping Buffer was used for stripping the membrane for 10 min at 37°C 
wherever re-probing with another antibody was required. The membrane 
was subjected to a blocking treatment prior to another primary antibody 
treatment.
2.12- Proteome Profiler Array
For determination of relative mouse cytokines and chemokine levels, an 
antibody based cytokine array-Proteome Profiler Array (ARY006, R & D 
Biosystems) was used.
The supernatant from the treated BMDM T75 flasks was pooled and 
aliquoted into 1.5 ml tubes and frozen at -80°C. BMDM cells were washed 
in ice-cold PBS and harvested. The cells were pelleted at 160 g  for 5 min. 
PBS was then aspirated and the cell pellet was soubilized in 1 ml lysis 
buffer (1% Igepal CA-630, 20mM Tris-HCl ph 8.0, 137mM NaCl, 10% 
glycerol, 2mM EDTA). 10 pg/ml each of protease inhibitors Aprotinin 
(A6279, Sigma Aldrich), Leupeptin (L8511, Sigma Aldrich), Pepstatin 
(P4265, Sigma Aldrich) were added to the lysis buffer just before use. The 
cell pellet was gently re-suspended by pipetting and gently rocked at 4°C for 
30 min. The lysate was then centrifuged at 13, 201 g  for 5 min. The 
supernatant was transferred on a clean tube and protein in the lysate was 
quantified using Bradford assay. The cytokine array detection was then 
performed on cell lysates (122pg of protein) and supernatants (600pl) as per 
manufacturer’s instructions.
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Signal detection was achieved using Supersignal West Pico Chemi- 
luminescent detection system by Pierce ansd X-Ray film Kodak Biomax™ 
Light-1 (Kodak). Signal quantification via densitometry was performed 
using Vision Works LS Software version 6.8 by UVP and Chemidoc-It 
Imaging system (UVP).
2.13-Fluorescence activated cell sorter (FACS)
2.13.1- Thioglycollate elicitation of macrophages and NLs
To assess recruitment of inflammatory cells mice were injected 
intraperitoneally with oxidized 4% Brewer’s thioglycollate solution (Sigma 
Aldrich) according to body weight (10 ml/kg). At 1 d or 4 d after 
thioglycollate treatment mice were euthanised by cervical dislocation, and 
cells were recovered by peritoneal lavage using 5 ml of cold DMEM. 
DMEM was aspirated back into the syringe, transferred to a 15 ml tube and 
stored on wet ice. Cells were counted and analysed using an ADVIA 
haematology analyser (Siemens) as well used for FACS analysis using BD 
FACS Canto II.
For FACS analysis cells were stained with Allophycocyanin (APC) 
conjugated anti-mouse F4/80 (MF48005, Caltac Labrotaries), FITC 
conjugated anti-CDllb (557396, BD Pharmingen) and PerCP-Cy 5.5 anti­
mouse Gr-1 (552093, BD Pharmingen). Cells were added to a 96 well plate 
and fixed with lysis buffer before incubation with the antibodies. A dilution 
of 1:400 was used for CD1 lb and F4/80 while a dilution of 1:1600 was used 
for Gr-1.
2.13.2- Neutrophil leukocyte apoptosis assay
BM derived NLs were harvested and incubated in normoxic or hypoxic 
conditions for 20 h. Apoptosis and cell necrosis was assessed by FACS with
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fluorescein isocynate (FITC) labeled Annexin V and Propidium Iodide (PI) 
staining using a Apoptosis Detection Kit by BD Pharmingen as per 
manufacturer’s instructions.
2.13.3- Lox-1 assay
Lox-l/SR-El-Phycoerythrin was obtained from R & D Systems. Lox-1 
expression on BMDM was assayed by FACS.
2.13.4- Ox-LDL Assay
Serum samples were collected from Jbo/+ and WT littermate controls and 
stored at -80°C. Middle ear fluid from the same cohort of Jbo/+ mice was 
collected in lOOpl of ice-cold PBS. The samples were mixed gently and 
centrifuged at 5000 g  for 20s at 8°C. Supernatant was aliquoted into 95pl 
batches and stored at -80°C until assay. Ox-LDL in the samples was then 
measured using the mouse ox-LDL ELISA kit (Uscn Life Science Inc.).
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4. Immune cell function in
Junbo
3.1-Introduction
Many OM models exhibit a continuum of pleiotropic effects of mutation
which result in systemic auto-immune defects and chronic OM. Examples
include MyD88~f~ mice (Rye et al, 2011a), Ipr/lpr mice (Rivkin et al, 2005)
amongst others. Heterozygous Junbo mice (Jbo/+) develop spontaneous
OM. Jbo/+ mice develop spontaneous inflammation even in germ-free
conditions (unpublished results) and it is important to consider whether the
chronic middle ear inflammation is a result of systemic defects in immune
cell recruitment and inflammation resolution. My hypothesis is that OM in
Jbo/+ mice is a result of dysregulated response of inflammatory cells to
specific micro-environmental conditions unique to the Jbo/+ middle ear
which augments the inflammation and prolongs its persistence.
NLs and macrophages are the innate immune cells which determine host’s
ability to ward off infection and resolve inflammation. NLs are the first
inflammatory cells to be recruited to the site of inflammation followed by
macrophages. Defects in systemic recruitment of NLs and macrophages can
result in susceptibility to inflammation or infection. Resolution of
inflammation requires both appropriate cell recruitment and subsequent
removal of recruited cells in a controlled manner. Both processes are
essential for proper clearance of inflammation. For instance, low circulating
NL numbers, neutropenia, can render a patient susceptible to microbial
infection whilst chronic inflammation is characterized by a continued influx
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of NLs into the inflamed site (Sadik et al, 2011). Infiltrating NLs play a 
tissue damaging role in a number of chronic conditions such as chronic 
obstructive pulmonary disease (COPD), asthma, and rheumatoid arthritis 
usually due to dysregulation of their recruitment in tissues (Drost et al, 
2005; Edwards & Hallett, 1997; Hogg, 2004; Monteseirin, 2009). These 
infiltrating neutrophils release toxic oxygen intermediates and proteases, 
which can result in tissue damage (Movat, 1979)
Monocyte recruitment follows NLs recruitment during the course of 
inflammation and on activation release important NL attracting CXC 
chemokines (Hume et al, 2002; Lee et al, 1993). A higher number of 
recruited and activated macrophages would result in increased influx of NLs 
resulting in further tissue damage if the inflammation is not resolved. In 
inflammation, apoptosis is a crucial cellular process which requires 
phagocytic removal of damaged or necrotic cells from the site of 
inflammation. This process is mediated via apoptosis and rapid 
phagocytosis primarily by macrophages. Macrophages ingest apoptotic NLs 
and a reduced macrophage recruitment would result in delayed clearance of 
apoptotic NLs resulting in secondary necrosis. Debris released after necrosis 
is loaded with macrophage activating endogenous factors, such as heat- 
shock proteins (Zhang & Mosser, 2008). These proteins and cytokines 
facilitate a shift towards pro-inflammatory cytokine production by 
macrophages and other NLs which would exacerbate inflammation.
No differences have been observed in the numbers and maturity of NLs in 
blood between WT and Jbo/+ mice (Parkinson et al, 2006). However, NL 
and macrophage recruitment has not been studied.
In this chapter, I have investigated the presence of H if-la signal in the ear-
exudate from the middle ear of Jbo/+ mice. Ear exudates from Jbo/+ mice
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contain large numbers of hypoxic viable, apoptotic and necrotic NLs as well
as hypoxic foamy macrophages (Parkinson et al, 2006). Hypoxia stabilizes
H if-la and evidence for this in Jbo/+ ear exudates was sought by H if-la
western blotting. Evi-1 protein expression was also checked in the ear
exudates obtained from Jbo/+ mice using western blotting.
One of the regulating factors of inflammation is the ability of NLs to
undergo apoptosis (Haslett, 1992) which triggers clearance of apoptotic NLs
by macrophages, initiating M2 polarization of macrophages and inducing
wound-repair (Laskin et al, 2011; Savill, 1997a; Savill, 1997b; Savill et al,
1989; Serhan & Savill, 2005). Intrinsic apoptotic threshold of NLs can be
modified by a range of external stimuli such as cytokines and oxidative
stress. Hypoxia has also been shown to prolong NL survival (Cramer &
Johnson, 2003; Walmsley et al, 2005). Studies on anoxia challenge of
murine bone marrow derived NLs (BMDNLs) from H if-la'7' mice and
human NLs show that hypoxia inhibits NL apoptosis and a role of HIF
pathway in regulation of NL apoptosis via MIP-lp, NF-kB and HIF-la
(Walmsley et al, 2005). Delayed NL apoptosis can in turn release more pro-
inflammatory mediators and cytokines that amplify further recruitment and
activation of inflammatory cells. NLs have a short life-span of ~ 6 - 8  h in
humans and ~11 h in mice (Rankin, 2010; Summers et al, 2010) which
makes them difficult to utilize in gene and protein expression studies which
involved treatments lasting up to 72 h. This is why macrophages were made
the focus of study in this thesis henceforth. Macrophages play a major role
in resolution of inflammation, initiate NL influx by releasing NL attracting
chemokines and are also found in exudates from Jbo/+ mice. As the number
of macrophages recovered from the middle ear of Jbo/+ mice is too low to
study in isolation, all gene expression studies from this chapter onwards
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were performed on BMDM. This is a system which also allows for addition 
of further levels of complications to mimic the complex micro-environment 
of inflamed middle ear.
3.2- Results
3.2.1- Immune cell recruitment in Jbo/+ is not dysregulated in a 
standard intra-peritoneal challenge model
One of the first experiments performed was to investigate NL and 
macrophage recruitment in Junbo mice using a well-established model of 
inflammation; an intra-peritoneal injection of thioglycollate. Thioglycollate 
broth has been used extensively to study kinetics of inflammation (Leijh et 
al, 1984; Melnicoff et al, 1989). Peritoneal injection of thioglycollate elicits 
an inflammatory response resulting in the recruitment of NLs after 1 day 
and macrophages after 3-4 days (Leijh et al, 1984; Melnicoff et al, 1989; 
Qureshi & Jakschik, 1988). NLs were detected by FACS using combined 
markers of CD l ib  and Gr-1 antigen which allows their definitive detection 
(Goni et al, 2002). Macrophages were detected by using surface markers 
CD1 lb and F4/80(Henkel et al, 1999). FACS analysis of inflammatory cells 
elicited by thioglycollate challenge in Jbo/+ and WT mice was performed. 
No differences were observed between Jbo/+ and WT mice in neutrophil 
recruitment, macrophage recruitment or white blood cell (WBC) numbers. 
This suggests that the Evi-1 mutation does not have a global effect on 
inflammation in the peritoneal inflammation model in Junbo (Figure 3.1).
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Figure 4.1- Intra-peritoneal thioglycollate injection reveals no global 
defects in inflammatory cell recruitment in Jbo/+ mice
Thioglycollate was injected in Jbo/+ mice intra-peritoneally as described in 
Chapter 2. Peritoneal fluid was collected and analysed using FACS. 
Majority of cells collected after day 1 were Gr-1 and CD l ib  positive NLs. 
The majority of cells collected at day 4 were Gr-1 and F4/80 positive 
macrophages. Closed blue squares/circles represent WT NLs/ macrophages 
and closed red squares/circles represent Jbo/+ NLs /macrophages. Error 
bars denote SEM. Statistics was performed on arc-sin values of percentage 
using student’s t-test. P >0.05. n=6 .
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3.2.2- Stabilization of Hif-la in the middle ear in Jbo/+ mice 
Western blotting for H if-la was performed on ear exudates (Figure 3.2). As 
ear exudate from Junbo mice contains a mixture of NLs and macrophages, 
BMDNLs were used as negative control for hypoxia. Myeloperoxidase 
(MPO) is a peroxidase enzyme present in neutrophil granules. MPO and P- 
actin were used as a loading control for this experiment. Ear exudates from 
five Jbo/+ mice were collected in 150 pi cell lysis buffer and protein 
extraction was carried out using Paris kit by Ambion as per manufacturer’s 
instructions.Total cell lysate (nuclear lysate + cytoplasmic lysate) and 
western-blotted for Hif-la. As there is no exudate present in WT mice, 
BMDNLs were used as a negative control. A strong H if-la signal was 
observed in Junbo ear exudates, albeit at a lower band size of ~88-90kD as 
compared to the expected 110 kD band size. (Explanation in section 3.3). 
However, a H if-la signal was not observed in the negative control normoxic 
BMDNLs. Stabilization of Hif-la is consistent with the demonstration of 
hypoxia in vivo using histo-chemical pimonidazole labelling (Cheeseman et 
al, 2 0 1 1 ).
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Figure 4.2- Ear exudates in Jbo/+ mice is hypoxic
35 pg of total cell lysate from ear exudates were prepared and blotted for
Hif-la and P-actin using Hif-la antibody NB100-479 and p-actin antibody
Ab8227 respectively.
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3.2.3- Evi-1 is expressed in Jbo/+ ear exudates
Total cell lysate obtained from ear exudates was blotted for Evi-1 (Figure 
3.3) and a signal was observed in ear exudates. Kidney lysates were used as 
a positive control as kidney cells are known to express the Evi-1 gene 
(Morishita et al, 1990b). This was an independent confirmation that Evi-1 is 
expressed in Jbo/+ middle ear which suggests that the Evi-1 mutation does 
not affect the protein expression. However, there was no suitable WT 
counterpart for measuring the relative levels between the genotypes is not 
available as WT mice do not have ear-exudate.
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Figure 4.3- Evi-1 protein is expressed in Jbo/+ ear-exudate
20 pg of total cell lysates from pooled ear-exudate Jbo/+ ear-exudate from 6  
individual 6 -8 wk old mice was western blotted for Evi-1 (1:1000). Total 
kidney lysates (3 pi) was used as a positive control as Evi-1 is highly 
expressed in kidneys. Evi-1 band was observed at 115-120 kD.
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3.2.4- Neutrophil apoptosis is not dysregulated in Jbo/+ mice
To observe if NL apoptosis in Jbo/+ mice is delayed or dysregulated 
compared to WT mice, a series of NLs apoptosis studies on Junbo 
BMDNLs was performed using FACS. BMDNLs were used to study NL 
apoptosis in hypoxia in Junbo mice as inflamed middle ear in Jbo/+ is 
hypoxic (Cheeseman et al, 2011). This approach was chosen because WT 
Junbo mice do not have ear fluids to harvest NLs as controls and NLs from 
Jbo/+ ear fluid exudates are a mixture of viable, apoptotic and necrotic cells 
and are relatively few in number. Apoptosis is identified by a specific chain 
of morphological changes occurring in dying cells. Extemalization of 
phosphotidylserine (PS) is an early event in apoptosis and occurs whilst 
cellular membrane is still intact. Annexin V specifically binds to PS and 
hence detects early stages of apoptosis (van Engeland et al, 1998). In late 
apoptotic or necrotic cell, loss of cell membrane’s structural integrity occurs 
and results in uptake of membrane impermeable dyes such as propidium 
iodide which allows for detection of necrosis and latter stages of apoptosis 
(McCarthy & Evan, 1998). To quantify apoptosis in Jbo/+ and WT 
BMDNLs, NLs were isolated from bone marrow of mice and exposed to 20 
h normoxia or hypoxia to study effect of hypoxia on NL apoptosis. Grl- 
staining for NLs, Annexin V staining for apototic cells and PI (propidium 
iodide) staining for cell necrosis and late apoptosis was performed and 
analysed using FACS. No difference in early or late apoptosis stages was 
observed between Jbo/+ and WT BMDNLs (Figure 3.4).
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Figure 4.4- NL apoptosis is comparable in WT and Jbo/+ BMDM in 
conditions of normoxia and hypoxia
BMDNLs were treated to 20 h hypoxia or normoxia. FACS was then 
performed for Annexin V which binds to phosphotidylserine (PS) 
externalized on apoptosis. Closed blue squares represent WT and closed red 
squares represent Jbo/+ mice. Error bars denote SEM. Statistics was 
performed on arc-sin values of percentage of apoptotic cells using student’s 
t-test. Genotypic differences were not considered significant as P > 0.05. 
N=5 for WT BMDNLs; N=7 for Jbo/+ BMDNLs; N= 6  for WT and Jbo/+ 
hypoxia treated BMDNLs.
3.2.5- Evi-1 is expressed in Junbo BMDM
RT-qPCR assays for Evi-1 were performed on BMDM differentiated with 
GM-CSF for 8  d using preamplification PCR as Evi-1 levels were at 
borderline detection level with standard RT-qPCR assay. Ppia was used as 
an endogenous control for the assay. The results indicate that Evi-1 was 
expressed in both Jbo/+ and WT BMDM in normoxic controls albeit at low 
levels (Figure 3.5a).
A strong Evi-1 protein signal was detected in both Jbo/+ and WT BMDM in 
unstimulated and normoxic conditions with western blotting using total cell 
lysate extracted from 8  d old (Figure 3.5b).
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Evi-1 expression has been observed in myeloid and epithelial cells of 
middle ears without any genotypic differences between WT and Jbo/+ 
(Parkinson et al, 2006). This result is of importance because it suggested 
that the Evi-1 mutation in Jbo/+ does not affect the expression of Evi- 
1 .
Evi-1
a)
Evi-1
110-115kD
0.5
0.25
0.125
WT Jbo/+
RQ 1.0 1.2
RQMin 0.9 1.1
RQMax 1.1 1.4
1
B-actin ^
42kD
b)
Figure 4.5- Evi-1 gene and protein is expressed in WT and Jbo/+
BMDM at comparable levels
a) Relative Evi-1 expression was comparable in both WT and Jbo/+ resting 
BMDM. Pre-amplification PCR was performed prior to RT-qPCR due to 
high average cycle threshold of Evi-1 (>32). Statistics were performed using 
RQ min-max as recommended by Applied Biosystems using the ABI 7500 
sds software. N= 3.
b) 20 pg of total cell lysates from WT and Jbo/+ BMDM were western 
blotted for Evi-1 (1:1000) and p actin (1:10,000). Evi-1 is expressed in both 
WT (Lane 1) and Jbo/+ BMDM (Lane 2) at comparable levels. Blot was 
qyantified using Vision Works LS Software v 6 . 8  (UVP).
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3.2.6- Resting WT and Jbo/+ BMDM have comparable levels of Evi-1 
responsive, hypoxia responsive and TGF-p responsive genes in 
normoxia
Next, basal gene expression levels (RQ Jbo/+ /  RQ WT) of SmadS, H if-la , 
Abcal (a key cholesterol transport controlling gene) as well as Evi-1 
responsive genes (Gata2, Map3kl4, Jun, Fos), hypoxia and TGF-P 
responsive genes {Vegf, Glut-1, Phd2, Pai-1) and an inflammatory gene 
panel {II-If, 11-6, Ccl2, Cxcl2, Tnf-a, Nos-2) were compared between WT 
and Jbo/+ BMDM using RT-qPCR. My hypothesis is that HIF signalling 
and TGF-P signalling is dysregulated in Jbo/+ BMDM due to the Evi- 
1 mutation. A significant difference (P <0.05) in gene expression 
levels between the two genotypes at basal level of Evi-1 responsive genes 
Gata2, Map3kl4, Jun, and Fos as well as Ccl2, the gene encoding for NL 
and monocyte chemoattractant Ccl2 was observed. However the difference 
in gene expression levels observed was at all cases less than the 2  fold cut­
off threshold level which is the generally accepted as the minimum 
difference that is likely to be biologically robust. Ppia was used as an 
endogenous control. No significant differences between expression of Vegf, 
Glut-1, Phd2, Pai-, Il-lp, 11-6, Cxcl2, Tnf-a and Nos-2 was observed 
between Jbo/+ and WT mice (Figure 3.6).
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Figure 4.6- Comparative gene expression levels of Evi-1 responsive, 
hypoxia responsive and pro-inflammatory genes
This figure illustrates relative gene expression levels between WT and 
J 6 o/+resting BMDM in normoxia. Three biological replicates were used for 
this study. Each replicate was obtained from 8 d old BMDM from a pool of 
5-6 individual mice (6 - 8  wk old). Statistics were performed using RQ min- 
max as recommended by Applied Biosystems using the ABI 7500 sds 
software. Blue bars denote WT levels and red bars denote Jbo/+ levels. 
Jbo/+ were calibrated to WT. The error bars represent RQ min and RQ max. 
Gene expression data obtained was normalized to Ppia gene expression. * P 
< 0.05. Figure panel shows difference in relative levels of (a) Gata-2 (b) 
Map Ski 4 (c) Fos (d) Ccl2
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Table 4.1- Difference in gene expression level between WT and Jbo/+ in 
resting condition
- <0am>
Abcal 1.0 (0.7, 1.4) 10(0 .7 , 1.4)
Ccl2 1.0 (1.0, 1.0) 0.8 (0.7, 0.8)
Cxcl2 1.0(1.0, 1.0) 1 .0(10, 1.1)
Fos 1.0(1.0, 1.0) 1.1 (1.1, 1.1)
Gata-2 1.0 (0.9, 1.1) 1 .4(13 , 1.5)
Glut-1 1.0 (1.0,1.0) 0.9 (0.8,1.0)
Il-lp 10(0.8 , 1.2) 10(0 .8 , 1.1)
11-6 10(0.9 , 1.1) 0.8 (0.7, 0.9)
Jun 1.0(0.9,1.1) 12(1.1,1.3)
Map3kl4 1.0 (0.9,1.1) 13(1.2,1.3)
Nos-2 1.0 (1.0,1.0) 1.0 (0.9,1.0)
Pai-1 10(0.5,2.1) 0.9 (0.5,1.6)
Phd2 10(0.9,1.1) 11(1.1,1.1)
Smad3 1.0 (0.8,1.2) 0.8 (0.7, 0.9)
Tnf-a 1.0 (1.0,1.0) 1.0 (0.9,1.0)
Vegf 10(0.9,1.1) 1.0 (0.9,1.0)
Table 3.1 shows the difference in gene expression level between WT and 
Jbo/+ BMDM at resting state. Values in parenthesis represent RQmin-max 
values. Coloured numerical values (blue) represent significant difference 
between genotypes (P< 0.05). However, numerical figures in blue were not 
considered biologically relevant as they did not make a cut-off threshold of 
2  fold up/downregulation.
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3.3- Discussion
No difference in NL or macrophage recruitment was observed in the 
thioglycollate model of inflammation which suggests that Jbo/+ mice do not 
have a global defect in the inflammatory response. This indicates that the 
Evi-1 mutation in Jbo/+ mice does not affect systemic recruitment of 
inflammatory cells or the resolution of inflammation so must have a more 
specific role in OM. This brings environmental factors such as hypoxia to 
the forefront of my subsequent investigations of chronic OM observed in 
Junbo.
In vivo labelling of middle ear in Junbo with hypoxia marker pimonidazole 
has previously revealed the site to be hypoxic and filled with ear exudate 
composed of hypoxic populations of NLs and foamy macrophages 
(Cheeseman et al., 2011). Hypoxia commonly occurs at sites of 
inflammation and the unmet oxygen demand of large numbers of NLs in ear 
exudates may drive this process. Under normoxic conditions, H if-la is 
degraded after hydroxylation of its prolyl residues by PHD2 (Masson et al., 
2001; Lando et al., 2002). However, in hypoxic conditions stabilization of 
H if-la occurs. Hence, anti-Hif-la is often used as a protein marker for 
hypoxia. Western blotting of ear exudates with anti-Hif-la displayed a 
strong signal albeit at a lower size of 88-90 kD. This may be due to partial 
proteolysis by neutrophil elastases and proteases. A strong MPO signal was 
also observed in ear exudates which confirmed that large number of NLs is 
present in ear-exudate. The demonstration of H if-la stabilization is 
consistent with result obtained by Cheeseman et al. (2011) that the inflamed 
middle ear of Jbo/+ mice middle ear is hypoxic.
Evi-lprotein was detected in ear exudates from the Jbo/+ middle ear. This
result was confirmed in BMDM when low but constant levels of Evi-1 gene
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expression were observed in both WT and Jbo/+ BMDM, accompanied 
with high levels of protein expression in both genotypes. These results 
suggest that the mutation in Evi-1 in Jbo/+ mice does not interfere with 
transcription or translation of the protein. Future work into the half-life of 
Evi-1 and its binding to other proteins with pull down assays will throw 
more light on how Evi-1 mutation might affect Evi-1 binding in Jbo/+ mice. 
As mentioned before, ear-exudate from Jbo/+ middle ear is rich in NLs. In 
such a scenario, understanding NLs apoptosis and necrosis is critical 
because it can potentially alter their phagocytic uptake by macrophages and 
result in release of pro-inflammatory cytokines in the middle ear of Jbo/+ 
mice. Results showed no difference in NL apoptosis between Jbo/+ and WT 
mice under hypoxic or normoxic conditions. Contrary, to the observation 
by Walmsley et al. (2005) that hypoxia exerts a protective mechanism on 
human NLs we did not observe any reduction or delay in NL apoptosis in 
hypoxic murine BMDNLs relative to normoxic BMDNLs. It has been 
suggested before that murine BMDNLs display different AV/PI staining 
properties and that might explain the different results (Walmsley et al, 
2005). Also, the source of PMN might explain the different result as well. 
NLs isolated from peripheral blood PMN might be undergoing apoptosis 
already by the time of their isolation and might contribute to the difference 
in results.
No differences between WT and Jbo/+ BMDM in the expression of genes
from panel of selected genes was observed under normoxic conditions. This
panel of genes included genes for inflammatory cytokines, Evi-1 responsive
genes, TGF-p responsive genes, hypoxia responsive genes as well as genes
encoding key component of TGF-P and HIF pathway. This is not
unexpected as it is possible that the mutation exerts its effect in
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inflammatory micro-environment that would be present in the Jbo/+ middle 
ear. All this data taken collectively suggests that OM in Jbo/+ is not due to 
specific global immune defect or global systemic cell recruitment defects. 
OM seen in Jbo/+ mice may be a result of dysregulated response of 
macrophages to specific inflammatory hypoxia in the Jbo/+ middle ear 
which may exacerbate inflammation.
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Chapter 4
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5. Studies of cellular processes 
in Junbo mice
4.1- Introduction
Unstimulated normoxic BMDM from Junbo mice did not exhibit anomalous 
expression of specific Evi-1 responsive or pro-inflammatory genes or in 
genes involved in the HIF pathway or TGF-p pathway (Chapter 3). Hence, 
the complexity of the BMDM model was increased to mimic the prevalent 
micro-environment of the inflamed Jbo/+ middle ear by subjecting Junbo 
BMDM to hypoxia, LPS activation and oxysterol treatment. Differential 
expression of a panel of hypoxia-responsive and pro-inflammatory genes in 
Jbo/+ and WT BMDM was then investigated using RT-qPCR. This 
approach was adopted to elucidate the contribution of EVZ-i^ 2887 mutation 
to the chronic middle ear inflammation in Jbo/+ mice and also to provide 
further understanding of the role of Evi-1 in the HIF pathway and the innate 
immune system.
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4.2- Hypoxia studies: Dysregulated HIF signalling and 
dysregulated expression of hypoxia responsive genes Vegf, 
Glut-1, Pai-1 and Ccl2 in Jbo/+ BMDM
As described in detail in Chapter 1, hypoxia leads to stabilization of the Hif- 
la  subunit of the HIF complex and activation of the HIF pathway (Lando et 
al, 2002; Masson et al, 2001; Rius et al, 2008). The HIF pathway modulates 
more than 1 0 0  hypoxia-responsive genes, which are involved in cell 
mediated inflammation and affect a broad range of myeloid cell functions, 
such as phagocytosis, myeloid cell aggregation, cytokine secretion, cell 
adhesion and migration (Cramer & Johnson, 2003; Lewis et al, 2000; 
Semenza & Wang, 1992; Vengellur et al, 2003). H if-la promotes NF-kB 
transcriptional activity through upregulation of the NF-kB activity factor 
(Chandel et al, 2000; Elbarghati et al, 2008). HIF-la is also regulated (O2 
independently) at the transcriptional level through its interaction with NF- 
kB (Rius et al, 2008; Taylor, 2009; Walmsley et al, 2005). Furthermore, the 
HIF pathway interacts with the AP-1 pathway (Laderoute, 2005; Taylor, 
2009; Yu et al, 2009). Both NF-kB and AP-1 are transcription factors that 
induce expression of a number of pro-inflammatory genes. Many key genes 
involved in macrophage and NLs recruitment, innate immunity and 
angiogenesis such as TNF-a, CXCL8, IL-lfi, NOS-2, VEGF are upregulated 
in hypoxic conditions (Rius et al, 2008). Hypoxia is also known to enhance 
the ability of macrophages to phagocytose bacteria and reduce bacterial 
infection (Anand et al, 2007; Peyssonnaux et al, 2005; Zinkemagel et al, 
2008). These reports show that HIF responses are adaptive in nature and are 
an integral part of the complex innate immune system. These reports are 
evidence that pathologic hypoxia found in inflammatory lesions creates a
unique micro-environment, that modulates recruitment and functioning of 
both macrophages and NLs. Dysregulated HIF signalling is associated with 
an aggressive HIF response that drives inflammation, decreases 
susceptibility to infection and is commonly linked with chronic diseases 
such as rheumatoid arthritis and fibrosis (Dehne & Brune, 2009; 
Zinkemagel et al, 2008).
Hypoxia has been identified as a characteristic feature of chronic OM in the 
Jbo/+ and Jf/+ mutants (Cheeseman et al, 2011). Prevalent hypoxic 
conditions and H if-la stabilization in the Jbo/+ mucosa and ear exudates 
can be attributed to the high influx of NLs to the middle ear. However, 
generation of Nos-2 and pro-inflammatory cytokines such as TNF-a, IL-lp 
may further modulate HIF signalling and promote a hypoxic micro­
environment (Dehne & Brune, 2009; Frede et al, 2006).
Based on these reports in combination with evidence that Evi-1 is linked to 
HIF signalling by Smad3 and AP-1 pathway activation (Kurokawa et al, 
1998b; Tanaka et al, 1994), it was hypothesized that the Evi-1 mutation in 
Jbo/+ mice perpetuates inflammation through dysregulation of the HIF 
pathway. To test this hypothesis, BMDM were subjected to hypoxic 
conditions and relative gene expression of a panel of Evi-responsive, 
hypoxia-responsive, TGF-p responsive and inflammatory genes was 
analysed over time using RT-qPCR.
4.2.1- Hif-la stabilization in hypoxia
The RAW 264.7 cell line, which is derived from immortalized murine 
macrophages were used as an appropriate control for experimental 
investigation of the effects of hypoxia in BMDM. H if-la stabilization was 
investigated in RAW cells subjected to hypoxia over a time-course ranging
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from 1 h to 16 h. Hif-la expression was detected in nuclear lysates by 
Western blot analysis. H if-la protein was visualized as a band at 
approximately 100-110 kD in samples subjected to hypoxia for 2 h, 4 h and 
16 h, demonstrating that H if-la protein is stabilized to detectable levels in 
RAW 264.7 cells from 2 h hypoxia onwards (Figure 4.1 a).
An experiment was then performed to establish the earliest optimum 
conditions for detection of H if-la stabilization and H if-la responsive gene 
expression in Junbo BMDM in hypoxia. BMDM were subjected to hypoxia 
for 2 h and 4 h and H if-la expression was detected in nuclear lysates by 
Western blot analysis. Stabilized H if-la was detected from 4 h in hypoxia 
treated Junbo BMDM (Figure 4.1b). RAW cells subjected to hypoxia for 24 
h were used as a positive control in these experiments. A doublet band was 
observed in hypoxia treated BMDM. A doublet band with hypoxia 
treatment has been reported previously and occurs due to post translational 
modifications with a signal observed for unprocessed H if-la ~95kD and a 
processed H if-la ~116kD (Duan et al, 2005; Wang & Semenza, 1993).
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Figure 5.1- Western blot of stabilized H if-la expression in Raw 264.7 
and BMDM nuclear lysates under hypoxic conditions
a) Time-course o f H if-la  response to hypoxia in RAW cells. Nuclear 
lysates (35 jag) from hypoxia treated RAW cells were loaded in 
individual lanes. High H if-la  expression was observed at 4 h and 16 
h. Weak H if-la  expression was detected at 2 h. H if-la  expression 
was not detected at 1 h.
b) Nuclear lysate (35 pg) from WT and Jbo/+ BMDM subjected to 
hypoxia for 2 h and 4 h were loaded in individual lanes. Nuclear 
lysate from RAW cells subjected to hypoxia for 24 h served as a 
positive control. H if-la  expression was detected at 4 h in hypoxia 
treated Junbo BMDM but not with 2 h hypoxia treatment.
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4.2.2- HIF signalling is dysregulated in Jbo/+ BMDM - Relative gene 
expression studies in WT and Jbo/+ BMDM
Relative gene expression was analysed by RT-qPCR over a hypoxia time- 
course in Jbo/+ and WT BMDM to determine the effect of mutation on a 
key panel of genes (Evi-1 responsive, hypoxia-responsive genes and 
inflammatory response genes) (Table 4.1). An alteration in Evi-1 
responsiveness in Jbo/+ mice might indicate direct effect of the Evi-1 
mutation on the transcriptional activity of Evi-1. An anomaly in the 
expression of hypoxia responsive and pro-inflammatory genes would 
indicate that the Evi-1 A22^ T mutation in Jbo/+ BMDM does dysregulate 
HIF signalling under hypoxic conditions. Each experiment was replicated 
on three separate occasions. Each replicate represented BMDM 
differentiated for 7-9 d from pooled BM isolated from five individual mice 
(aged 6 - 8  wk). Although H if-la stabilization in response to hypoxia was 
detected in BMDM from Junbo mice from 4 h, later time-points (24, 48 and 
72 h) were analysed to mimic the prolonged hypoxic conditions present in 
the Jbo/+ middle ear during prolonged periods of inflammation. Relative 
gene expression was calculated using delta C t (ACt) and expressed as RQ 
or fold-change compared with respective genotypic control calibrators. 
Prolonged time course of 24 h, 48 h and 72 h was studied till a seven to nine 
day endpoint. RQ is henceforth always calibrated within the genotype to the 
untreated normoxic control.
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Table 5.1- Panel of genes for studying cellular processes in Jbo/+ 
BMDM showing cellular function of each gene
Ccl2 chemokine C-C motif ligand 2 Chemokine
Cxcl2 chemokine C-X-C ligand 2 Chemokine
Evi-1 Ecotropic viralintegration site-1 Transcription factor
Fos FBJ murine osteosarcoma homolog
Transcrip tion  factor, apoptosis, survival, 
proliferation. Transform ation
Gata-2 Gata binding protein 2
Transcrip tion  factor, development, 
pro liferation  o f  hem atopoietic cells
Glut-1 Glucose transporter-1 Survival
H if-la Hypoxia induciblefactor-lalpha Transcrip tion  factor
II-lfl Interleukin-1 beta Proinflammatory
11-6 Interleukin 6 Proinflammatory
Abcal ATP binding cassetter, sub familyA member 1
Jun Jun Transcrip tion  factor, apoptosis, survival, pro liferation
Map3kl4 Mitogen activated protein kinase kinase kinase Kinase, participates in N F-kP signalling
Nos-2 Nitric oxide synthase 2, inducible Proinflammatory
Pai-1 Plasminogen activator inhibitor type 1 Proteinase inhibitor o f  plasm inogen activator
Phd2 Prolyl hydroxylase domain-containing protein 2 Hif-1 alpha degradation in normoxia
SmadS Smad3 Transcrip tion  factor
Tnf-a Tumour necrosis factor-alpha Proinflammatory
Vegf Vascular endothelial growth factor A ngiogenesis
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4.2.3- Effect of £V/-7A2288T mutation on Evi-1 responsive genes in 
hypoxia
Gene expression o f Evi-1 and Evi-1 responsive genes (Gata-2, Map Ski 4, c- 
Jun and Fos) were analysed using RT-qPCR. Detection of Evi-1 gene 
expression required pre-amplification PCR as the levels were below the 
level of sensitivity for detection by traditional RT-qPCR. Ppia was used as 
an endogenous control.
Evi-1 expression (Figure 4.2) was downregulated to 0.3 fold in hypoxia 
treated BMDM at 72 h. No changes (>2 fold up or down) in Evi-1 
expression were observed prior to this point. No differences were observed 
between the Jbo/+ and WT BMDM.
16-i Evi-1
crcc
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Figure 5.2-Comparable Evi-1 expression levels in WT and Jbo/+
BMDM after treatment with hypoxia
This figure illustrates relative Evi-1 gene expression levels between WT and 
Jbo/+ BMDM treated with hypoxia at 24 h, 48 h and 72 h. Blue bars denote 
WT levels and red bars denote Jbo/+ levels. The error bars represent RQ 
min and RQ max. Gene expression data obtained was normalized to Ppia 
gene expression, n= 3 where each replicate was from a pool of 5-6 mice.
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Map3kl4 and Gata-2 gene expression (Figures 4.3a and 4.3b) was time- 
dependently downregulated with hypoxia in both genotypes with maximum 
downregulation observed at 72 h hypoxia with a 0.4 fold expression in both 
genotypes. No differences were observed between the Jbo/+ and WT 
BMDM. These data indicated that that Map3kl4 and Gata-2 are hypoxia 
responsive genes which are downregulated on exposure to prolonged 
hypoxia. This cannot be attributed to cells dying as the RNA yield was 
unaltered.
Fos gene expression (Figure 4.3c) was upregulated with 24 h hypoxia (2 
fold in WT vs. 1.8 fold in Jbo/+ BMDM) although expression returned to 
basal level at 48 h. No differences were observed between the Jbo/+ and 
WT BMDM. Interestingly, upregulation of Fos gene expression was 
observed following further prolongation of hypoxic treatment at 72 h in WT 
but not in Jbo/+ BMDM (1.5 fold in WT vs. 1.2 fold in Jbo/+ BMDM). 
Although this difference was significant (P < 0.05) the upregulation 
observed in WT BMDM at 72 h falls short of the generally accepted 2-fold 
threshold true difference (calculation described in chapter 2 ), thus casting 
doubt on the biological relevance of this observation.
Expression of another Evi-1 responsive gene, Jun, (Figure 4.3d) was 
upregulated in response to hypoxia with a peak expression observed at 48 h 
of hypoxia (2.2 fold in WT vs. 2.0 fold in Jbo/+). No differences in Jun 
expression were observed between the Jbo/+ and WT BMDM at 24 h and 
48 h. However, a significant difference in Jun induction was observed at 72 
h hypoxia (1.9 in WT vs. 1.6 in Jbo/+ BMDM; P <0.05). However the 
change was small and the induction of Jun, falls short of 2-fold threshold, 
indicating that the biological relevance of this difference is questionable.
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Figure 5.3- Relative expression of Evi-1 responsive genes in hypoxia 
treated WT and Jbo/+ BMDM
This figure illustrates relative gene expression levels between WT and 
Jbo/+ BMDM treated with hypoxia at 24 h, 48 h and 72 h. Figure panels 
show relative (a) Map3kl4 gene expression, (b) Gata-2 gene expression (c) 
Fos gene expression and (d) Jun gene expression between the two 
genotypes, n=3. Each replicate was obtained from 8  d old BMDM from a 
pool of 5-6 individual mice (6 - 8  wk old). Statistics were performed using 
RQ min-max as recommended by Applied Biosystems using the ABI 7500 
sds software. The bars represents fold increase (RQ) in gene expression 
observed in hypoxia treated BMDM over the normoxic control calibrator of 
respective genotype. Blue bars denote WT levels and red bars denote Jbo/+ 
levels. The error bars represent RQ min and RQ max. Gene expression data 
obtained was normalized to Ppia gene expression. * P < 0.05.
136
4.2.4- The A2288T Evi-1 mutation in Jbo/+ induces altered expression 
of Vegf, Glut-1 and Pai-1 in hypoxia
Relative gene expression levels of Hif-la  and hypoxia and TGF-p 
responsive genes (Phd2, Vegf, Glut-1, and Pai-1) were compared in WT and 
Jbo/+ BMDM using RT-qPCR. According to my hypothesis that HIF 
signalling in Jbo/+ mice results in aberrant HIF and TGF-P signalling; 
hypoxia responsive genes and TGF-p responsive genes were chosen for this 
study.
Hypoxia did not have any impact on Hif-la  gene expression in WT and 
Jbo/+ BMDM (Figure 4.4).
Hif- la16-i
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Figure 5.4- Comparable H if-la  expression levels in WT and Jbo/+ 
BMDM after treatment with hypoxia
This figure illustrates relative Hif-la  gene expression levels between WT 
and Jbo/+ BMDM treated with hypoxia at 24 h, 48 h and 72 h. Blue bars 
denote WT levels and red bars denote Jbo/+ levels. The error bars represent 
RQ min and RQ max. Gene expression data obtained was normalized to 
Ppia gene expression. Three biological replicates were used for the study 
where each replicate was from a pool of 5-6 mice.
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Vegf gene is involved in angiogenesis and its expression increased in 
response to hypoxia in a time-dependent manner (Figure 4.5a). Vegf 
expression was increased in both genotypes at 24 h (9.2 in WT vs. 9.0 in 
Jbo/+ BMDM). Vegf levels were further increased on prolonged hypoxia 
exposure of 48 h (26.2 vs. 38.4 Jbo/+ BMDM) and 72 h (26.8 in WT vs. 
36.0 in Jbo/+ BMDM) with a significant difference (P < 0.01) observed in 
Vegf expression levels between genotypes.
Glut-1 gene expression also increased in response to hypoxia in a time- 
dependent manner (Figure 4.5b). Glut-1 expression was increased at 24 h 
(4.4 in WT vs. 5.1 in Jbo/+ BMDM) with no significant difference between 
the genotypes. Glut-1 levels were further increased on prolonged hypoxia 
exposure at 48 h (7.3 fold in WT vs. 9.3 in Jbo/+ BMDM) and 72 h (7.1 
fold in WT and 10.6 fold in Jbo/+ BMDM; P <0.01).
Upregulation of Phd2 was also observed in response to hypoxia in a time- 
dependent manner (Figure 4.5c) with the expression levels increasing from 
24 h hypoxia (5.0 fold in WT vs. 4.7 fold in Jbo/+ BMDM) to prolonged 
hypoxia exposure at 72 h (7.0 fold WT vs. 6 . 6  fold Jbo/+ BMDM). No 
significant differences in Phd2 expression were observed between the two 
genotypes at any point.
Pai-1 expression was induced after a relatively short hypoxia exposure of 24 
h. A significant difference between the genotypes was observed at this point 
(6.9 fold WT vs. 5.4 fold Jbo/+; P<0.01) (Figure 4.5d). Pai-1 expression 
declined with longer hypoxia exposure to the point that no differences were 
detectable between the genotypes at 48 h (Figure 4.5d). However, a 
significant differences in downregluated Pai-1 level was detected at 72 h 
hypoxia (0.5 vs. 0.7 Jbo/+ BMDM; P <0.01).
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Figure 5.5- Relative expression of hypoxia-responsive genes in hypoxia 
treated WT and Jbo/+ BMDM
This figure illustrates relative gene expression levels between WT and 
Jbo/+ BMDM treated with hypoxia at 24 h, 48 h and 72 h. Three biological 
replicates were used for the study where each replicate was from a pool of 
5-6 mice. Figure panels show relative (a) Vegf gene expression, (b) Glut-1 
gene expression (c) Phd2 gene expression and (d) Pai-1 gene expression 
between the two genotypes. Gene expression data obtained was normalized 
to Ppia gene expression. ** P < 0.01.
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4.2.5- Inflammatory response gene panel
It was hypothesized that differential gene expression of the key 
inflammation markers, 11-6, II-lp  and Tnf-a in hypoxia treated Jbo/+ 
BMDM would be indicative of a dysregulated inflammatory response to 
hypoxia, indicating perpetuation of inflammation.
Tnf-a expression (Figure 4.6a) was not affected by hypoxia treatment at 24 
h although expression was downregulated in both genotypes at 48 h (0.5 
fold in both genotypes) and 72 h (0.6 WT vs. 0.7 in Jbo/+) respectively. No 
significant differences were observed between the genotypes.
Il-lp  expression (Figure 4.6b) increased following 24 h hypoxia treatment in 
both genotypes (2.0 fold WT vs. 1.8 fold in Jbo/+ BMDM). Expression 
gradually decreased to approximate basal levels with further exposure. A 
significant difference (P < 0.05) in I l l - f  expression was observed at 48 h 
(1.2 fold in WT vs. 0.6 fold in Jbo/+ BMDM).
11-6 expression (Figure 4.6c) was not affected by hypoxia until treatment 
was prolonged to 72 h where upregulation was observed in both WT and 
Jbo/+ BMDM (1.6 fold WT vs. 1.8 fold in Jbo/+ BMDM). No significant 
differences were observed between the genotypes.
Nos-2 expression (Figure 4.6d) was increased in BMDM under hypoxic 
conditions from 24 h (3.9 WT vs. 3.5 Jbo/+ BMDM; P < 0.05) to 48 h (2.8 
fold in WT vs. 3.2 fold in Jbo/+ BMDM). A significant difference between 
Nos-2 levels was also observed at 72 h hypoxia (1.2 fold in WT vs. 1.3 fold 
in Jbo/+ BMDM; P < 0.05). However the differences between the 
genotypes were small and less than 25% and beneath the 2-fold cut off 
threshold.
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No changes in Cxcl2 expression (Figure 4.6e) were observed in response to 
hypoxia in Jbo/+ BMDM and WT BMDM. Although a modest increase (1.5 
fold in WT vs. 1.4 fold in Jbo/+) in Cxcl2 expression was observed in both 
genotypes at 48 h. A significant difference (1.1 fold WT vs. 0.9 fold Jbo/+; 
P<0.05) was observed in Cxcl2 expression at 72 h but the difference was 
very minute to be biologically relevant.
Ccl2 gene expression decreased in response to hypoxia in a time-dependent 
manner (Figure 4.6f). Ccl2 expression levels between WT and Jbo/+ 
BMDM at 24 h hypoxia (0.7 fold WT vs. 0.5 fold Jbo/+ BMDM; P < 0.05) 
as levels in Jbo/+ BMDM and 72 h hypoxia (0.2 fold WT vs. 0.3 fold Jbo/+ 
BMDM; P < 0.05) were significantly different. However, no significant 
difference was observed at 48 h hypoxia.
142
4-
2-
1
0.5
0.25
0.125
Tnf-a
a) Hypoxia
b)
c)
n - ip
0.25-
HYPOXIA
0.5-
0.25-
HYPOXIA
0.5J— r
Nos-2
I 1
■  r*n  1—s Ifiini  r* i
d)
HYPOXIA
143
Cxc/2
o£
0.5
0.25
0.125-
.c
CMC~
Hypoxia
Cc/2
O£
0.5-
0.25-
0.125-
£CNh-£
I---------------------------------- 1
Hypoxia
Figure 5.6- Relative expression of inflammatory genes in hypoxia 
treated WT and Jbo/+ BMDM
This figure illustrates relative gene expression levels of pro-inflammatory 
genes between WT and Jbo/+ BMDM treated with hypoxia at 24 h, 48 h 
and 72 h. Three biological replicates were used for the study. Each replicate 
was obtained from 8 d old BMDM from a pool of 5-6 individual mice (6 - 8  
wk old). Figure panels show relative (a) Tnf-a gene expression, (b) II-lp  
gene expression (c) 11-6 gene expression (d) Nos-2 gene expression, (e) Ccl2 
gene expression and (f) Cxcl2 gene expression between the two genotypes. 
Gene expression data obtained was normalized to Ppia gene expression. * P 
< 0.05.
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4.3- LPS studies: Activated Jbo/+ BMDM have altered gene expression 
profiles for Tnf-a, I I - I f  Vegf and 11-6
Jbo/+ mice exhibit chronic inflammation in the middle ear. LPS challenge 
is a classic model for investigating inflammatory processes. As mentioned 
in Chapter 1, macrophages exist in a number of activation states that are 
associated with differential gene expression depending on the activating 
signal they are exposed to (Laskin et al, 2011). LPS, a glycolipid component 
of bacterial cell wall is a potent trigger for macrophage activation and 
results in activation of phagocytic cells such as monocytes/macrophages and 
neutrophils (Dobrovolskaia & Vogel, 2002). LPS recognition by receptors 
such as TLRs induces MyD8 8  dependent activation of the NF-kB pathway 
(Takeda & Akira, 2004). NF-kB is a transcription factor that regulates 
expression of I L - l f  IL-6, IL-8, TNF-a, NOS-2 (Guha & Mackman, 2001). 
LPS also activates transcription factors involved in the AP-1 and MAPK 
signalling pathways (Guha & Mackman, 2001) resulting in release of 
cytokines that regulate the stages of inflammation and resolution or 
initiation of chronic conditions such as otitis media (Smirnova et al., 2002). 
LPS is also known to act as a non-hypoxic stimulus that strongly 
upregulates the HIF-1 complex in normoxia and modulates expression of 
hypoxia-responsive genes (Blouin et al, 2004). Furthermore, activation of 
NF-kB and production of pro-inflammatory cytokines by LPS induces HIF- 
la  transcription and protein (Blouin et al, 2004). Some of these pro- 
inflammatory genes upregulated on LPS activation of macrophages, such as 
TNF-a and I I - I f  further activate HIF-1 at the translational level (Brune & 
Zhou, 2007; Dehne & Brune, 2009; Hellwig-Burgel et al, 1999). This cross­
talk with the NF-kB pathway serves to enhance H if-la transcriptional
activity and is known to upregulate hypoxia-responsive genes such as Vegf
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and Glut-1, even under normoxic conditions (Elson et al, 2000). HIF-1 is 
also reported to be a mediator of inflammatory responses (Cramer & 
Johnson, 2003; Cramer et al, 2003; Peyssonnaux et al, 2005; Walmsley et 
al, 2005). These observations provide crucial evidence of a link between 
HIF signalling and NF-kB signalling. It can be hypothesized that the Jbo/+ 
mutation A2288T in Evi-1 influences both of these major signalling 
pathways via Evi-1 leading to alterations in the functional role of activated 
macrophages. This is supported by evidence demonstrating that bacterial 
load decreases the age of disease onset in Jbo/+ mice (Parkinson et al, 
2006). It is hypothesized that chronic inflammation in Jbo/+ mice is caused 
by a dysregulated macrophage activation profile leading to defective 
resolution of inflammation.
In order to better mimic the in vivo conditions of middle ear and to study
responses to inflammation and/or hypoxia in Jbo/+ BMDM, LPS
challenged cells were exposed to hypoxia. LPS challenge on hypoxic cells
was also performed to study effect of hypoxia conditioning on LPS-
responsiveness of BMDM. The results from hypoxia challenge suggests a
predisposition of Jbo/+ BMDM towards a dysregulated HIF signalling and
it is important to see if this dysregulation is manifested in inflammatory
conditions. To determine the effects of the A2288T Evi-1 mutation in Junbo
mice on the functionality of activated macrophages, the following
experiments were performed. Expression of Evi-1 protein was initially
investigated to discount the existence of abnormal Evi-1 expression in
Jbo/+ BMDM following classical activation of Junbo BMDM. The LPS
dosage optimisation and time-course studies using RT-qPCR and Tnf-a
assays (10 ng/ml, 100 ng/ml, 250 ng/ml, 500 ng/ml and 1000 ng/ml) (Figure
4.7) were performed to define the optimal conditions for subsequent
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experiments. BMDM were stimulated with a standard LPS dose (250 ng/ml) 
over 2 time points representing acute (2 h) and prolonged (24 h) exposure 
under defined conditions of normoxia and hypoxia. Analysis of exposure for 
72 h was not included as the RNA yield was prohibitively low due to 
pyroapoptosis (Fink & Cookson, 2005). Gene and protein expression of key 
inflammatory response genes were then analysed using the ACt method to 
provide an insight into the mechanism of chronic inflammation in middle 
ear in Jbo/+ mice.
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RQ 1.3 255.5 493.3 488.2 755.3
RQMIn 1.2 212.4 382.2 426.7 685.5
RQMax 1.4 307.3 636.6 558.5 832.2
Figure 5.7- LPS dosage optimisation
Pooled BMDM isolated from WT mice (n = 6 ) were used in this 
experiment. Bars represent fold-increase in Tnf-a gene expression in LPS 
(10 to 1000 ng/ml) treated WT and Jbo/+ BMDM compared with control 
untreated, genotype-matched BMDM. The y axis is presented on a Log2 
scale and shows fold-changes (RQ) compared with genotype-matched 
controls. Error bars represent RQ min and RQ max, which were calculated 
using three technical replicates. Gene expression data obtained were 
normalized to Ppia gene expression.
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4.3.1- Evi-1 expression is comparable in WT and Jbo/+ BMDM upon 
classical activation
Upregulated Evi-1 expression in response to LPS stimulation has been 
reported to reach a maximum after 2 h (Wells et al, 2003). Evi-1 and Evi-1 
expression are not affected in resting Junbo BMDM (Chapter 3). Therefore, 
LPS-induced activation o f BMDM was investigated to assess the effects o f 
the A2288T Evi-1 mutation in Jbo/+ mice. Results o f these studies indicated 
that E vi-1 protein expression was upregulated in response to LPS treatment 
by 15% in both WT and Jbo/+ BMDM compared with genotype-matched 
controls (Figure 5.8).
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Figure 5.8- Evi-1 is expressed equally in both WT and Jbo/+ BMDM
a) Western blot analysis of Evi-1 (115 kD) expression in total cell lysates 
from WT and Jbo/+ BMDM activated with and without LPS (2 h and 24 h). 
Protein (20 jug) was loaded in individual lanes. Protein extraction was 
performed with Nucleospin kits.
b) Western blot and densitometric analysis of Western blots for Evi-1 at 
basal level and after 2 h LPS activation. Lane 1 -unstimulated WT, Lane 2- 
unstimulated Jbo/+, Lane 3- LPS treated WT, Lane 4- LPS treated Jbo/+. 
No difference in Evi-1 expression was detected between the genotypes. 
Results are representative of three individual western blot experiments. 
Error bars denote SEM. Fold-change over WT (for Jbo/+) and genotype- 
matched untreated controls was calculated by measuring mean pixel density 
using Vision Works LS on Chemidoc. LPS increased Evi-1 expression by 
15% in both WT and Jbo/+ BMDM.
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4.3.2- Relative gene expression studies in LPS activated Junbo BMDM 
reveals altered Vegf, 11-6, Il-lp  and Tnf-a expression in Jbo/+ BMDM
Gene and protein expression of key inflammatory response genes {Tnf-a, II- 
6, II-If) and H if-la and hypoxia responsive genes {Vegf, Jun, Nos-2) were 
analysed in Jbo/+ BMDM and WT BMDM after LPS treatment in normoxia 
and hypoxia by RT-qPCR to provide an insight into the mechanism of 
chronic inflammation in the middle ear in Jbo/+ mice (Table 4.3).
Tnf-a expression (Figure 4.9a) was upregulated at 2 h LPS treatment (69.8 
fold in WT vs. 72.2 fold in Jbo/+ BMDM) and the induction was reduced 
by 24 h LPS activation (4.9 fold WT vs. 4.8 fold Jbo/+) but there was no 
significant difference between the genotypes. However on LPS and hypoxia 
induction of Tnf-a expression at 2 h displayed a genotypic difference (71.6 
fold WT vs. 45.8 fold Jbo/+ BMDM; P < 0.05). This trend of lower Tnf-a 
levels in treated Jbo/+ BMDM was maintained at 24 h hypoxia and LPS 
treatment (9.1 fold in WT vs. 7.3 fold in Jbo/+) but there was no significant 
difference between the genotypes at that time-point.
11-6 expression (Figure 4.9b) was induced in a time-dependent manner with
LPS treatment in normoxia. 11-6 levels were comparable between the
genotypes at 2 h LPS activation in normoxia (332 fold WT vs. 334 fold
Jbo/+ BMDM) but significantly different at 24 h activation (1200 fold WT
vs. 1720 fold in Jbo/+ BMDM; P < 0.05). The combination of hypoxia to
the LPS treatment induced 11-6 levels at 2h (1850 fold WT vs. 1547 fold in
Jbo/+ BMDM) and 24h (756 WT vs. 911 in Jbo/+ BMDM) but no
significant difference between the genotypes was observed.
Il-ip  expression (Figure 4.9c) was induced by LPS treatment in a time-
dependent manner as well. Greater I l - l f  induction was detected in response
to LPS stimulation at 24 h normoxia (1049 WT vs. 1075 in Jbo/+ BMDM)
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compared with that observed at 2 h normoxia (347 WT vs. 338 in Jbo/+ 
BMDM). Combination of LPS-stimulation and hypoxia resulted in reduced
II-lp induction in Jbo/+ BMDM at 2 h (584 in WT vs. 415 in Jbo/+ 
BMDM; P < 0.05). However, the difference was not significant under the 24 
h hypoxia and LPS (1267 fold in WT vs. 1208 fold in Jbo/+ BMDM). 
Expression of the key hypoxia responsive gene, Vegf was also analysed in 
LPS and hypoxia treated BMDM (Figure 4.9d). Vegf expression was 
increased by hypoxia and LPS had an additive effect on Vegf induction. 
Vegf expression modestly increased (1.9 WT vs. 1.7 in Jbo/+ BMDM) in 
both genotypes at 2 h LPS treatment in normoxia and no significant 
differences were observed between the genotypes. However, Vegf was 
induced by 13.3 fold in WT and 29.1 fold in Jbo/+ BMDM at 24 h LPS 
treatment in normoxia (P < 0.05). LPS-stimulation in hypoxia increased 
Feg/'levels at 2 h (4.9 fold WT vs. 2.9 fold Jbo/+) and at 24 h (12.1 fold vs. 
14.9 fold Jbo/+) but no significant genotypic difference was observed.
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Figure 5.9- Relative gene expression of Tnf-a. II-W, 11-6. Kgg/in LPS 
activated WT and Jbo/+ BMDM under normoxia and hypoxia
This figure illustrates relative gene expression levels between WT and 
Jbo/+ BMDM treated with 250ng/ml LPS (2 h, 24 h) in normoxia and 
hypoxia. Here, n= 6  where each replicate was from from individual mice. 
Figure panels show relative (a) Tnf-a gene expression, (b) I I-I f  gene 
expression (c) 11-6 gene expression and (d) Vegf gene expression between 
the two genotypes. Gene expression data obtained was normalized to Ppia 
gene expression. * P < 0.05, **P< 0.01.
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Jun expression (Figure 4.10a) was not affected by LPS treatment regardless 
of oxygen levels at 2 h. Nos-2 expression (Figure 4.10b) was analysed only 
at 2 h following LPS stimulation and was found to be increased with LPS 
stimulation in normoxia in both genotypes without any significant 
difference (37 WT vs. 32 Jbo/+). LPS induced Nos-2 levels were enhanced 
by hypoxia at 2 h (297 fold WT vs. 287 fold Jbo/+ BMDM) with no 
significant differences observed between the two both genotypes.
Jun
ini
Hypoxia
a) b)
Figure 5.10- Relative gene expression of Jun and Nos-2 in LPS activated 
WT and Jbo/+ BMDM under normoxia and hypoxia
This figure illustrates relative gene expression levels between WT and 
Jbo/+ BMDM treated with 250ng/ml LPS (2 h) in normoxia and hypoxia. 
Here, n= 6  where each replicate was from from individual mice. Figure 
panels show relative (a) Jun gene expression, and (b) Nos-2 gene expression 
between the two genotypes. Gene expression data obtained was normalized 
to Ppia gene expression.
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4.4- Hypoxic conditioning increases LPS-responsiveness in 
both WT and Jbo/+ BMDM to comparable levels
Having observed genotypic differences on with LPS activation in normoxia 
and hypoxia, it was important to find out if pre-treatment hypoxia had an 
effect on classical macrophage activation. It is plausible that prolonged 
hypoxic conditions prevalent in inflamed Jbo/+ middle ear might affect 
inflammatory response of Jbo/+ macrophages.
This was analyzed by treating BMDM to 22 h hypoxia prior to 2 h LPS 
treatment in hypoxia. Tnf-a, I I-I f  and 11-6 were the three key markers 
chosen for this study as they are classical LPS activation and inflammatory 
markers. No significant difference was observed in induction levels of Tnf- 
a, 11-6, and I I-I f  between the genotypes when conditioned with 2 2  h 
hypoxia and followed by 2 h LPS activation in hypoxia. However, hypoxic 
conditioning greatly augmented LPS induced inflammatory gene activation 
for these genes. Tnf-a levels were greatly induced in both genotypes (168.2 
fold WT vs. 158.1 fold Jbo/+ BMDM) with no difference in genotypes 
(Figure 4.11).
Hypoxia conditioning of BMDM also elevated 11-6 levels on LPS activation 
by 6360 fold in WT BMDM and 7050 fold in Jbo/+ BMDM over 
genotype-matched untreated control with no significant difference between 
genotypes (Figure 4.11).
Hypoxia conditioning prior to 2h LPS activation in hypoxia elevated I I- I f  
levels by 813 and 698 fold in WT and Jbo/+ BMDM respectively but was 
not significantly different between genotypes.
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Figure 5.11- Relative gene expression of 2h hypoxic LPS activation of 
hypoxia conditioned (22 h) WT and Jbo/+ BMDM
This figure illustrates relative gene expression levels o f Tnf-a, 11-6, 11-1$ 
between WT and Jbo/+ BMDM treated with 250ng/ml LPS in hypoxia for 
2h after a 22 h hypoxic pre-treatment conditioning. In this figure, n =6 
where each replicate is from individual 6-8 wk old mice. No significant 
differences were detected between Jbo/+ and WT.
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4.5- Resolution of Inflammation in hypoxia is impaired in 
Jbo/+ BMDM
As expression of key inflammation bio-markers Tnf-a, 11-6, I I-I f  and HIF 
signalling was dysregulated in Jbo/+ BMDM on prolonged LPS treatment 
and with combination of LPS and hypoxia; it was crucial to observe if the 
resolution of inflammation in hypoxia was compromised in Jbo/+ BMDM 
under hypoxic conditions, potentially explaining the persistent inflammation 
observed in Jbo. (Figure 4.12).
However 11-6 levels (918 WT vs. 1343 Jbo/+ BMDM; P < 0.05) and II-ip 
levels (929 WT vs. 1207 Jbo/+ BMDM; P < 0.05) were significantly 
different in Jbo/+ middle ear. LPS activation results in a downstream 
cascade of pro-inflammatory signals which might be encountered by Jbo/+ 
inflammatory cells during the course of an inflammatory response and I 
hypothesize that the Evi-1A22*ST mutation
might interfere with resolution of inflammation in hypoxic conditions in 
Jbo/+ mice. For this 2 h LPS activation in normoxia was followed by a 
hypoxic washout and a 24 h hypoxic incubation. The washout was carried 
out to remove the LPS stimulation and observe the resolution of 
inflammation in hypoxic conditions. This resulted in a significant genotypic 
difference in Tnf-a levels between the genotypes (3.7 fold WT vs. 4.5 fold 
Jbo/+ BMDM; P<0.05). Both 11-6 and I I-I f  were significantly greater in 
Jbo/+ BMDM than WT BMDM which indicates an aberrant resolution of 
inflammatory response in Jbo/+ BMDM in hypoxia (Figure 4.12).
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Figure 5.12- Resolution of inflammation is impaired in Jbo/+ BMDM in 
hypoxia
This figure illustrates relative gene expression levels o f Tnf-a, 11-6, II-1(3 
between WT and Jbo/+ BMDM treated with 250ng/ml LPS in normoxia for 
2h followed by a LPS washout and 24 h treatment in hypoxia. Six biological 
replicates were used for the study, each replicate was obtained from 8d old 
BMDM from individual 6-8 wk old mice. * P < 0.05.
4.6- Jbo/+ middle ears have high Ox-LDL concentrations
Another key characteristic o f inflamed Jbo/+ ear exudates is the presence o f 
foamy macrophages (Cheeseman et al, 2011; Parkinson et al, 2006). Foamy 
macrophages are formed by uptake o f oxidized low-density lipoporotein 
(LDL) and subsequent accumulation o f cholesterol esters and oxysterols 
which gives these macrophages a characteristic foamy appearance (Brown 
et al, 2000; Heinecke et al, 1991). Foamy macrophages are associated with 
other chronic inflammatory diseases such as artherosclerosis (Steinberg, 
1997a; Steinberg, 1997b; Steinberg, 2009). Jbo/+ middle ear is hypoxic
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(Cheeseman et al, 2011). Hypoxia is conducive to oxysterol presence and 
foam cell formation (Cheeseman et al, 2011; Hulten & Levin, 2009; 
Parkinson et al, 2006; Rydberg et al, 2004). Ox-LDL assay performed on
12-21 wk old mice (section 2.13.4) revealed that Ox-LDL concentrations in 
Jbo/+ ear exudates are 240 folds greater than the Ox-LDL levels in Jbo/+ or 
WT serum which are comparable (Figure 4.13). The presence o f foamy 
macrophages and higher amounts o f Ox-LDL along with hypoxia might 
affect the inflammatory response in Jbo/+ mice. This led to my next 
hypothesis that the chronic inflammation in Jbo/+ mice is a result o f 
dysregulated and hypo-responsive foamy macrophages in Jbo/+ BMDM.
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Figure 5.13- Jbo/+ mice have high Ox-LDL concentration in middle ear
This figure illustrates Ox-LDL concentrations in Jbo/+ middle ear fluid. 
Serum samples from WT and Jbo/+ mice o f same cohort were used as 
control due to absence o f fluid in WT middle ear. NS= not significant, ***P 
<0.0001, n =18 for WT serum, n=15 for Jbo/+ serum, n=21 for Jbo/+ ear 
fluid.
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4.7- Foamy Jbo/+ BMDM under hypoxic conditions have 
reduced Nos-2 expression levels
To test hypothesis that Jbo/+ foamy macrophages are hypo-responsive in 
hypoxic conditions the following experiments were performed. BMDM 
from Junbo mice were subjected to oxysterol treatment in normoxia or 
hypoxia as well as subjected to an oxysterol washout and LPS activation 
and 2  h hypoxia exposure to explore if a shift in gene expression profile of 
Ox-LDL responsive inflammatory genes in Jbo/+ foamy macrophages 
results in chronic inflammation observed in Jbo/+ middle ear. To induce 
foam cell formation BMDM were treated with oxysterol at a concentration 
of 5 pg/ml under normoxia for 24 h to load the cells with oxysterol followed 
by a 12 h oxysterol incubation in normoxia or hypoxia (Figure 4.14) (See 
section 2.3 for method). A washout of oxysterol was performed to see if the 
effect of oxysterol was reversed. LPS-responsiveness post oxysterol 
treatment was also analysed by activating BMDM with 2 h LPS in hypoxia 
post-washout. Analysis of the response to oxysterol in Junbo BMDM was 
performed by real-time gene expression analysis of an oxysterol responsive 
gene panel containing cholesterol efflux protein encoding gene Abcal, 
inflammatory marker genes Tnf-a, Nos-2, and chemokine Cxcl2. Alteration 
in Abcal expression may indicate defective cholesterol efflux and 
susceptibility to foam cell formation by Jbo/+ BMDM. Cxcl2 was chosen 
as it is a homolog of IL-8 in mice and a key inflammatory chemokine that 
attracts macrophages. IL- 8  induction in response to oxysterol has been 
reported in the literature (Liu et al, 1997).
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Figure 5.14- Diagrammatic representation of oxysterol studies
BMDM from femurs of 6-9 wk old mice were cultured in GM-CSF. BMDM 
were treated to 5 pg/ml of oxysterol in normoxia for 24 h to lipid load the 
BMDM. BMDM were then exposed to one of the 4 treatment conditions. 
Cells were then harvested and analysed using RT-qPCR.
• 1 2  h oxysterol incubation in normoxia
• 1 2  h oxysterol incubation in hypoxia
• Oxysterol washout followed by 2 h hypoxia
• Oxysterol washout followed by 2 h hypoxia and LPS
yt
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w ashout
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Abcal expression was upregulated by oxysterol treatment in normoxia (7.3 
fold WT vs. 9.0 fold) and hypoxia (15.7 fold WT vs. 13.3 fold Jbo/+ 
BMDM) with no significant genotypic difference in its expression (Figure 
14.15a). Removal of oxysterol stimulus by washout in hypoxia resulted 
rapid reduction of induced Abcal levels (2 fold in WT vs. 3.6 fold in Jbo/+ 
BMDM). 2 h hypoxic LPS activation post-oxysterol treatment and washout 
resulted in induction of Abcal levels (14.3 fold WT vs. 14.9 fold Jbo/+ 
BMDM) (Figurel4.15a).
Tnf-a expression was induced with oxysterol treatment in normoxia (4.9 
fold WT vs. 4.3 fold Jbo/+) but not in hypoxia (0.9 fold in WT and Jbo/+ 
BMDM). No difference between genotypes was observed with either 
treatment. Tnf-a levels were induced with 2 h hypoxia exposure post- 
oxysterol treatment and washout (12.0 fold in WT vs. 10.6 fold Jbo/+ 
BMDM). Exposure of BMDM to oxysterol reduced LPS responsiveness and 
reduced Tnf-a induction by LPS in hypoxia (22.3 fold WT vs. 19.8 fold 
Jbo/+ BMDM) (Figure 14.5b).
Cxcl2 levels were upregulated by oxysterol treatment in normoxia (2.7 fold 
WT vs. 2.3 fold Jbo/+ BMDM) and hypoxia (2.7 fold WT vs. 3.1 fold in 
Jbo/+ BMDM) with no significant difference between genotypes. Cxcl2 
levels were downregulated with the removal of oxysterol in both genotypes 
(0.4 in WT and Jbo/+ BMDM). Hypoxic LPS activation post oxysterol 
treatment and washout resulted in Cxcl2 upregulation (80.1 fold vs. 55.5 
fold). However, no significant genotypic difference in Cxcl2 levels was 
observed (Figure 14.5c).
Nos-2 expression was elevated by 3.1 fold in WT BMDM vs. 1.3 fold in
Jbo/+ BMDM on oxysterol treatment in normoxia with no significant
difference between the genotypes. Oxysterol treatment in hypoxia resulted
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in a significant difference in Nos-2 levels between the genotypes. Nos-2 
levels were 2.5 fold induced in WT vs. 0.6 in Jbo/+ BMDM (P < 0.05). 
Oxysterol washout and 2 h hypoxia exposure post-treatment increased Nos- 
2 to comparable levels (2.8 in WT vs. 3.3 in Jbo/+ BMDM; P > 0.05) LPS 
responsive Nos-2 activation in hypoxia was inhibited with oxysterol 
treatment to comparable levels in both genotypes (4.4 fold in WT vs. 4.6 
fold in Jbo/+ BMDM; P > 0.05 ) (Figure 14.5d).
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Figure 5.15- Oxysterol treatment modulates gene expression in Junbo 
BMDM
This figure illustrates relative gene expression levels of Tnf-a, Abcal, Nos2, 
Cxcl2 between WT and Jbo/+ BMDM treated with oxysterol in hypoxia and 
normoxia, n= 6  where each replicate was obtained from 8 d old BMDM from 
individual 6 - 8  wk old mice. *P<0.05.
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4.7- Discussion
Evi-1A2288T mutation lies in the ZF2, and ZF2 interacting Evi-1 responsive 
genes Fos and Jun encode for components of transcriptional factors AP-1. 
HIF pathway is known to crosstalk with AP-1 (Laderoute, 2005). According 
to the literature hypoxia increases the gene expression of Fos and Jun 
(Ausserer et al, 1994; Laderoute, 2005; Wang et al, 1995). c-Fos and c-Jun 
are reportedly a member of early group of genes where their expression is 
characterized by early induction by stimuli such as hypoxia. It has been 
reported that hypoxia responsive early induction of Jun is independent of 
H if-la but hypoxia responsive late induction on prolonged hypoxia is 
dependent on H if-la and HIF signalling (Laderoute, 2005). Results from c- 
Jun and c-Fos expression from hypoxia responsive studies possibly 
mimicked the above mentioned biphasic activation. 24 h hypoxia saw 
induction of both Jun and Fos expression without a significant difference 
between genotypes (Table 4.2).
A significant difference (P < 0.05) at late induction (72 h hypoxia) of Jun 
and Fos was observed between genotypes. Jun levels were 15% less 
induced in Jbo/+ than WT at 72 h hypoxia. Similarly, Fos levels were 20% 
less induced in Jbo/+ than WT at 72 h hypoxia. However, the difference 
between the genotypes was < 25%. Also, the individual fold change in 
either of the genotype did not meet the 2 fold cut-off value (See Table 4.2) 
so the difference was not arguably biologically relevant.
Relative gene expression of H if-la  and hypoxia responsive genes Vegf, 
Glut-1, Phd2, and Pai-1 (Murdoch et al, 2005) was also analyzed. H if-la  is 
not reported to be a hypoxia responsive gene and as expected its gene 
expression was not affected by hypoxia.
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Vegf is involved in angiogenesis and other cellular processes such as NL 
recruitment, and mast cell activation (Ferrara, 2009). Vegf is known to be 
Hif-la dependent hypoxia responsive gene (Forsythe et al, 1996). Vegf 
expression was upregulated with hypoxia in a time dependent manner. No 
significant difference was observed at earlier time point of 24 h hypoxia in 
Vegf levels between genotypes. However, a significant increase (P < 0 .0 1 ) 
in keg/*levels in Jbo/+ BMDM was observed with further hypoxic exposure 
of 48 h (46% increase) and 72 h (33% increase). Vegf is known to be co­
activated by Smad3 and H if-la in hypoxic conditions (Sanchez-Elsner et al, 
2001) and the differential upreglation of Vegf by the Jbo/+ Evi-1A2288T 
mutation suggests the mutation may act via Smad3. Evi-1 is a repressor of 
Smad3 (Kurokawa et al, 1998b) and a potential Evi-1 loss of function would 
increase transcriptional activity of Smad3 to increase Vegf expression in 
hypoxia as was observed. Vegf is also reported to be upregulated by just 
LPS under normoxic conditions (Blouin et al, 2004; Karin, 2006; Sakuta et 
al, 2001). Vegf expression was upregulated with 2h and 24 h LPS treatment 
in a time-dependent manner in WT and Jbo/+ BMDM in normoxia. 
Interestingly, LPS induced Vegf activation was 123% higher in Jbo/+ than 
WT BMDM at 24 h LPS activation in normoxia (P < 0.05). At 24 h LPS and 
hypoxia treatment the significant difference in Vegf levels was absent. 
However, the trend of higher Vegf levels in Jbo/+ BMDM was still 
apparent.
Glut-1 is another hypoxia responsive gene which functions as a glucose 
transporter and is implicated in cell survival (Burke et al, 2003). Glut-1 
expression pattern in hypoxia was similar to Vegf pattern in that Glut-1
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induction with hypoxia was significantly greater in Jbo/+ BMDM than WT 
BMDM at 48 h (28%) and 72 h (57%).
Pai-1 is also a hypoxia responsive as well as Smad3 responsive gene 
(Dennler et al, 1998b; Pinsky et al, 1998). Pai-1 levels were increased with 
hypoxia but the levels gradually decreased on prolonged hypoxia. Pai-1 
levels were 21% less induced in Jbo/+ BMDM than WT BMDM at 24 h (P 
<0.01). Prolonged hypoxia at 72 h decreased Pai-1 expression below the 
basal level but interestingly Pai-1 levels were 40% more in Jbo/+ than WT 
(P < 0.01). This differential expression of Pai-1 may be explained by 
complex regulation of Pai-1. Pai-1 expression is induced by different 
signalling pathways as Pai-1 promoter has various cis-regulatory sites such 
as SP1 site, AP-1 sites, HRE sites and Smad binding sites which indicates 
complex transcriptional regulation of this gene (Liao et al, 2007; Nagamine, 
2008). Increased Vegf levels has been linked to inhibition of Pai-1 
expression and that is one plausible reason for downregulation of Pai-1 
expression with prolonged hypoxia (Mukai et al, 2007). However, is
a OOOO'T
possible that the Evi-1 mutation in Jbo/+ affects Pai-1 gene expression 
through another novel pathway.
Phd2 encodes for an enzyme that is involved in hydroxylation and 
ubiquitination of Hif-la (Masson et al, 2001). Expression of Phd2 is known 
to increase with hypoxia (D'Angelo et al, 2003a; Metzen et al, 2005). 
Elevated but comparable Phd2 expression was observed in both genotypes 
on hypoxic stimulation which indicates a feedback loop to compensate for 
reduced hydroxylase activity and prepare cells to clear H if-la in normoxia 
(D'Angelo et al, 2003a).
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Expression of key inflammatory gene markers Tnf-a, 11-6, II-lp  and Nos-2 
as well as chemokines Ccl2 and Cxcl2 were analysed. Ccl2 levels decreased 
in response to hypoxia in a time dependent manner (Table 4.3). However, 
Jbo/+ BMDM had 28% lower Ccl2 levels than WT at 24 h hypoxia (P 
<0.05) (Table 4.3). However, at 72 h Ccl2 expression was 50% higher in 
Jbo/+ at 72 h (P <0.05). Hypoxia is known to downregulate Ccl2 in 
macrophages (Bosco et al, 2004a).
Hypoxia decreased level of Tnf-a on its own but the levels were comparable 
in both genotypes. Tnf-a is an early LPS responsive gene (Hume et al, 
2002; Locati et al, 2002; Yamakawa et al, 1999). As expected Tnf-a levels 
were upregulated with LPS treatment at 2 h and 24 h in both normoxia and 
hypoxia with a peak time of 2 h. A genotypic difference in Tnf-a expression 
was observed at combination treatment of 2 h LPS and hypoxia where 
Jbo/+ Tnf-a levels were 36% lower than WT BMDM (P < 0.05). Although, 
similar trend was present even with 24 h hypoxia and LPS treatment but it 
was not significantly different between the genotypes. This suggests that 
Tnf-a expression is dysregulated in hypoxic activated Jbo/+ BMDM in 
acute inflammatory conditions.
11-6 is also a upregulated with LPS in an NFkB dependent manner (Begum 
et al, 2004; Yang et al, 2010). 11-6 expression is known to be upregulated 
with hypoxia (Albina et al, 1995; Matsui et al, 1999). An upregulation of II- 
6 was observed at prolonged hypoxia (72 h) was observed in both genotypes 
with no significant genotypic difference in its levels. 11-6 levels were also 
upregulated by LPS treatment in a time dependent manner in normoxia. 
Although 11-6 levels at 2h were comparable between the two genotypes; 11-6 
induction at 24 h LPS activation was 43% increased in Jbo/+ BMDM than
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WT BMDM (P <0.05). This indicated a dysregulation of expression of 
inflammatory marker 11-6 in activated macrophages at 24 h LPS.
Il-lp  gene expression levels are reported to increase with hypoxia (Scanned, 
1996). Il-lp  gene levels were observed to be upregulated at 24 h but the 
level of induction was comparable in both genotypes. Il-lp  levels gradually 
decreased to basal level with further hypoxic exposure. At 48 h hypoxia Il- 
lp  levels were 50% reduced in Jbo/+ BMDM compared to WT (Table 4.3). 
However, the result was not considered a biologically relevant result as II- 
lp  in both genotypes was below the arbitrary cut-off value. II-lp  is also 
upregulated by LPS (Hume et al, 2002; Locati et al, 2002; Perera et al, 
1998). In the LPS activation studies performed for this chapter, Il-ip  levels 
were upregulated with LPS activation in a time dependent manner in 
normoxia and hypoxia (Table 4.3). Similar to Tnf-a, Il-ip  levels were 30% 
lower in Jbo/+ with 2h LPS and hypoxia treatment (P < 0.05). However, 
this difference was not observed at combined 24 h activation of LPS and 
hypoxia.
Nos-2 is a gene associated with production of reactive nitrogen species NO 
(Leone et al, 1991; Palmer et al, 1988). Nos-2 expression is upregulated by 
LPS via hypoxia and NF-kB (Angele et al, 1999; Blouin et al, 2004; 
Heitmeier et al, 1998; Song et al, 2004). Nos-2 levels were induced with 
hypoxia at 24 h and gradually declined with further hypoxia exposure 
(Table 4.2). LPS activation induced Nos-2 expression in both genotypes in 
normoxia as well as hypoxia with no significant difference (Table 4.3). Nos- 
2 expression was synergistically enhanced by hypoxia and LPS activation.
These results validate that HIF signalling in Jbo/+ BMDM is dysregulated 
in resting hypoxic BMDM and activated hypoxic BMDM.
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Significant differences between genotypes in expression of inflammatory 
markers were observed in resolution of inflammation studies in which 
BMDM were activated with LPS for 2 h followed by LPS washout and 24 h 
hypoxia exposure. Tnf-a, 11-6, Il-lp  levels were all higher in Jbo/+ BMDM 
by 24%, 46% and 30% respectively (P < 0.05). These results support the 
hypothesis that resolution of inflammation is dysregulated in Jbo/+ BMDM 
in hypoxic conditions.
Ox-LDL and its gene regulating component oxysterol accumulate in 
macrophages to form foamy macrophages which are a key feature of ear 
exudates in Jbo/+. My next hypothesis was that Evi-1A2288T mutation 
predisposes Jbo/+ BMDM to foam cell formation in hypoxia and that Jbo/+ 
foamy macrophages have an aberrant transcriptional profile that affects their 
function and renders them pro-inflammatory.
Oxysterol is known to induce Abcal expression (Jiang et al, 2006; Tang et 
al, 2004). Abcal levels were upregulated comparably in both WT BMDM 
(7.3 fold) and Jbo/+ BMDM (9 fold) with oxysterol treatment in 
normoxia.(P > 0.05). Hypoxia and LPS enhanced the increase in Abcal 
expression despite oxysterol washout. No significant difference in Abcal 
levels between the genotypes was present which suggests cholesterol efflux 
in Jbo/+ BMDM was not affected and that Jbo/+ BMDM. Abcal 
expression in both genotypes was comparable (Table 4.4). This indicated 
that cholesterol efflux in Jbo/+ was not affected because of Evi-1A22^ T 
mutation and that both WT and Jbo/+ were equally prone to foam cell 
formation.
Oxysterols have been shown to increase IL-8 levels in macrophages which
are further enhanced by hypoxia via AP-1 binding (Liu et al, 1997; Rydberg
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et al, 2003). Cxcl2, also known as Mip-2, is the mouse homolog of human 
IL-8 and a key inflammatory chemotactic for macrophages. Results from 
this chapter revealed that hypoxia did not induce Cxcl2 expression (Table 
4.2; Table 4.6). However, oxysterol increased Cxcl2 expression in both 
genotypes (Table 4.6) with no significant difference between the genotypes. 
Removal of oxysterol stimulus by washout in hypoxia decreased Cxcl2 
expression below basal level (Table 4.6) which confirms role of oxysterol in 
Cxctt induction. Hypoxic oxysterol treatment followed by washout and 2 h 
LPS and hypoxia exposure induced Cxctt levels by 80 fold in WT and 55 
fold in Jbo/+ BMDM. Although a trend of lower Cxctt levels in Jbo/+ was 
apparent with LPS activation of pre-treatment oxysterol incubated BMDM, 
the difference was not significant.
Oxysterols in foamy macrophages are known to activate nuclear receptors 
such as LXRs to modulate gene expression (Ghisletti et al, 2007; Janowski 
et al, 1999). Activation of PPARy and LXR in cultured macrophages by 
oxysterol represses expression of inflammatory mediators such as Nos-2, 
Tnf-a in response to LPS stimulation by working as a promoter specific 
repressor (Castrillo et al, 2003; Ghisletti et al, 2007; Liu & Shuai, 2008; 
Pascual et al, 2005). Nos-2 expression via AP-1 and NF-kB is inhibited by 
PPARy and LXR activation of oxysterols (Castrillo et al, 2003; Ghisletti et 
al, 2007; Liu & Shuai, 2008; Pascual et al, 2005). The current study showed 
oxysterol treatment enhanced Nos-2 expression under normoxia and 
hypoxia in WT but Nos-2 levels in Jbo/+ BMDM were 76% lower than WT 
on oxysterol treatment in hypoxia (P <0.0.5) (Table 4.4). Removal of 
oxysterol stimuli by hypoxic washout increased Nos-2 levels in Jbo/+ 
BMDM to comparable WT levels. LPS stimulation of Nos-2 was repressed
with oxysterol pre treatment. This suggests that Nos-2 activation by AP-1 
and NF-kB was repressed in both genotypes under conditions of hypoxia 
and LPS activation by oxysterol activation of LXR (Ghisletti et al, 2007). 
However, Nos-2 regulation involves complex interactions between different 
transcriptional activators such as GATA, CREB, NF-IL6 , p53, SP1 etc apart 
from NF-kB and AP-1 (Pautz et al, 2010). The increase in Nos-2 expression 
studies on hypoxic oxysterol treatment may involve an alternate 
upregulation via oxysterol which seems to be inhibited in Jbo/+. Lower NO 
due to lower Nos-2 levels might also make Jbo /+ BMDM prone to bacterial 
infection as NO is has key anti-bacterial properties (Bogdan et al, 2000).
Tnf-a is also a NF-kB controlled gene and level of Tnf-a induction with LPS 
following oxysterol incubation was reduced due to LXR activation by 
oxysterol (Ghisletti et al, 2007). However a comparable induction of Tnf-a 
by oxysterols in normoxic resting BMDM from both genotypes was 
observed, which is attributed to Tnf-a being a direct target for LXR in 
macrophages (Landis et al, 2002). Hypoxia decreased induced Tnf-a level 
back to basal level. Tnf-a levels were upregulated again with oxysterol 
washout suggesting a complex network of Tnf-a regulation and that Tnf-a 
via different mechanisms.
Conclusion:
In summary, studies of cellular processes in Jbo/+ BMDM are pre-disposed 
to inflammation under hypoxia and activation state due to dysregulated HIF 
signalling involving pro-angiogenic genes such as Vegf, Glut-1, Pai-1; 
genes involved in inflammation 11-6, Tnf-a, 11-1(1; and the chemokine Ccl2.
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Results from this chapter also indicated an impaired resolution of 
inflammation in Jbo/+ BMDM under hypoxic conditions. Reduced Nos-2 
expression in Jbo/+ foamy macrophages suggests the possibility of 
increased susceptibility of Jbo/+ BMDM to bacterial infections in hypoxia.
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Chapter 5
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6. TGF-p dysregulation in 
Junbo and Jeff
5.1- Introduction
TGF-P is a potent immunosuppressive agent produced by a variety of cells 
including and is involved in a variety of cellular processes (Massague, 1998; 
Massague et al, 1990).
As previously noted, Junbo and Jeff are spontaneous chronic OM models 
generated at MRC Harwell through an ENU mutagenesis programme. Jbo/+ 
mice carry a mutation in the trans-activator protein Evi-1 gene (Parkinson et 
al, 2006) and Jf/+ mice carry a mutation in Fbox protein Fbxoll (Hardisty 
et al, 2003). Both models display phenotype of chronic inflamed middle ear
A998RTwhich manifests as conductive deafness. Both the Evi-1 mutation in 
Junbo and the Fbxol l Al472T mutation in Jeff are implicated in TGF-P 
signalling via their interactions with Smads. Evi-1 is a co-repressor and 
interacting partner of Smad3. Fbxoll on the other hand has been shown to 
interact indirectly with Smad2. Fbxoll is implicated in stabilization of 
Smad2 interacting p53 via an unknown mechanism (Tateossian et al, 2009). 
I hypothesize that the mutation in Jeff and Junbo heterozygotes impacts 
upon TGF-p signalling to result in chronic middle ear inflammation. 
Cellular hypoxia is a key feature of inflammation in both these mutants and 
TGF-p is known to interact with the HIF pathway to modulate gene 
expression of target genes under hypoxia (McMahon et al, 2006; Sanchez- 
Elsner et al, 2001). Elevated Smad3 target genes like Vegf and Glut-1 have 
been observed in middle ear fluids from both mutants which hints towards a
role of this ubiquitous pathway in chronic middle ear inflammation 
(Cheeseman et al, 2011).
To study the effect of how the Evi-1A2288T and Fbxol 1M412T mutations 
impact upon TGF-/? signalling, an in-vitro model using BMDM was 
developed. BMDM were treated with TGF-p under normoxia and hypoxia 
to uncover the effect of mutations on TGF-p signalling. Dosage 
optimization for TGF-p was performed on pooled BMDM from 3 WT mice. 
BMDM was stimulated with TGF-P at 0 pmol, 25 pmol, 50 pmol, 200 pmol 
for 48 h. FACS analysis was performed for Lectin-like oxidized LDL 
receptor-1 (Lox-1) expression on BMDM. Lox-1 is a receptor for Ox-LDL 
uptake expressed on the cell surface of macrophages and is upregulated by 
TGF-P treatment (Draude & Lorenz, 2000). Maximum response of Lox-1 to 
TGF-P cwas observed at of 200 pmol. Upregulation of Lox-1 receptor was 
observed in both WT and Jbo/+ BMDM at 24 h time-point with 200pmol 
TGF-p treatment. No significant difference between the two genotypes was 
observed (Figure 5.1).
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Figure 6.1- Lox-1 is upregulated in both WT and Jbo/+ BMDM after 
TGF-P treatment (200 pmol) for 24 h
Result is a mean of 5 individual experiments. Error bars represent the 
standard deviation. MFI- Mean fluorescence intensity.
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5.2- TGF-p (Transforming growth factor-P) pathway is 
dysregulated Jbo/+ BMDM under normoxic and hypoxic 
conditions
Smad3 is a key intracellular effector of TGF-p signalling. It is a 
transcriptional activator which interacts with other transcriptional activators 
like H if-la and AP-1 transcriptional complex members to co-activate target 
TGF-p genes such as TIMP-1, PAI-1, VEGF, FOXP3 (Liberati et al, 1999; 
Zhang et al, 1998) or co-repress genes such as NOS-2 (Yoshimura et al). My
A99RRThypothesis is that the Evi-1 mutation dysregulates TGF-P signalling in 
Junbo which results in perpetuation of inflammation. Evi-1 suppresses 
Smad3 via its C-terminal binding protein(CtBP) binding consensus motif 
containing repression domain between the 2 zinc finger domains (Izutsu et 
al, 2001; Kurokawa et al, 1998b). Evi-1 also activates JNK and AP-1 
pathways via ZF1 and ZF2 respectively (Kurokawa et al, 1998a; Kurokawa 
et al, 1998b; Kurokawa et al, 2000). These interactions link Evi-1 to TGF-p 
signalling pathway, suggesting that the mutation may cause OM through 
effects on TGF-p signalling. Elevated Smad3 downstream targets such as 
Vegf and Glut-1 have been observed in the inflammatory cell population 
containing Jbo/+ middle ear fluid in comparison to WT serum by RT- 
qPCR array (Cheeseman et al, 2011) as well as in hypoxic Jbo/+ BMDM in 
the preceding chapter. This information provides a crucial link between HIF 
pathway and TGF-p pathway as Vegf is co-activated by Smad3 and Hif-la. 
Interestingly, elevated Hif-la  levels have also been observed in the middle 
ear of Jbo/+ mice (Cheeseman et al., 2011). This suggests the possibility
A 9 9 R R Tthat the Evi-1 mutation may impact upon TGF-p signalling via the 
canonical Smad3 pathway. If the Evi-1A22in mutation is a loss of function
then an upregulation of Smad3 activated genes would be observed after 
TGF-p treatment of Junbo BMDM.
5.2.1- Comparative gene expression analysis of WT and Jbo/+ BMDM 
with TGF-p treatment in normoxic and hypoxic condition reveals key 
genotypic differences in Pai-1, Vegf, II-If and 11-6 expression
RT-qPCR was used to perform a series of comparative gene expression 
studies for key TGF-p responsive genes Vegf Pai-1, Phd2, II-If, Tnf-a, 11-6, 
c-Jun, c-Fos, Ccl2, Cxcl2) (Dennler et al, 2002; Fadok et al, 1998b; 
Feinberg et al, 2004; Jeon et al, 2007; McDonald et al, 1999; Naiki et al, 
2005; Schluns et al, 1997; Stroschein et al, 1999; Subramaniam et al, 1995; 
Viard et al, 1993) as well as Smad3 and Hif-la  (also see section 5.3 for 
details). A standard dose of 200 pmol was used throughout the experiments 
and a time course range of 6  h, 24 h and 48 h of TGF-p treatment under both 
normoxic and hypoxic conditions.
TGF-p treatment in normoxia enhanced Vegf expression. Vegf levels with 6  
h of TGF-p treatment in normoxia were lower in Jbo/+ BMDM (2.3 fold in 
WT vs. 1.6 fold in Jbo/+; P < 0.01) (Figure 5.2a). This trend of lower Vegf 
in Jbo/+ BMDM with TGF-p treatment was also manifested at 24 h (2.1 
fold in WT vs. 1.8 fold in Jbo/+ BMDM; P < 0.05) and 48 h TGF-P 
treatment in normoxia (1.5 fold WT vs. 1.2 fold in Jbo/+ BMDM). 
Exposure of BMDM to hypoxia and TGF-p treatment enhanced induced 
Vegf expression (Figure 5.2a). The elevation in Vegf gene expression was 
most pronounced at 48 h TGF-p (61 fold in WT vs. 55 fold in Jbo/+ 
BMDM) but the levels were not significantly different between the 
genotypes. Exposure of BMDM to hypoxia and TGF-p led to further 
increment in Vegf expression. Interestingly after exposure of BMDM to 6  h
TGF-P and hypoxia, Peg/levels in Jbo/+ were higher than WT (13 fold WT 
vs. 16 fold in Jbo/+; P < 0.05). Vegf levels were however comparable 
between both genotypes at 24 h and 48 h of combination treatment and not 
significantly different.
6  h TGF-p treatment in normoxia upregulated Pai-1 expression in WT but 
the Pai-1 levels in treated Jbo/+ were lower (2.1 fold WT vs. 1.3 fold 
Jbo/+; P < 0.01) (Figure 5.2b). This trend was maintained till 24 h TGF-p 
treatment in normoxia (but there was no significant difference between the 
genotypes) and declined back to basal level (1.3 fold WT vs. 1.1 fold Jbo/+) 
in both genotypes by 48 h TGF-p treatment in normoxia. Hypoxia 
synergistically increased Pai-1 induction in TGF-p treated BMDM. 
Interestingly a trend of lower Pai-1 levels was present in Jbo/+ (5.7 WT vs. 
3.5 fold Jbo/+) at 6  h TGF-P and hypoxia exposure, however, the difference 
between the genotypes was not significant. Pai-1 levels started declining 
and were comparable with further hypoxic treatment exposure. Phd2 
expression was not affected by TGF-P treatment under normoxia (Figure 
5.2c). However, the addition of hypoxia to the TGF-P treatment saw an 
upregulation in Phd2 gene expression which was most pronounced at 48 h 
of treatment. Although genotypic differences were observed at 6  h (1 fold 
WT vs. 0.9 fold Jbo/+) and 48 h TGF-P treatment (1 fold WT vs. 1.1 fold 
Jbo/+) in normoxia; the differences were too small to be relevant.
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Figure 6.2- Comparative relative gene expression of Vegf, Pai-1, Phd2 
between WT and Jbo/+ BMDM after TGF-B treatment in normoxia and 
hypoxia
This figure illustrates relative gene expression levels between WT and 
Jbo/+ BMDM treated with 200 pmol TGF-P under normoxia and hypoxia at 
6  h, 24 h and 48 h under normoxia and hypoxia. In this figure, n=3 for all 
TGF-p normoxia studies; n=12 for TGF-p hypoxia studies at 6  h and n= 6  
for TGF-p hypoxia studies at 24 h and 48 h. Each replicate was obtained 
from 8 d old BMDM from individual 6 - 8  wk old mice. Figure panels show 
relative (a) Vegf expression, (b) Pai-1 expression and (c) Phd2 expression. 
Statistics were performed as per described in section 2.8 of this thesis. In 
this figure and all subsequent figures in this chapter, all further figures in 
this chapter, the bars represents fold increase (RQ) in gene expression 
observed in 200 pmol TGF-P treated BMDM over the untreated control 
calibrator. Both WT and Jbo/+ were calibrated within genotype. Gene 
expression data obtained was normalized to Ppia gene expression. The error 
bars represent RQ min and RQ max. Blue bars denote WT levels and red 
bars denote Jbo/+ levels. * P < 0.05
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Tnf-a expression was downregulated by TGF-P treatment in normoxia in a 
time-dependent manner (Figure 5.3a). A 0.5 fold downregulation was 
observed in both genotypes at 24 h and 48 h TGF-P treatment in normoxia. 
Hypoxia and TGF-p exposure reversed the normoxic TGF-P responsive 
downregulation with Tnf-a expression coming back to basal level by 48 h 
hypoxia despite the TGF-P exposure. No difference in expression was 
observed between the genotypes except at 6  h TGF-p treatment in normoxia. 
Jbo/+ Tnf-a levels were lower in Jbo/+ BMDM (Ohypoxia and TGF-P (P < 
0.01). 11-6 expression in Jbo/+ BMDM was higher in Jbo/+ BMDM (1.4 
WT vs. 4.4 fold Jbo/+; P <0.01).
II-ip  expression was downregulated by normoxic TGF-p treatment in a 
time-dependent manner (Figure 5.3b). Genotypic differences in the form of 
lower II-1 p levels in Jbo/+ were observed at 6  h (0.8 fold WT vs. 0.7 fold 
Jbo/+; P < 0.05) and 48 h TGF-P treatment (0.6 fold WT vs. 0.4 fold Jbo/+; 
P <0.01) in normoxia. TGF-p treatment in hypoxia gradually increased II-lp 
expression in a time-dependent manner such that a 3.2 fold upregulation 
was observed in its levels in WT and a 2.5 fold upregulation in Jbo/+ levels 
by 48 h but the difference was not significant.
11-6 gene expression was down-regulated by TGF-p treatment by 0.3 fold in 
both WT and Jbo/+ BMDM at 24 h and 48 h of TGF-p treatment in 
normoxia (Figure 5.3c). TGF-P treatment in hypoxia reversed the 
downregulation trend in a time-dependent manner. A significant difference 
between the genotypes was observed under prolonged hypoxia and TGF-p 
(P < 0.01). 11-6 expression in Jbo/+ BMDM was higher in Jbo/+ BMDM 
(1.4 WT vs. 4.4 fold Jbo/+; P <0.01).
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Figure 6.3- Comparative relative gene expression of Tnf-a. Il-IB. 11-6 
between WT and Jbo/+ BMDM after TGF-B treatment in normoxia and 
hypoxia
This figure illustrates relative gene expression levels between WT and 
Jbo/+ BMDM treated with 200 pmol TGF-p under normoxia and hypoxia at 
6  h, 24 h and 48 h under normoxia and hypoxia. In this figure, n=3 for all 
TGF-p normoxia studies; n= 6  for all TGF-p hypoxia studies. Each replicate 
was obtained from 8 d old BMDM from individual 6 - 8  wk old mice. Figure 
panels show relative (a) Tnf-a expression, (b) I I-If  expression and (c) 11-6 
expression. Statistics were performed as per described in section 2.8 of this 
thesis. Legend is as per in figure 5.2. Blue bars denote WT levels and red 
bars denote Jbo/+ levels. ** P < 0.01.
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5.2.2- Comparative gene expression analysis of WT and Jbo/+ BMDM 
with TGF-p treatment in normoxic and hypoxic condition reveals key 
genotypic differences in Ccl2, Jun
Expression of chemokines Ccl2, Cxctt and AP-1 transcription factors Fos 
and Jun was checked only at 48 h of TGF-p treatment in hypoxia and 
normoxia as that seemed the most interesting time-point in previous 
experiment (Figure 5.4a).
Cctt expression was downregulated at 48 h normoxic TGF-p treatment (0.2 
fold WT vs. 0.1 Jbo/+ BMDM) but the difference was not significant 
(Figure 5.4b). TGF-p treatment in hypoxia revealed a genotypic difference 
as Jbo/+ Cctt levels were higher than WT (0.3 fold in WT vs. 0.4 fold 
Jbo/+ BMDM; P <0.05).
Cxctt gene expression was down regulated in both WT and Jbo/+ (0.3 fold 
WT vs. 0.2 fold Jbo/F) with 48 h TGF-p treatment in normoxia (Figure 
5.4c). Hypoxia and TGF-P exposure at 48 h elevated Cxctt levels above 
baseline (4.2 fold WT vs. 5.6 Jbo/+ ) but the differences were not 
significant.
No difference in expression of Fos expression was observed with the 
treatment of 48 h TGF-p or 48 h TGF-P and hypoxia.
Jun expression did not change with 48 h TGF-p treatment in normoxia (0.8 
fold vs. 0.6 fold Jbo/+). With 48 h treatment of hypoxia and TGF-P Jun 
expression in WT was elevated in comparison to Jbo/+ (1.60 fold WT vs. 1 
fold Jbo/+; P <0.01) (Figure 5.4d).
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Figure 6.4- Indications of a possible Cctt. Jun dvsregulation but 
absence of dvsregulation of Cxcl2, Fos at 48 h TGF-B treatment in 
Jbo/+ BMDM
This figure illustrates relative gene expression levels between WT and 
Jbo/+ BMDM treated with 200 pmol TGF-P under normoxia and hypoxia at 
6  h, 24 h and 48 h under normoxia and hypoxia. 3-6 biological replicates 
were used as described in figure 5.3. Each replicate was obtained from 8 d 
old BMDM from individual 6 - 8  wk old mice. Figure panels show relative 
(a) Cctt expression, (b) Cxctt expression and (c) Jun expression. Statistics 
were performed as per described in section 2.8 of this thesis. Legend is as 
per figure 5.2. Blue bars denote WT levels and red bars denote Jbo/+ levels. 
* P < 0.05; ** p < 0.01.
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5.2.3- Comparative gene expression analysis of WT and Jbo/+ BMDM 
with TGF-p treatment in normoxic and hypoxic condition reveals no 
significant difference in Smad3 and H if-la
Next, expression of Hif-la  and Smad3 were checked for the different time- 
points in TGF-p and hypoxia combined treatment. Expression of Hif-la  did 
not change with TGF-p in normoxia or hypoxia. Smad3 expression did not 
change except at 48 h TGF-p treatment in hypoxia where Smad3 levels 
downregulated 0.2 fold in WT and 0.1 fold in Jbo/+ BMDM. There was no 
significant difference between the genotypes (Figure 5.5a). H if-la levels did 
not change with TGF-p and hypoxia treatment across the time-points 
(Figure 5.5b).
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Figure 6.5- Sntad3 and H if-la  expression is not dvsregulated in Jbo/+ 
BMDM after TGF-B treatment in hypoxia
This figure illustrates relative SmadS, Hif-la  expression levels between WT 
and Jbo/+ BMDM treated with 200 pmol TGF-p under hypoxia for 6  h, 24 
h, 48 h. 6  biological replicates were used for the study. Each replicate was 
obtained from 8 d old BMDM from individual 6 - 8  wk old mice. Figure 
panels show relative (a) Smad3 expression and (b) Hif-la expression. 
Statistics were performed as per described in section 2.8 of this thesis. 
Legend is as per figure 5.2. Blue bars denote WT levels and red bars denote 
Jbo/+ levels.
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5.4- Comparative protein expression analysis between WT 
and Jbo/+ BMDM after 48 h TGF-fi and hypoxia treatment 
reveals genotypic differences
As RT-qPCR experiments revealed significant differences in pro- 
inflammatory cytokine 11-6 gene expression after 48 h TGF-p treatment in 
hypoxia, it was crucial to see of protein expression of 1 1 -6  or any of the 
other cytokines was dysregulated in Jbo/+ BMDM under those conditions. 
Hence, mouse cytokine arrays (section 2.12) were used to compare relative 
cytokine and chemokine expression levels between WT and Jbo/+ BMDM. 
Cell lysates and supernatant were prepared from Junbo BMDM and treated 
with 48 h hypoxia and TGF-/? to compare the relative levels of cytokines at 
the intracellular and extracellular levels by Proteome Profiler Array by R & 
D Systems. Multiple exposures of the membrane were obtained between 
30s and 5 min. Mean pixel density of the signal for each cytokine was 
obtained by using Chemidoc-It Imaging System and analysed by 
densitometry with Vision Works software (See Chapter 2 for details). The 
density signal was compared across both genotypes in untreated and TGF-p 
treated samples.
122 pg of cell lysate protein and 700 pi of supernatants from 48 h TGF-p 
and hypoxia treated WT and Jbo/+ BMDM were loaded on the membrane. 
48 h hypoxia and TGF-p was used as this prolonged hypoxia condition 
would best mimic the micro-environment of the inflamed Jbo/+ middle ear 
the most. Also 11-6 levels under these conditions were 214% higher in Jbo/+ 
BMDM than WT (section 5.3). 5 min membrane exposure was used for 
analysis of cell lysates and 1 min exposure was used for analysis of 
supernatants after checking for signal-saturation (section 2 .1 2 ).
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For cell lysates from treated BMDM, the array membrane was processed 
and developed by 5 min X-ray film exposure. Further analysis was 
performed by estimating level o f protein expression by densitometry. The 
protein data in this thesis is expressed as mean pixel density (section 2.12) 
after removing background signal. Fold change at basal level was calculated 
by calibrating untreated Jbo/+ signal to WT as a control. Differences 
between treated Jbo/+ with respect to treated WT were calculated by 
calibrating treated Jbo/+ signal to treated WT. Throughout this chapter, 
difference in cytokine expression is described as fold change in Jbo/+ over 
treatment matched WT control.
5.4.1- Proteins detected in cell lysates
Interestingly, out o f 40 cytokines on the array, signals for only 4 cytokines 
(Il-ra, Ccl3, Ccl2, Timp-1) were detected at 48 h hypoxia and TGF-P treated 
cell lysates from BMDM (Figure 5.6).
WT Control Jbo/+ Control
WT Treatment Jbo/+  Treatment
2 * *  2 .. 4MMI IMHM
Figure 6 .6 - Cytokines detected in untreated and 48 h TGF-B and 
hypoxia teated WT and Jbo/+ BMDM cell lysates
Untreated and 48 h TGF-p (200 pmol) and hypoxia treated WT and Jbo/+ 
BMDM. Each cytokine present was detected as a duplex o f dots. Analysis 
was performed by measuring mean pixel density o f each dot on membrane 
to measure the level o f expression o f each cytokine/chemokine as described 
in section 2.12. Cytokine array membrane processed and developed with 5 
min exposure to X -ray  film. Reference co-ordinates and reference template 
was used to label cytokines. Cytokines detected are labelled on the figure as 
follows: (1)- Il-ra; (2) - Ccl3; (3) -  Ccl2; (4) -  Timp-1.
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II-Ira is a counter-inflammatory cytokine which acts as receptor antagonist 
for II-1 cytokines (Dinarello, 2000). Il-ra was present in cell lysates from 
both untreated WT and Jbo/+ BMDM controls. II-Ira levels in the cell 
lysates were lower in Jbo/+ BMDM at basal level (0.9 fold WT). 48 h TGF- 
P and hypoxia treatment reduced expression of II-Ira in the cell lysates of 
both genotypes. II-Ira signal was almost negligible (0 . 0 1  fold) in treated 
Jbo/+ cell lysates in comparison to treated WT BMDM lysates (Figures 5.6 
and 5.7). However, in the supernatants, secreted II-Ira expression followed 
a different pattern (figure 5.9; table 5.2, 5.3). Secreted Il-lra was 0.84 fold 
compared to WT at basal level. 48 h TGF-P and hypoxia treatment 
decreased Il-ra levels in supernatant but increased Il-lra levels in Jbo/+ 
supernatant such that after treatment Jbo/+ Il-lra levels were 0.96 fold of 
WT signal.
Ccl3 is a C-C chemokine which acts as chemoattractant for NLs (Moser, 
2004). It was present in all 4 cell lysate samples but its expression level was 
lower in Jbo/+ BMDM lysate (0.86 fold) than WT BMDM at basal level. 
Ccl3 levels decreased in both WT and Jbo/+ BMDM after 48 h hypoxia and 
TGF-p treatment. However, after treatment the Ccl3 levels in Jbo/+ BMDM 
were 1.15 fold higher than WT. Secreted Ccl3 levels in supernatants from 
control WT and Jbo/+ BMDM displayed a similar pattern (figure 5.9; table 
5.2, 5.3) as Ccl3 levels in Jbo/+ supernatant were comparable at 1.03 fold.
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C3Jbo/+ control/WT control
■ X/Y
X=Jbo/+ (Treatment/Control) 
Y=WT (Treatment/Control)}
a)
WT Jbo/+ WT Treatment Jbo/+Treatment
Il-lra 39.7391 35.6344 12.5843 0.0913
Ccl3 48.4787 41.8589 29.4129 33.9345
Figure 6.7- Genotypic difference in Il-lra and Ccl3 expression between 
WT and Jbo/+ treated and untreated BMDM
BMDM from WT and Jbo/+ BMDM were either untreated (used as control) 
or treated with 48 h of TGF-p (200 pmol) and hypoxia and mean pixel 
density of each dot on membrane was measured (section 2 .1 2 ).
a) Relative Il-lra and Ccl3 levels between WT and Jbo/+ at basal untreated 
level and with 48 h of TGF-p and hypoxia treatment. Light purple bars 
denote difference in relative cytokine expression levels in untreated 
Jbo/+ BMDM (Jbo/+ control /WT control. Dark purple bars denote 
expression levels in 48 h TGF-p and hypoxia treated WT and Jbo/+ 
BMDM difference in relative cytokine expression levels after 48 h TGF- 
P and hypoxia treatment (Jbo/+ treatment/ WT treatment). Relative 
effect of TGF-p and hypoxia on protein expression levels was calculated 
for each genotype by calibrating it to the untreated control within 
genotype. The value obtained for treated Jbo/+ BMDM was then 
normalized to treated WT BMDM value. This gave a fold change of 
cytokine expression level in Jbo/+ BMDM over WT BMDM after 
treatment and this fold change was represented graphically. Il-ra level 
in Jbo/+ BMDM at basal level was 0.9 fold of WT BMDM. After the 
treatment, Il-ra level in Jbo/+ BMDM was .01 fold decline in expression 
relative to WT.
b) Mean pixel density of untreated and treated WT and Jbo/+ BMDM for 
Il-lra and Ccl2 show that the TGF-p and hypoxia treatment reduced Il- 
lra and Ccl2 expression in both genotypes.
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Ccl2 is a monocyte chemoattractant protein which is also a C-C chemokine 
and is involved in recruitment of NLs as well as monocytes (Moser, 2004). 
Ccl2 levels were lower in Jbo/+ BMDM lysates (0.73 fold) than WT 
BMDM lysate. 48 h hypoxia and TGF-p treatment reduced intracellular 
Ccl2 levels to below detection levels in both WT and Jbo/+ BMDM (Figure
5.8). However, in the supernatants, Ccl2 at basal level was again lower in 
Jbo/+ supernatant (0.90 fold over WT) at basal level. Ccl2 was detected in 
supernatant after 48 h hypoxia and TGF-p treatment where Ccl2 levels in 
treated Jbo/+ supernatant were 0.95 fold over treated WT supernatant. 
Timp-1 is a glycoprotein inhibitor of metalloproteinases (MMPs) (Crocker 
et al, 2004). Timp-1 levels were below detection level in untreated WT and 
Jbo/+ control BMDM lysates in both genotypes. Its expression was 
massively elevated in treated Jbo/+ BMDM (6313 fold over treated WT). 
Secreted Timp-1 was detected in supernatant from all 4 samples (Figure
5.8). Its secretory levels were elevated in Jbo/ + untreated supernatant (1.08 
fold) compared to WT BMDM and Jbo/+ treated supernatant (1.09 fold) 
over corresponding WT calibrator.
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Timp-1
a) ■ Timp-1
W TTreatment Jbo/+Treatm ent
6313
b)
Ccl2
WT Jbo/+ TTreatm e Jbo/+ Treatm ent
Ccl2/Mcp-1 36.5721 26.6868 ABSENT ABSENT
Timp-1 ABSENT ABSENT 0.0025 15.7827
c)
Figure 6.8- Cytokines detected in untreated and 48 h TGF-B and 
hypoxia treated WT and Jbo/+ BMDM cell lysates reveal genotypic 
difference in Timp-1 and Ccl2 expression
BMDM from WT and Jbo/+ BMDM were either untreated (used as control) 
or treated with 48 h of TGF-p (200 pmol) and hypoxia and mean pixel 
density of each dot on membrane was measured (section 2 .1 2 ).
a) Timp-1 was below detection levels in untreated control and Ccl2 levels 
were below detection levels in treated BMDM. So, only treated Timp-1 
relative mean pixel density fold change (Jbo/+ treatment/ WT treatment) 
was represented graphically for WT and Jbo/+. Timp-1 in Jbo/+ 
BMDM was 6313 fold over treated WT BMDM.
b) Relative mean pixel density fold change for Ccl2 untreated samples 
(Jbo/+ control/ WT control) was represented graphically for WT and 
Jbo/+. Ccl2 levels in untreated Jbo/+ BMDM were 0.72 fold of WT 
levels.
c) Mean pixel density signal values for Timp-1 and Ccl2 signals.
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5.4.2- Proteins detected in supernatant
A number o f cytokines were detected in supernatant which were below 
detection levels in the cell lysate. The result is presented in figure 5.9 and 
tables 5.2 and 5.3.
To add to experimental stringency, I have only described cytokines with an 
arbitrary fold change difference o f 2 fold or more between the genotypes at 
basal level or after treatment in the discussion (section 5.5).
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Figure 6.9- Cytokines detected in supernatant from of WT and Jbo/+ 
BMDM show TGF-P dvsregulation in Jbo/+ BMDM at basal level and 
with TGF-B and hypoxic treatment
Relative cytokine levels were obtained using protein profiler array on 600 pi 
supernatant from untreated and 48 h TGF-p and hypoxia treated WT and 
Jbo/+ BMDM. Each cytokine present was detected as a duplex of dots. 
Analysis was performed by measuring mean pixel density of each dot on 
membrane to measure the level of expression of each cytokine/chemokine. 
Vision Works LS software 6 . 8  by UVP was used for densitometry.
(a) Cytokine array membrane processed and developed with 10 sec 
exposure to X -ray film. Red arrows donate location of cytokines which 
were detected in cell lysates and are labelled as follows: ( 1 )- Il-ra; (2 ) - 
Ccl3; (3) -  Ccl2; (4) -  Timp-1
(b) Relative fold change in untreated Jbo/+ over untreated at basal 
untreated level. Relative values were obtained for basal level by 
calibrating Jbo/+ untreated BMDM to WT BMDM to give a fold 
change. Relative effect of TGF-P and hypoxia on protein expression 
levels was calculated for each genotype by calibrating it to the untreated 
control within genotype and represented in graph. Fold change values 
are given in Table 5.2.
(c) Relative fold change in Jbo/+ treated BMDM over WT treated BMDM 
after 48 h TGF-P and hypoxia treatment. Relative effect of TGF-P and 
hypoxia on protein expression levels was calculated for Jbo/+ by 
calibrating its mean pixel density value to that of treated control. This 
gave a fold change of cytokine expression level in Jbo/+ BMDM over 
WT BMDM after treatment and this fold change was represented 
graphically. Fold change values after treatment are given in Table 5.3.
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Table 5.2- Relative fold change in cytokines at basal level (untreated 
Jbo/+ vs. untreated WT)
" ' **■ 'A ** ' ' f
11-23 41.669
11-10 4.465
l-tac 2.701
C5a 2.430
Tnf-a 2.161
CXCL13 1.860
11-27 1.671
Trem-1 1.670
11-4 1.596
11-17 1.428
11-16 1.233
ll-la 1.202
Ccl4 1.165
Ip-10 1.086
Timp-1 1.078
M-csf 1.041
Gm-csf 1.009
11-7 0.986
Ifn-y 0.947
Ccll7/Tarc 0.938
Ccl5 0.920
Ccl3 0.917
Ccl2 0.900
11-13 0.841
ll-lra 0.835
Cell 0.815
Mig/Cxcl9 0.803
Cxcll 0.801
Ccll2 0.800
11-2 0.797
Cxcl2 0.746
CO.
H
0.545
Cxcll2 0.493
Values in black represent cytokines upregulated in Jbo/+ BMDM along 
with the fold change. Values in green are cytokines which were 
downregulated in Jbo/+ BMDM at basal level in untreated controls.
Table 5.3- Relative fold change in treated Jbo/+ over treated WT 
BMDM
. amd ..**
11-1(3 1.879
Ccl5/Rantes 1.489
11-16 1.454
11-23 1.452
ll-la 1.354
11-17 1.271
C5a 1.234
Ccll7/Tarc 1.189
11-13 1.100
Timp-1 1.093
Mip-lp/Ccl4 1.088
Mip-la/Ccl3 1.032
11-2 0.992
ll-lra 0.957
11-27 0.953
Ccl2/Mcp-1 0.950
Cd54 0.939
Mig/Cxcl9 0.934
Ifn-y 0.914
lp-10/Cxcll0/Crg-2 0.854
11-4 0.811
Cxcll3 0.763
GM-CSF 0.614
11-10 0.567
G-CSF 0.525
Mip-2/Cxcl2 0.524
Kc/Cxcll 0.484
1-tac/Cxclll 0.458
Ccll/Tca-3 0.426
M-csf 0.387
Mcp-5/Ccll2 0.219
Cxcll2 0.213
Tnf-a 0.181
Trem-1 0.095
11-7 0.010
Values in black represent cytokines higher in Jbo/+ BMDM after 
treatment. Values in green are cytokines which were lower in Jbo/+ 
BMDM after treatment.
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5.5- TGF-p pathway is dysregulated in Jf/+ BMDM in 
normoxic conditions
Whilst this thesis concentrates on Jbo/+ mice as a model for OM, limited 
Jf/+ mice were available for analysis. Jeff is a dominant mouse mutant who 
displays COME phenotype in humans along with conductive hearing loss 
(Hardisty-Hughes et al, 2006; Hardisty et al, 2003). The Jf/+  mouse carries 
a point mutation in F box gene Fbxoll (Hardisty-Hughes et al, 2006). 
Developmental defects in palate, eyes, lungs in homozygote Jf/Jf mice due 
to the perturbation of the TGF-p pathway has been observed (Tateossian et 
al, 2009). Even though the Jbo/+ phenotype is slightly different from Jf/+ 
(OM is less penetrant with serous effusion in comparison to suppurative 
exudates in Jbo/+ mice); its hypoxic signalling mechanism seems to acting 
via Vegf and H if-la signalling as the cellular hypoxia in Jf/+ middle ear has 
been observed along with upregulated Vegf levels in the middle ear 
effusions (Cheeseman et al, 2011). Fbxoll is part of a large family of F- 
box proteins which function as a part of SKPl-cullin-F-box (SCF) E3 
protein ligase complex. These proteins promote proteosomal ubiquitination 
and degradation by recognizing and binding to phosphorylated proteins (Jin 
et al, 2004; Kipreos & Pagano, 2000).
Publications suggest that Fbxol 1 might be indirectly interacting with Smad2 
protein and be involved in TGF-P signalling regulation. Fbxol 1 protein acts 
as a Nedd8 -ligase to p53 (Abida et al, 2007). However, a co- 
immunoprecipitation study performed Jeff WT embryo lung extracts failed 
to reveal any direct interaction between the two proteins (Tateossian et al, 
2009). Although Jf/Jf homozygotes and Jf/+ heterozygotes had markedly 
reduced and intermediate p53 protein levels respectively in comparison to
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WT. This suggests that Fbxol 1 may be required for the stabilization of p53 
protein (Tateossian et al, 2009). P53 protein is required for co-activating 
TGF-p target genes with Smad2 protein (Cordenonsi et al, 2003). Given the 
above outlined interactions between Fbxoll protein, p53 and Smad2; my 
hypothesis is that in Jf/+ mice, loss of Fbxoll protein function affects the 
transcriptional activity of p53 (Figure 1.8). So Fbxol 1AU72T mutation might 
result in a decrease of p53 transcriptional targets. Mutant p53 has been 
shown to result in attenuation of TGF-p responses, reduction in Smad2/3 
phosphorylation, inhibition of Smad2/Smad4 complex formation and Smad4 
translocation to the nucleus (Kalo et al, 2007). Perturbation in TGF-P 
signalling might underlie the chronic inflammation observed in Jf/+ by 
resulting in an abnormal innate immune response to commensal 
nasopharyngeal flora resulting in disease. To understand if the Fbxol yA1472T 
mutation affects TGF- p signalling in Jf/+ gene expression of TGF-p 
responsive and p53 responsive genes were studied in both WT and Jf/+ 
BMDM. RT-qPCR was used to perform a series of comparative gene 
expression studies for F bxoll,and TGF-p responsive and p53 responsive 
genes Pai-1 and Pai-2. Pai-1 and Pai-2 are genes which encode for 
plasminogen activator inhibitors which regulate serine proteases and 
fibrinolysis (Kruithof, 1988; Kruithof, 2008; Kruithof et al, 1995). Pai-1 and 
Pai-2 induction is often associated with apoptosis and monocyte 
differentiation and inflammation (Kruithof, 1988; Kruithof, 2008; Kruithof 
et al, 1995).
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No difference between the genotypes was observed in expression of the 
Fbxoll gene; TGF-p treatment did not affect Fbxoll expression under 
normoxia or hypoxia (Figure 5.10a).
No genotypic difference in Pai-1 levels (Figure 5.10b) at basal level 
between WT and Jf/+ BMDM. Pai-1 expression was upregulated by TGF-p 
in both genotypes under normoxia and hypoxia. A significant difference (P 
< 0.05) was observed in Pai-1 expression levels with 6  h TGF-p treatment 
in normoxia. 6  h TGF-P treatment in normoxia induced 18.8 fold 
upregulation in treated WT BMDM vs. 2.4 fold upregulation in treated Jf/+ 
BMDM. Addition of hypoxia to the 6  h TGF-treatment induced comparable 
Pai-1 expression in both genotypes (4.7 fold in WT vs. 4.6 fold upregulation 
in Jf/+ BMDM; P >0.05)
A significant difference in Pai-2 expression levels (Figure 5.10c) was 
observed at basal level between WT and Jf/+ BMDM as Jf/+ Pai-2 levels 
were 0.6 fold in comparison to WT BMDM. However this difference was 
below the threshold cut-off level of 2  fold difference considered to be 
biologically significant. TGF-P treatment did not affect expression of Pai-2 
in either genotype under normoxia or hypoxia.
Fbxo11
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Figure 6.10-Relative gene expression between WT and Jf/+ BMDM 
treated with 200 pmol TGF-B for 6 h under normoxia and hypoxia.
This Figure illustrate relative gene expression levels between WT and Jf/+ 
BMDM treated with 200pmol TGF-p under normoxia and hypoxia at 6  h 
under normoxia and hypoxia, n= 9 for TGF-p under normoxia,; n = ll for 
TGF-P under hypoxia. The bars represents fold increase (RQ) in gene 
expression observed in 200pmol TGF-p treated BMDM over the untreated 
control calibrator. Green bars denote WT levels and pink bars denote Jf/+ 
levels. Both WT and Jf/+ were calibrated within genotype. The error bars 
represent RQ min and RQ max. The y axis is fold change over genotype. 
Gene expression data obtained was normalized to Ppia gene expression. *P 
<0.05.
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5.6- Discussion
Both Evi-1 gene and Evi-1 protein are expressed in at comparable levels in 
WT and Jbo/+ BMDM, suggesting that the mutation in Junbo mice does not 
affect the transcription or translation of the Evi-1 protein (see chapter 3). 
Evi-1 is a transcription factor which binds and represses TGF-P effector 
Smad3 (Kurokawa et al., 1998). Evi-1 also binds c-fos promoters to activate 
JNK and AP-1 pathways via ZF1 and ZF2 respectively (Kurokawa et al, 
1998a; Kurokawa et al, 1998b; Kurokawa et al, 2000). This suggests that a 
mutation in Evi-1 may impact upon TGF-p signalling. As Smad3 is part of 
the canonical pathway for TGF-p signalling and if the mutation affects 
binding of Evi-1 to Smad3 then I hypothesized that elevated levels of 
Smad3 activated genes and proteins would be present in Jbo/+ BMDM. 
HEF pathway and TGF-p cross-talk extensively via Smad3 and AP-1 (See 
chapter 1). As the inflamed middle ear in Jbo/+ is hypoxic it was also 
important to check for TGF-P dysregulation under hypoxia.
TGF-P increased expression of TGF-p/Smad3 responsive genes Pai-1, Vegf 
and decreased expression of pro-inflammatory genes Tnf-a, Il-lp, 11-6, Ccl2, 
Cxcl2 under normoxia. Combination of hypoxia and TGF-p led to an 
additive increase in Vegf and Pai-1 gene expression. However, nosignificant 
difference in Vegf expression in Junbo BMDM was observed with TGF-p 
stimulation under hypoxic conditions. Expression of Pai-1 was significantly 
lower in Jbo/+ BMDM in comparison to treated BMDM by 38% in both 
normoxia and hypoxia but the difference was significant (P < 0.05) only 
under normoxic conditions.
Phd2 is a hypoxia-responsive gene involved in degradation of H if-la
subunit under normoxic conditions. Although Phd2 expression has been
shown to be downregulated with TGF-p via TGF-p/Smad pathway in
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HepG2 cells (McMahon et al, 2006) no effect of TGF-p on Phd2 gene 
expression in Jbo/+ BMDM was observed.
TGF-p is a known immunosuppressive agent and regulator of inflammation
and wound repair. To further explore TGF-p dysregulation and its effect on
inflammatory gene markers, 11-6, Tnf-a and II-lp  were included in the panel
of genes studied. TGF-P has been shown to decrease induction of Tnf-a
mRNA (Naiki et al, 2005) but TGF-p overexpression studies in lungs have
shown it to increase Tnf-a mRNA expression (Kang et al, 2007).
In comparative protein expression studies, genotypic differences in II-Ira
were observed. II-Ira is an anti-inflammatory member of II- 1 family that
binds II-1 receptor without inducing a pro-inflammatory cascade (Arend et
al, 1998). Il-ra is released by monocytes, macrophages, neutrophils,
keratinocytes and exists in three isoforms, 2  intracellular II-Ira isoforms
icll-lra and secreted Il-lra isoform (Arend & Guthridge, 2000). Although
Icll-lra and is-Il-lra can both act as II- 1 receptor antagonist, a role of icll-lra
has also been implicated in antagonizing intracellular signalling of II-ip and
II-la (Luheshi et al, 2009). Il-ra level was lower in Jbo/+ than WT in both
BMDM lysates (by 10%) and supernatant (16%). 48 h TGF-p treatment and
hypoxia treatment of BMDM decreased Il-lra levels in both genotypes.
However, Il-lra levels in Jbo/+ were lower (-99%) after the treatment in
BMDM lysates and 4% lower in supernatant. Hypoxia has been reported to
decrease IL-1RA expression in human alveolar macrophages (Hempel et al,
1996). On the other hand, TGF-p induces I1-1RA synthesis (Muzio et al,
1994; Yoshimura, 2010). Reduced Il-lra levels in BMDM lysates indicate
predisposition of Jbo/+ BMDM to chronic inflammation as Il-lra deficiency
in Il-lra-/- mice causes RA, spontaneous arterial inflammation,
autoimmunity along with delayed wound healing and augmented pro-
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inflammatory II-ip and 11-6 levels (Horai et al, 2000; Ishida et al, 2006;
Nicklin et al, 2000). Polymorphism in IL-1RA (ILRN*2) in humans results
in impaired IL-1RA and augmented IL-lp  and is associated with several
chronic diseases of epithelial origin such as psoriasis, SLE, ulcerative colitis
etc. (Arend & Guthridge, 2000; Tarlow et al, 1997; Tountas et al, 1999).
The balance between MMP and its reversible inhibitor TIMPs is a dynamic
balance essential for ECM synthesis or degradation (Moali & Hulmes,
2009). MMPs are involved in wound-healing, inflammation and
angiogenesis and have been implicated in rheumatoid arthritis (RA) (Nagase
et al, 2006). Timp-1 is produced mainly by B cells, mononuclear phagocytes
(macrophages, DCs), NLs, epithelial cells and fibroblasts (Verstappen &
Von den Hoff, 2006). Timp-1 expression was below detection levels in
resting Jbo/+ and WT BMDM lysates but TGF-p and hypoxia treatment at
48 h increased its expression. Jbo/+ BMDM levels after treatment were a
6313 fold more than WT in cell lysates. Secreted Timp-1 however was
detected at basal level and was 8 % more than WT while after treatment
secreted Timp-1 was only 9% more in Jbo/+ than WT. Timp-1 is reported to
be upregulated by TGF-P via a Smad3 dependent pathway in human and
mouse fibroblasts (Liberati et al, 1999; Verrecchia et al, 2001; Zhang et al,
1998). Hypoxia is also reported to increase TIMP-1 expression in
monocytes and enhance TGF-mediated amplification of TIMP-1 in
fibroblasts (Bosco et al, 2006; Papakonstantinou et al, 2002). IL- 6  is
reported to induce TIMP-1 expression in synoviocytes and chondrocytes
(Silacci et al, 1998). Recently, Timp-1 has been identified as a novel protein
regulation resistance to infection as Timp-1 KO are resistant to infection by
P. aeroguinosa (Lee et al, 2005). Timp-1 overexpression in fibroblasts is
associated with proliferation (Lu et al, 2011). TIMP-1 increase is associated
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with lung cancer, ulcerative colitis, atherosclerosis (Defawe et al, 2003; 
Fong et al, 1996; Okahara et al, 2005).
Timp-1 is a Smad3 co-activated gene, and Evi-1 is a co-repressor of Smad3 
(Kurokawa et al, 1998b). Hence, the higher Timp-1 levels in Jbo/+ BMDM 
lysates are suggestive of increased Smad3 activity due to impaired Evi- 
yA2288T fQnction Higher Timp-1 levels may predispose Jbo/+ BMDM to 
delayed wound healing in hypoxia and make those sites pre-disposed to 
infection as well as result in trapping of macrophages at the site of 
inflammation due to increased ECM deposition (Bosco et al, 2008).
11-23 is a pro-inflammatory heterodimeric cytokine made of p40 and p l9  
and secreted by macrophages and DCs in response to infection usually 
(Kastelein et al, 2007; Langrish et al, 2004; Oppmann et al, 2000). IL-23 is 
known to induce IFN-y production by T-cells and is very important for Th- 
17 cell development which themselves play a crucial role in inflammation 
and auto-immune disorders (Liu et al, 2009; Wozniak et al, 2006). High IL- 
23 levels are associated with inflammatory diseases such as rhinitis and 
Crohn’s diseases (Liu et al, 2010; Yen et al, 2006). Jbo/+ BMDM 
supernatant had 4167% higher 11-23 levels than WT at basal level. TGF-p 
treatment increased 11-23 levels in WT but decreased 11-23 signal in Jbo/+ 
supernatant. However, even after 48h TGF-p and hypoxia treatment 11-23 
levels in treated Jbo/+ supernatant were still 45% higher than WT. Whilst 
LPS is known to increase 11-23 expression, TGF-P is known negatively 
regulate the p40 11-23 subunit induction via Smad3 (Ogawa et al, 2008). 
Interestingly, a role of Smad3 in the p l9  11-23 subunit expression has also 
been implicated (Al-Salleeh & Petro, 2008). High Jbo/+ levels of 11-23 may 
be indicative of predisposition of Jbo/+ mice to chronic inflammation.
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1 1 - 1 0  is a immunoregulatory cytokine that is produced by a number of cells
such as macrophages, B cells, mast cells, epithelial cells, Thl cells, Th2
cells, Tregs, DCs (Moore et al, 2001; Zhang et al, 2010). It is an inhibitor of
antigen presentation and pro-inflammatory cytokines such as II-ip, 11-6 ,
Tnf-a, 11-12 and inducer of Il-lra cell (Fiorentino et al, 1991; Mosser &
Zhang, 2008b; Opal & Huber, 2000; Rousset et al, 1992). 11-10 has NF-kB
promoter (Xu et al, 2002). IL-10 knockout mice are susceptible to infection
(Matsukawa, 2007). IL-10 inhibits collagen synthesis and prevents fibrosis
caused by Tgf-p. IL -/- mice are prone to fibrosis. (Yamamoto et al, 2001)
A clear association between IL-10 and inflammation susceptibility have
been observed (Davidson & Diamond, 2001; Moore et al, 2001; Mosser &
Zhang, 2008b; Nathan & Ding, 2010; Zhang et al, 2010). 11-10 deficiency
levels are associated with RA, colitis, enhanced IL-17 response,
spontaneous inflammation, deregulated Thl response, spontaneous IBD
development, increased LPS susceptibility which manifests as severe hyper-
inflammatory response upon infection with pathogens (Davidson &
Diamond, 2001; Deckert et al, 2001; Kuhn et al, 1993; Liu et al, 2011;
McKinstry et al, 2009; Nathan & Ding, 2010; Pulendran, 2004; Xu et al,
2009; Zhang et al, 2010). Polymorphisms in IL-10 are linked to asthma with
reduced 11-10 production (Lim et al, 1998). IL-10 polymorphism is also
linked to AOM episode following RSV (Alper et al, 2009). Increased IL-10
levels have been observed in OM fluid in mice and humans (Cheeseman et
al, 2011; Zhao et al, 2009). 11-10 levels were 347% higher in Jbo/+ at basal
level but 43% lower in supernatant from Jbo/+ treated BMDM compared to
treated WT. 48 h TGF-p treatment increased 11-10 expression in WT but
nominally in Jbo/+ BMDM. TGF-P is reported to induce 11-10 mRNA in
T hl7 cells, antigen presenting cells and rat hepatic stellate cells (Moore et
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al, 2001; Wang et al, 1998; Xu et al, 2009). AP-1 is also known to activate
11-10 transcription in Th2 cell (Rooney et al, 1994). TGF-p increases 11-10
by activating DNA endogenous promoter (Kitani et al, 2003).TGF-P
activates IL-10 promoter via smad4 in Thl cells. TGF-P rapidly induces IL-
10 secretion via smad-4 binding to IL-10 promoter. It is plausible that Evi-
yA2288T mutatjon impairs n_io expression via impaired AP-1 activation.
However, it is interesting to note that 11-10 levels are higher in Jbo/+ at
basal level but lower under hypoxia and TGF-P treatment.
Inducible T cell a chemoattractant (I-tac) also known as CXCL11 is a
cytokine which is known to drive Thl type inflammatory conditions such as
RA and psoriasis. It activates CXCR3 bearing cells such as Thl cells, B
cells, NK cells and has a role in T cell recruitment to the site of
inflammation (Petkovic et al, 2004). I-tac gene expression is upregulated by
NF-kB (Hinata et al, 2003). I-tac levels were 170% more in Jbo/+ BMDM
at basal level but on 48 h hypoxia and TGF-P treatment, I-tac expression in
treated Jbo/+ BMDM was 83% lower than treated WT BMDM. TGF-P and
hypoxia treatment decreased I-tac expression in both genotypes. This again
implicates a pro-inflammatory profile of Jbo/+ at basal level.
The complement system is one of the main effectors of antibody mediated
immunity and C5a is released by cleavage of complement system
component C5 by serine proteases in activated macrophages and NLs
(Amara et al, 2008). C5a functions as a potent chemoattractant with role in
eosinophil, NL, monocyte, T lymphocyte recruitment, activation of
phagocytic cells, vascular permeability, respiratory burst and adaptive
immunity (Guo & Ward, 2005). C5a levels were higher in Jbo/+ both in
untreated and treated supernatant by 140% and 23% respectively. TGF-P
and hypoxia treatment increased C5a levels in both genotypes but treatment
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induced increment in C5a levels was lower in Jbo/+. TGF-p is known to 
increase C5a mRNA in PANC-I cells (Jazag et al, 2005). This potentially 
indicates higher C5a levels in Jbo/+ predispose it to inflammation. 
Triggering receptor expressed on myeloid cells-1 (Trem-1) is a cytokine 
which is expressed by neutrophils and macrophages and serves as an 
amplifier of the TLR initiated pro-inflammatory response to invading 
pathogens and PAMPs (Bouchon et al, 2000; Zeng et al, 2007). Trem-1 
upregulation is associated with animal models of severe bacterial infection 
and sepsis (Gibot, 2005; Ho et al, 2008; Zeng et al, 2007). TREM-1 
upregulation is also observed in IBD patients and polymorphisms in TREM- 
1 are associated with IBD (Jung et al, 2011). Trem-1 promoter has NF-kB 
and AP-1 binding site and is regulated by NF-kB (Zeng et al, 2007). 
Recently, TREM-1 has been reported as a hypoxia responsive gene as its 
upregulation in monocyte derived DCs in inflamed hypoxic joints of 
children has also been reported (Bosco et al, 2011). All this data suggests 
that Trem-1 is a classic NF-kB responsive and hypoxia responsive gene. 
Trem-1 level was observed to be 67% higher in Jbo/+ BMDM at basal 
level. TGF-P and hypoxia treatment induced Trem-1 expression in WT 
BMDM (13.26 fold) but not in Jbo/+ BMDM (0.75 fold) (Table 5.2). Trem- 
1 levels were 94.3% lower in treated Jbo/+ BMDM compared to 
corresponding WT after 48 h TGF-P and hypoxia treatment (Table 5.3). 
Increased levels of Trem-1 at basal level indicate a pre-disposition of Jbo/+ 
BMDM to inflammation. However, reduced Trem-1 levels on 48 h hypoxia 
and TGF-P exposure indicate a dysregulated Smad3 and TGF-P signaling. It
A99RRTmay also be indicative of dysregulated Ap-1 activation due to Evi-1 
mutation.
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Cxcll3 is a LPS responsive B lymphocyte chemoattractant which is also
known to be upregulated in joints of RA mouse models (Fujikado et al,
2006; Mikita et al, 2001). Cxcll3 levels were 8 6 % higher in Jbo/+ BMDM
at basal level but lower by 59% after TGF-p and hypoxia treatment.
M-csf is a growth factor involved in differentiation, survival, proliferation
as well as cytokine production of monocytes. M-csf is expressed by
endothelial cells, fibroblasts as well as macrophages (Hamilton, 2008). M-
csf is also known to promote foam cell formation by upregulating scavenger
receptor SR-A and M-CSF overexpression has been reported in
atherosclerotic plaques (Clinton et al, 1992). M-csf deficient op/op mice
have congenital osteoporosis, neuronal and endocrine deficiencies along
with a markedly reduced numbers of tissue macrophages (Gow et al, 2010).
TGF-P has been reported to increase M-csf production through a non-
Smad3 pathway involving Bmp-2 in mesenchymial cells and osteoblasts
(Ghosh-Choudhury et al, 2006; Nelimarkka et al, 1997; Takaishi et al,
1994). M-csf expression is also increased by LPS via NF-kB (Huleihel et al,
1993). M-csf expression was comparable in WT and Jbo/+ at basal level as
Jbo/+ M-csf levels were only 4.1% higher. However, M-csf levels were
63% lower in Jbo/+ after treatment. Lower M-csf levels again indicate an
over-active Smad3 which might be competitively inhibiting M-csf
expression by binding to NF-kB and AP-1 binding site of M-csf promoter.
Cell 2 is a structural and functional homologue of human CCL2 (Sarafi et al,
1997). It is more homologous in function and sequence to human CCL2
than murine Ccl2. Ccll2 functions as a chemoattractant for monocytes. Both
Cell2 and Cel2 have HRE binding site on their promoter and although their
expression is upregulated on short hypoxia exposure of up to 6  h; CCL2
expression is down regulated on longer hypoxia exposure of 18 h (Bosco et
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al, 2004b; Mojsilovic-Petrovic et al, 2007). Smad3 is known to 
downregulate CCL2 in J774A cells (Feinberg et al, 2004). Due to structural 
and functional homology between Ccll2 and CCL2, it was of interest to 
note down-regulation on prolonged hypoxic and TGF-P expression in both 
genotypes (By 64% in WT vs. 90% in Jbo/+) (Table 5.3). Cell2 expression 
was 25% lower at basal level in Jbo/+ BMDM and 56% lower after 
treatment in comparison to respective treatment matched WT counterpart 
(Table 5.2, 5.3). This can be implicated to enhanced activity of Smad3 due 
to Evi-1A2288T mutation.
11-7 functions as a growth factor and an anti-apoptotic factor for T cells and
B cells. 11-7 signalling via Il-7r activates Stat 5 pathway as well as PI3K/Akt
pathway (Ponchel et al, 2011). It has been reported that 11-7 deficient mice
have reduced numbers of T and B cells (Peschon et al, 1994). Although 11-7
levels in WT and Jbo/+ BMDM are comparable at basal level, 11-7 levels
after 48 h TGF-P and hypoxia treatment were 90% lower in Jbo/+ BMDM
compared to WT. TGF-P is known to be a negative regulator of 11-7 protein
and hypoxia has been reported to down-regulate IL-7 mRNA (Lu et al,
2009; Tang et al, 1997). Reduced number of lymphocytes is observed in a
number of auto-immune diseases such as RA, SLE, MS (Ponchel et al,
2011). Low level of 11-7 in Jbo/+ BMDM after treatment is indicative of
dysregulated TGF-p and HLF signaling which potentially effects T cell
survival and differentiation at the site of inflammation.
Dysregulated TGF-P signalling was also observed in BMDM from Jf/+
mice. As only limited mice were available for studying Jf/+ mice; a study at
6  h time point was performed to study the effect of Fbxol /  A1472T mutation
on p53, Smad2 and TGF-P responsive genes Pai-1 and Pai-2. It has been
reported previously that Fbxoll mutation in Jf/+ is implicated in p53
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stabilization (Tateossian et al, 2009). P53 is essential for expression of
Smad2 responsive genes. Based on these findings my hypothesis was that
p53 and TGF-P responsive genes would be expressed at a lower level in Jf/+
due to a potential TGF-p dysregulation and reduced p53 stabilization. At 6 h
TGF-p treatment in normoxia, Pai-1 levels in Jf/+ were lower by 87.2% (P
< 0.05). which validated the hypothesis that Fbxol 1AU72T mutation affected
TGF-p signalling due to potential reduced p53 stabilization. However,
additional genes were not added to the panel due to limited amount of time.
Although Pai-2 levels were also lower in Jf/+ BMDM (at basal level),
however the difference was small and did not meet the theshold cut-off
point of 2 fold so were not considered biologically relevant.
In conclusion, TGF-p signalling is dysregulated in both Jbo/+ and Jf/+
BMDM and this is consistent with perturbation of Smad3 and Smad2.
Smad3 has also been known to co-activate TIMP-1 gene (Liberati et al,
1999; Zhang et al, 1998) and Timp-1 signal was strongly present only in
TGF-p and hypoxia treated BMDM lysates. Evi-1 is a co-repressor of
Smad3. A loss of function of Evi-1 would mean increased transcriptional
activity of Smad3 which is reflected in increased relative levels of 11-6,
Timp-1, II-lp observed in Jbo/+ BMDM. Together this data is suggestive of
a TGF-p dysregulation in Jbo/+ via canonical Smad pathway. Evi-1 also
interacts with AP-1 and JNK pathways to increase c-Jun expression. c-Jun
is downregulated in TGF-P treated Jbo/+ BMDM which might affect its
target genes explaining the down-regulation observed in Pai-1 and other
differences observed in supernatants and cell lysates from BMDM
suggesting a non-canonical pathway of TGF-P to be dysregulated in Jbo/+
as well under conditions of hypoxia which might result in exacerbating of
inflammation as is observed in Jbo/+ mice. These differences might explain
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the predisposition of Jbo/+ mice to inflammation. There is a complex level 
of control by hypoxia exerted on macrophages. The hypoxic 
microenvironment in inflamed Jbo/+ middle ear might exacerbate the 
inflammation effect which may have implications for the histo-pathological 
changes observed in Jbo/+ middle ear. Further studies may yield a bigger 
picture of functional alteration of macrophages in Junbo mice which results 
in perpetual middle ear inflammation.
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Chapter 6
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7. Discussion
6.1- Background summary
OM is the most common cause of hearing loss and surgery in children 
(Clarke & De, 2005; Kubba et al, 2000). Over the last few years an 
increasing number of studies have suggested a strong genetic component to 
OM (Casselbrant & Mandel, 2001; Casselbrant & Mandel, 2005; 
Casselbrant et al, 1999; Casselbrant et al, 2009; Kvestad et al, 2004; 
Kvestad et al, 2006; Rovers et al, 2002). However, our knowledge of the 
genetic susceptibility factors and pathways underlying OM development 
and pathogenesis is still limited. Single gene mouse models and bacteria 
challenged inducible models can play a key role in investigation of cellular 
and genetic pathways and genes involved in OM. Recently, Junbo and Jeff 
mice were generated at MRC Harwell through a large-scale ENU 
mutagenesis program and were subsequently identified as first non- 
syndromic spontaneous chronic OM models. Jbo/+ mice have a mutation in
  i OIOOT_________________________
Evi-1 (Parkinson et al, 2006). Evi-1 is a transcription factor and a co­
repressor of Smad3 (Kurokawa et al, 1998b). Smad3 is a transcriptional 
activator of genes involved in TGF-p signalling (Jeon et al, 2007; Massague 
& Chen, 2000; Massague & Wotton, 2000; Sanchez-Elsner et al, 2001; Shi 
et al, 1998; Yoshimura, 2010). Under hypoxic conditions, Smad3 also co- 
activates gene expression of hypoxia-responsive genes along with H if-la - a 
transcriptional factor stabilized in hypoxia (Jeon et al, 2007). The HEF 
pathway cross-talks extensively with NF-kB pathway to upregulate many of 
its target pro-inflammatory genes (Blouin et al, 2004; Murdoch et al, 2005). 
Jf/+ mice have an Fbxol l Al412T mutation
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in Fbxoll (Hardisty et al, 2003; Parkinson et al, 2006). Fbxoll is 
implicated in the stabilization of p53 (a transcriptional activator that co- 
activates the target TGF-P genes with Smad2) (Tateossian et al, 2009).
The OM phenotype in Jbo/+ mice resembles human phenotype of CSOM 
with highly suppurative exudates containing high numbers of viable and 
necrotic NLs, and few foamy macrophages (Cheeseman et al, 2011). 
Thickening of the bulla lining is also observed in Jbo/+ inflamed ear 
although perforation of the tympanic membrane is absent (Parkinson et al, 
2006). Interestingly, Jbo/+ mice also develop OM in germ-free conditions 
(unpublished data) but a delayed onset of OM is observed which suggests 
that microbes are not necessary for OM development in Jbo/+ but do 
accelerate its progression. The OM phenotype in Jf/+ is similar to the 
COME symptoms observed in patients as the middle ear in Jf/+ contains 
serous fluid (Cheeseman et al, 2011; Hardisty-Hughes et al, 2006). 
Although gross OM phenotype is more penetrant in Jbo/+ than Jf/+, both 
models develop spontaneous OM (Cheeseman et al, 2011). Pathologic 
hypoxia and upregulation of HIF-signalling pathways has been found in 
middle ear fluid from both Jbo/+ and Jf/+ which indicates a role of HIF 
pathways in chronic OM pathogenesis. However the Jbo/+ middle ear was 
found to be chronically more hypoxic as the inflammatory cells in middle 
ear exudates, mucosal epithelium, connective tissues were all hypoxic in 
comparison to Jf/+ where hypoxia was only observed in inflammatory cells. 
Recently, a role for HIF-VEGF signalling pathways has been described in 
OM development in Jbo/+ and Jf/+.
TGF-p signalling has been implicated as a common pathway in
development of chronic OM in Jbo/+ and JJ7+. TGF-p signalling is
involved in cell development, cell differentiation, proliferation, M2
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polarization, wound repair and inhibition of inflammatory cytokine 
production. TGF-p'7' and Smad3'7' mice display chronic inflammation, which 
further suggests their crucial role in autoimmunity and inflammation. TGF-P 
interacts with HIF signalling under hypoxic conditions which are reported to 
be a key pathologic feature of middle ear in Jbo/+ and Jf/+ mice. TGF-p 
also interacts with the HIF pathway and modulates the expression of target 
genes such as Timp-1, Pai-1 and Vegf, which also depend on Smad 
interacting partners such as Evi-1 protein for expression (Derynck & Zhang, 
2003; Sanchez-Elsner et al, 2001; Yu et al, 2002; Zhang, 2009). The HIF 
signalling pathway cross-talks extensively with the NF-kB pathway to 
upregulate many of its target pro-inflammatory genes (Blouin et al, 2004; 
Murdoch et al, 2005). The mutations in Jbo/+ and Jf/+ may impact TGF-P 
signalling and result in chronic inflammation. Extensive cross-talk exists 
between TGF-P, HIF pathways and inflammatory signalling pathways via 
their interaction with NF-kB and AP-1 transcriptional activators. The 
dysregulated or abrogated HIF or TGF-P pathway can have a profound 
effect on NF-kB. Evi-1A2288T mutation in Jbo/+ might also affect its 
interaction with AP-1, as their interaction with the HIF pathway. 
Dysregulated HIF signalling pathway has been implicated in other chronic 
inflammatory diseases (Dehne & Brune, 2009; Zinkemagel et al, 2008).
ZF2 of Evi-1 also binds to and raises transcriptional activity of AP-1, 
another factor which interacts with both HIF and TGF-p signalling (Tanaka 
et al, 1994); (Laderoute, 2005) and TGF-p signalling (Zhang et al, 1998). In 
light of this information, a hypothesis was developed that A2288T Evi-1 
mutation in Jbo/+ mice perpetuates inflammation through a dysregulated 
HIF pathway and TGF-P signalling pathway.
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6.2- Aim
A 9 9 R R TThe overall, aim of this thesis was to understand how the Evi-1 and 
Fbxol 1AU72T mutation contribute to chronic OM development and to 
identify new mechanisms and genes involved in OM pathogenesis. I 
proposed TGF-p signalling and HIF signalling as the common pathways 
implicated in OM in Jbo/+ and Jf/+ models. The aim of this thesis was to 
understand how these mutations (in particular A2288T Evi-1 mutation) 
impact upon HIF, TGF-p pathways and affect the innate immune system 
regulation. Although most of this thesis concentrated on the Jbo/+ model, a 
limited number of Jf/+ mice were available towards the end of this thesis for 
analysis. However, Jeff studies were limited to key experiments examining 
TGF-p at a single time-point.
Understanding of pathways and mechanisms underlying OM in these 
models will be useful in discovering novel genes associated with OM 
development and pathogenesis and development of non-surgical therapeutic 
measures for management of OM which is the most prevalent cause of 
deafness and surgery in children of the developed world.
6.3-Summary of key results in this thesis
6.3.1- Global inflammatory cell recruitment is not dysregulated in Jbo/+ 
mice
Innate immunity plays a crucial role in development and resolution of 
inflammation. NLs along with macrophages, DCs, and mast cells are players 
in innate immunity. However, NLs and macrophages are the key 
inflammatory cells which orchestrate the initiation and resolution of 
inflammation. Data from intra-peritoneal thioglycollate elicitation study in
A99R8Tthis thesis indicated that Evi-1 mutation does not impair systemic
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recruitment of NLs and macrophages in Jbo/+ mice. This brought 
environmental factors such as hypoxia to the forefront of subsequent 
investigations.
6.3.2- Apoptotic NL percentages in WT and Jbo/+ are comparable 
under normoxic and hypoxic conditions
Ear exudates in Jbo/+ are characterized by NLs and foamy macrophages. At 
the site of inflammation, NLs are the first inflammatory cells to arrive. 
Dysregulation in NL apoptosis can lead to non-resolving inflammation due 
to prolonged release of pro-inflammatory mediators. Data presented in this 
thesis revealed no significant difference in NLs apoptosis performed with 
BMDNLs from WT and Jbo/+ normoxic or hypoxic conditions (Section 
3.2.4). BMDNLs were used for NL apoptosis studies as WT Junbo mice do 
not have middle ear fluids to harvest for control NLs and also because the 
ear-exudates from Jbo/+ mice are a mixture of viable, apoptotic and 
necrotic NLs. Most of this thesis henceforth, focussed on macrophages as 
NLs have a short life-span of 6-12 h (Lee et al, 1993) which made them 
difficult work with (as apoptotis is underway at the time of their isolation). 
NLs were also unsuitable for studying cellular processes in OM which 
would involve longer time-points.
6.3.3- BMDM- A model for studying cellular processes in OM
Macrophages have a longer life-span and are found in middle ear exudates 
from Jbo/+ middle ear. Macrophages are involved in initiation, 
augmentation and resolution of an inflammatory response (Zhang & 
Mosser, 2008). Macrophages are involved in phagocytosis of infected, 
apoptotic and necrotic cells, release NL chemoattractants and a plethora of 
other cytokines depending on stimulatory signal. Macrophages also regulate
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adaptive and humoral immunity (Zhang & Mosser, 2008). Dysregulation in 
any of the key macrophage functions can result in chronic inflammation.
The number of macrophages that can be recovered the from middle ear of 
mice was too low to study cellular processes in OM. To circumvent this 
problem, in vivo to in vitro BMDM model was successfully developed. 
BMDM model can be used to investigate pathways, genes underlying OM 
by conventional approaches for studying macrophage activation and 
stimulation with different treatments. Most of this thesis is based on studies 
in Jbo/+ BMDM. However, some studies on Jf/+ BMDM were also 
performed due to limited availability of mice and time.
In this work the standard BMDM manipulations were exposure to hypoxia, 
LPS, oxysterol and TGF-p.. Combination of various treatments was 
performed to build up model complexity to mimic the inflamed middle-ear 
micro-environment. Dysregulation in HIF and TGF-P signaling was 
explored mainly by two techniques. Gene expression studies were 
performed using RT-qPCR and protein expression studies were performed 
using western blot and Proteome profiler array (only for TGF-p treatment 
under prolonged hypoxic conditions) which gave the subsequent key 
findings.
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6.3.4- Expression of Evi-1 gene and protein is not affected by Evi-1 
mutation in Jbo/+ BMDM
Evi-1 protein expression was observed in ear-exudate from Jbo/+ mice. 
Gene and protein expression studies on resting, hypoxic and activated 
BMDM from Junbo mice also did not reveal any difference in Evi-1 
expression between WT and Jbo/+ genotypes. This is important because it
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A 2 JR R Tindicated that the Evi-1 mutation does not affect expression of Evi-1 
but rather the mutation may impact upon the function of Evi-1.
Evi-1 expression is reported to be increased on activation with LPS at early 
time point of 2 h (Wells et al, 2003). Data from this thesis reveals a 
comparable 15% increase in Evi-1 protein expression with LPS activation at 
2  h in both genotypes.
Some of the interesting findings that came out of this work were the 
hypoxia-responsiveness of Evi-1 and Map3kl4, and Gata-2.Prolonged 
hypoxia (72 h) resulted in a 70% downregulation of Evi-1 in both 
genotypes. This downregulation was also reflected in time-dependent 
downregulation of Evi-1 responsive genes Map3kl4 and Gata-2 at 48 h and 
72 h hypoxia. Maximum downregulation was observed for both Map3kl4 
and Gata-2 at 72 h hypoxia exposure (60% downregulation). This is a first 
time evidence of hypoxia responsiveness of Gata-2, Map3kl4 or Evi-1. 
Chronic hypoxia is a feature of chronic inflammation. Evi-1 is a repressor of 
Smad3 (Kurokawa et al, 1998b). This may potentially serve to enhance HIF 
signalling in prolonged hypoxia as Evi-1 is a co-repressor of Smad3 
(Kurokawa et al, 1998b) which co-activates gene expression of hypoxia- 
responsive genes such as Vegf (Jeon et al, 2007). Which means that at 
hypoxia-rich sites Evi-1 downregulation may potentially result in reduced 
repression of Smad3 leading to enhanced Smad3 transcriptional activity.
6.3.5- Evi-1A2288T mutation in Jbo/+ perpetuates inflammation and 
angiogenesis under prolonged hypoxic conditions- Role for 
dysregulated expression of Vegf, Glut-1, Pai-1 and Ccl2
Throughout this thesis, I have focused only genes which are significantly
different between the genotypes (P <0.05) and with more than 30%
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difference in relative expression levels and only those genes were 
considered potentially biologically relevant. Also, only a 2 fold or more 
difference in a gene expression after treatment was considered as a true 
difference in expression due to treatment. As a result, it is possible that other 
genes showing smaller differences might have been overlooked in this 
analysis.
In hypoxia studies performed in this work, Jbo/+ BMDM were found to 
have higher levels of Vegf, Glut-1 expression on prolonged hypoxia.. Ccl2 
and Pai-1 were downregulated below basal level on prolonged hypoxia at 
72 h but the levels were higher in Jbo/+ compared to WT.
Vegf is a key angiogenic mediator (Ferrara, 2009) which was upregulated in 
hypoxic Junbo BMDM in time dependent manner during prolonged 
hypoxia. Vegf is known to be H if-la dependent hypoxia responsive gene 
which is co-activated by Smad3 and H if-la under hypoxic conditions 
(Forsythe et al, 1996; Jeon et al, 2007; Sanchez-Elsner et al, 2001). Vegf 
levels were 46% and 33% higher in prolonged hypoxic conditions of 48 h 
and 72 h respectively (P <0.01). Vascular changes and Vegf upregulation 
has been linked to a number of chronic inflammatory diseases and increased 
Vegf levels have been observed in diseases such as rheumatoid arthritis, 
inflammatory bowel disease (IBD), diabetic retinopathy (Angelo & 
Kurzrock, 2007). Vegf expression is associated with increased recruitment 
of NLs, macrophages and increased mast cell activation (Angelo & 
Kurzrock, 2007; Canavese et al, 2010; Detmar et al, 1998). Angiogenesis is 
required for maintenance of any chronic inflammatory condition as Vegf 
acts through multiple signalling pathways to stimulate cell proliferation, 
cellular migration and recruitment (Teige et al, 2009; Walshe et al, 2009).
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Glut-1 encodes for a transmembrane glucose transporter protein whose 
transcription is regulated by oncogenes, growth factor and hypoxia (Burke 
et al, 2003; Ohba et al, 2009; Wenger et al, 2005). Glut-1 expression pattern 
in hypoxia treated BMDM was similar to Vegf pattern. Glut-1 expression 
was significantly greater in Jbo/+ BMDM than WT BMDM after treatment 
with hypoxia at both 48h and 72h. Glut-1 levels were 28% and 57% more in 
Jbo/+ BMDM at 48 h and 72 h hypoxia time points. Increased Glut-1 
expression is linked with tumour angiogenesis and with various carcinomas 
(Ohba et al, 2009). Overexpression of Glut-1 in vascular smooth muscle 
cells (VSMCs) is associated with enhanced glucose uptake, increased 
recruitment of NLs, increased influx of glucose promotes inflammatory 
signalling pathways and inflammation in response to vascular injury in 
Sm22a-Glut-1 transgenic mice (Adhikari et al, 2011). VSMC hypertrophy is 
also associated with Glut-1 overexpression and is attributed to TGF-P- 
Smad3 pathway as increased phosphor-Smad2/3 staining is seen in VSMCs 
of Sm22aGlut-l mice (Adhikari et al, 2011).
Pai-1 is an inhibitor of tissue plasminogen activator and urokinase-type
plasminogen activator (Kruithof, 1988). Pai-1 is involved in fibrinolysis and
is associated delayed tissue repair, inhibition of cell adhesion and is
upregulated in inflammation and following bacterial infection (Kohler &
Grant, 2000; Lim et al, 2011; Stefansson & Lawrence, 1996). Pai-1 is a
hypoxia responsive gene (Pinsky et al, 1998). Pai-1 levels were increased
with hypoxia in BMDM but the levels gradually decreased on prolonged
hypoxia. Prolonged 72 h hypoxia decreased Pai-1 expression below the
basal level but Pai-1 levels were 40% higher in Jbo/+ BMDM. This
suggests that Pai-1 expression in Jbo/+ was less responsive to hypoxia. This
was a very interesting result as Pai-1 is a hypoxia responsive gene (Liao et
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al, 2007; Pinsky et al, 1998) as well as Smad3 responsive gene (Dennler et 
al, 1998b; Stroschein et al, 1999).
Ccl2, also known as Mcp-1, is a chemokine which is the homolog of human 
CCL2. It has been shown to be important in recruitment and activation of 
monocytes, T cells, mast cells, basophils as well as wound repair (Ferreira et 
al, 2005). Ccl2 levels were 50% higher in Jbo/+ compared to WT BMDM. 
Ccl2 is reported to be downregulated by hypoxia as well as Smad3 (Bosco 
et al, 2004b; Bosco et al, 2006; Feinberg et al, 2004). So potentially, loss of 
function of A2288T Evi-1 repression of Smad3 would result in lower Ccl2 
levels in Jbo/+. This was observed at 24 h hypoxia (P <0.05) but the 
difference between the genotypes was below the set arbitrary cut-off of 
30%. It could be that at prolonged hypoxia Ccl2 levels are regulated by 
other regulatory pathways such as AP-1. Higher Ccl2 levels on prolonged 
hypoxia can potentially favour chronic inflammation via increased 
macrophage mediated NL recruitment at the site of inflammation.
To summarise, Smad3 is implicated in induction of expression of Vegf, 
Glut-1 and Pai-1 and downregulation of Ccl2 (Adhikari et al, 2011; Dennler 
et al, 1998a; Feinberg et al, 2004; Sanchez-Elsner et al, 2001). Evi-1 is a co­
repressor of Smad3 and hypothetical loss of function of A2288T Evi-1 
would result in enhanced Smad3 activity. Vegf is a classic example of gene 
co-activated by Smad3. Higher levels of Vegf, and other Smad3 and hypoxia 
responsive genes such as Glut-1 and Pai-1 were observed in Jbo/+ BMDM 
under prolonged hypoxia (Figure 6.1). This indicates a potential loss of 
function as a result of theA2288T Evi-1 mutation. Increased levels of Vegf, 
Glut-1, Pai-1 and Ccl2 in Jbo/+ BMDM in prolonged hypoxia can also 
potentially exacerbate inflammation by increasing angiogenesis, NL
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infiltration, monocyte accumulation, hypertrophy, fibrin accumulation and 
impaired wound healing.
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Figure 7.1- HIF signalling is dysregulated in Jbo/+ BMDM
A')') RR TPotential loss o f Evi-1 function as co-repressor o f Smad3 resulted in 
induction o f Vegf, Glut-1 due to enhanced Smad3 activity. Higher levels o f 
Pai-1 and Ccl2 despite a downregulation o f expression under prolonged 
hypoxic condition were also observed. Higher levels o f Vegf, Glut-1, Ccl2, 
and Pai-1 in Jbo /+  BMDM compared to WT BMDM may result in 
enhanced angiogenesis, NL recruitment, mast cell activation, cellular 
hypertrophy and T h l7 cell recruitment exacerbating inflammation.
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6.3.6- Activated Jbo/+ BMDM are LPS-hyper-responsive in normoxia 
but have attenuated responses in hypoxia
6.3.6.1- Jbo/+ BMDM are hyper-responsive for Vegf in normoxia
Vegf expression was upregulated with 2 h and 24 h LPS treatment in a time- 
dependent manner in both WT and Jbo/+ BMDM. Interestingly, LPS 
induced Vegf activation was 123% higher in Jbo/+ BMDM (13 fold 
upregulation in WT, 29 fold upregulation in Jbo/+) at 24 h LPS activation 
in normoxia. This difference in Vegf expression levels was significant (P 
<0.05). This trend of higher Vegf levels in Jbo/+ was clearly apparent with 
24 h LPS treatment in hypoxia as well but the difference was not significant. 
Vegf is also upregulated by just LPS under normoxic conditions via the SP-1 
transcription factor (Sakuta et al, 2001). LPS can increase Vegf expression 
by increasing activity of NF-kB pathway as well because Vegf promoter has 
iKp binding site (Karin, 2006). LPS treatment can also increase Vegf 
expression by increasing H if-la expression (Blouin et al, 2004). LPS 
induced expression levels of Vegf was greater than Vegf induction by 
hypoxia alone. Vegf gene and protein expression has been found in the 
middle ear of LPS induced OME model (Jung et al, 1999). VEGF has also 
been detected in middle ear effusions from children with OME (Sekiyama et 
al, 2010). Injection of recombinant Vegf in rat middle is associated with 
fluid effusion and mucosal inflammation (Kim et al, 2005). These findings 
suggest that Vegf is produced in inflamed middle ear in response to LPS and 
hypoxia. Recently HIF-VEGF signalling pathway has also been shown to be 
upregulated in Jbo/+ and Jf/+ middle ear fluids (Cheeseman et al, 2011). 
VEGFR signalling inhibitors have also been found to suppress OM in Jbo/+ 
implicating a role of Vegf in OM development (Cheeseman et al, 2011). My
results indicate that when induced with hypoxia or endotoxin, Jbo/+ 
BMDM are prone to more Vegf production than WT. Increased Vegf levels 
in hypoxic or activated conditions can contribute to OM by recruiting more 
NLs, accumulating middle ear fluids and activating mast cells. Vegf can also 
polarise T cells to differentiate into pro-inflammatory Thl cells by 
increasing IFN-y production and decreasing 11-10 levels (Mauro et al, 2008; 
Mor et al, 2004).
6.3.6.2- Jbo/+ BMDM have attenuated Il-ip  levels in hypoxia and in 
activated hypoxic state
II-lp  is a prototypical inflammatory cytokine encoding gene. II-ip is 
released by macrophages, fibroblasts, mast cells, DCs and NK cells and is 
involved in a range of inflammatory functions such as the upregulation of 
adhesion molecules, inflammatory cell infiltration, synthesis of NO, 
production of IL- 6  and acute-phase proteins, apoptosis, angiogenesis, 
antibody formation, differentiation of T cells to pro-inflammatory T h l7 
cells etc (Dinarello, 2009). Mice deficient in II-lp  exhibit no spontaneous 
inflammation but instead display reduced systemic and local inflammation, 
reduced acute phase response but increased disease susceptibility to live 
pathogens (Dinarello, 2009). Il-ip  is upregulated by LPS as well as by 
hypoxia (Hume et al, 2002; Locati et al, 2002; Perera et al, 1998; Scanned, 
1996). II-lp is implicated in chronic inflammation such as RA, IBD, 
osteoarthritis, diabetes, Alzheimer’s disease etc (Dinarello, 2009). Higher II- 
lp  levels have been observed rat model of AOM as well as Jbo/+ ear 
exudates (Cheeseman et al, 2011; Tong et al, 2008). Polymorphisms in IL- 
ip  have been associated with COME/RAOM in humans (Rye et al, 2011a; 
Sale et al, 2008).
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II-ip  levels were upregulated as expected with LPS activation of BMDM in 
a time dependent manner. LPS induced levels of Il-lp  were comparable in 
both genotypes under normoxia conditions. Hypoxia enhanced the LPS 
induced upregulation of Il-ip  levels. However, Il-lp  levels were 30% lower 
(P <0.05) in hypoxic activated Jbo/+ BMDM at the short time-point of 2h 
but the levels reach WT levels on prolonged hypoxia. Although Smad3 is 
known to increase increase expression of II-ip protein suggesting an 
autocrine loop between TGF-p pathway and Il-lp protein expression (Aoki 
et al, 2006), reduced Il-ip  activation under hypoxia and LPS activation at 2 
h can potentially be attributed to hypothetical loss of function of A2288T 
Evi-1 as activator of AP-1 which acts to upregulate expression of pro- 
inflammatory genes including Il-ip  (Tanaka et al, 1994). Reduced II-ip  
levels in Jbo/+ BMDM under hypoxic conditions can potentially result in 
attenuation of macrophage function and susceptibility to bacterial infections 
independently. Although, it is important to note here that Jbo/+ mice 
develop OM in germ-free conditions as well.
6.3.6.3- Jbo/+ BMDM has lower Tnf-a level in LPS activated BMDM in 
hypoxia
TNF-a is a pro-inflammatory cytokine which is involved in Ml polarization 
(along with IFNy), apoptosis, cell proliferation and orchestration of pro- 
inflammatory cytokine response via activation of transcription factors such 
as NF-KBand AP-1 (Aggarwal, 2003; Chen & Goeddel, 2002; 
Parameswaran & Patial, 2010). TNF-a is produced by macrophages, mast 
cells, epithelial cells and stromal cells and is often associated with chronic 
inflammation such as atherosclerosis, IBD and arthritis (Clark, 2007; 
Parameswaran & Patial, 2010). Elevated TNF-a is also a primary cytokine
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often associated with OM (Juhn et al, 2008; Skotnicka & Hassmann, 2000; 
Smirnova et al, 2002). Polymorphisms in the TNF-a gene are associated 
with AOM (TNFA-238G/G, 376 G/G) (Emonts et al, 2007a; Patel et al, 
2006). In induced AOM models in rat and mice, increased TNF-a 
expression after NTHi transtympanic inoculation has been observed 
(Catanzaro et al, 1991; Melhus & Ryan, 2000). These studies indicate a role 
of TNFa induction in AOM. Higher Tnf-a Levels are also observed in Jbo/+ 
ear exudates (Cheeseman et al, 2011). However, persistent inflammation in 
induced OM in Tlr2'f’ and Tlr4~f~ mice has been associated with defective 
induction in TNF-a gene after infection (Leichtle et al, 2009; Leichtle et al, 
2010). TNF-a deficient mice also display OM similar to TLR2 and MyD88 
mutants with a reduced NT Hi phagocytosis by macrophages. In Tnf-a'1' mice 
there is diminished but prolonged NL recruitment in middle ear. 
Macrophages from Tnf-a"A mice display attenuated bactericidal phagocytosis 
which indicates impairment of macrophage function. TNFa also plays a 
major role in apoptosis and as a delayed OM resolution in Tnf-a'f~ deficient 
mice (Leichtle et al, 2009) it might indicate a role of TNF-a in apoptotic 
function and in recovery of OM.
Results from this work indicate that no difference was observed in Tnf-a 
gene levels between genotypes at basal level, hypoxia or LPS activation in 
normoxia. However, LPS induced Tnf-a expression in hypoxia was reduced 
in Jbo/+ BMDM by 36% vs. treated WT BMDM at 2h (P <0.05). This trend 
was maintained at 24h with a 23% reduction in Jbo/+ but the difference 
between the genotypes was not significant. Tnf-a is known to decrease 
scavenger receptor gene and protein expression (Hsu et al, 1996), reduced 
Tnf-a levels in hypoxia and infection may predispose Jbo/+ BMDM to 
foam cell formation and attenuate macrophage function.
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6.3.6.4- Jbo/+ BMDM are hyper-responsive to LPS for 11-6 expression in 
normoxia
IL- 6  is a multi-functional cytokine involved in acute phase response (Gabay, 
2006). IL- 6  protects T cell from apoptosis, promotes NL apoptosis and 
influences T cell polarization to inhibit T-regs and induce T hl7 
differentiation in presence of TGF-P (Bettelli et al, 2006; Ishihara & Hirano, 
2002; Jones, 2005; Kishimoto, 2010). IL- 6  is associated with RA, colitis, 
encephalomyelitis and development of inflammation owing to its role the 
transition from NL to macrophage inflammation (Alonzi et al, 1998; Hurst 
et al, 2001; Yamamoto et al, 2000). 11-6 levels are also upregulated in ear 
effusions from induced OM in mice (Barzilaia et al, 2000; Yellon et al, 
1992). Upregulated 11-6 levels have also been reported in induced AOM in 
rats after NTHi inoculation (Melhus & Ryan, 2000). Upregulated IL- 6  
protein is seen in humans in choleastoma tissue from patients with chronic 
OM (Kuczkowski et al, 2011). Polymorphism in IL-6 at position 174 is 
associated with OM in humans (Emonts et al, 2007a; Patel et al, 2006).
IL- 6  is upregulated with LPS in an NF-kB dependent manner (Begum et al, 
2004; Yang et al). IL- 6  levels in Jbo/+ BMDM were relatively higher by 
42% on LPS activation at 24 h normoxia (P <0.05). A trend of higher IL- 6  
levels in Jbo/+ was also present at 24 h LPS activation in hypoxia but the 
difference was not significant. Higher IL- 6  level in normoxic LPS activated 
Jbo/+ BMDM would potentially result in amplified inflammatory response, 
increased Ml activation and Thl polarization to result in chronic 
inflammation.
234
These results reveal a dysregulation in HIF signalling but this regulation 
may be regulated by more than just Hif-la. LPS results show that NF- 
KBmight have a role in HIF dysregulation observed in Jbo/+.
6.3.6.5- Jbo/+ foamy BMDM produce lower Nos-2 under hypoxia -  
implication for attenuated macrophage function
Jbo/+ ear exudates are characterized by presence of foamy macrophages 
(Cheeseman et al, 2011; Parkinson et al, 2006). Foamy macrophages are 
formed by uptake of ox-LDL which gives these macrophages a 
characteristic foamy appearance (Brown et al, 2000; Heinecke et al, 1991). 
Hypoxia is reported to promote foam cell formation and hypoxia in Jbo/+ 
middle ear would be conducive to foam cell formation (Cheeseman et al, 
2011; Hulten & Levin, 2009; Parkinson et al, 2006; Rydberg et al, 2004). 
The Ox-LDL concentration in Jbo/+ ear exudates is approximately 50 pg/ml 
and is 245 fold greater than in Jbo/+ or WT serum. To test if the presence of 
foamy macrophages,Ox-LDL, and with hypoxia might affect the 
inflammatory response in Jbo/+ mice, oxysterol studies on Junbo BMDM 
were performed. Although no defect in expression of cholesterol efflux was 
evident as Abcal expression levels were comparable in both genotypes with 
oxysterol treatment in normoxia and hypoxia, anomalous Nos-2 expression 
was observed in Jbo/+ BMDM with oxysterol treatment in hypoxia.
Nos-2 is a gene that encodes for NO generating enzyme Nos-2 (Leone et al, 
1991; Palmer et al, 1988). Nos-2 is expressed by macrophages, monocytes, 
NLs, eosinophils, DCs, mast cells, NK cells, endothelial cells, epithelial 
cells, VSMCs and fibroblasts in response to activation by LPS, hypoxia or 
pro-inflammatory cytokines such as Tnf-a, II-1 p, Ifn-y (Bogdan et al, 2000). 
Nos-2 expression is upregulated by LPS via NF-KB(Heitmeier et al, 1998;
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Song et al, 2004). Its expression is also upregulated with hypoxia (Angele et 
al, 1999; Blouin et al, 2004). Although no difference in Nos-2 levels of 
biological significance was observed on LPS or hypoxic treatment of Junbo 
BMDM on its own or in combination; a significant genotypic difference in 
Nos-2 levels between genotypes was observed on oxysterol treatment of 
Junbo BMDM. Nos-2 levels were 76% lower in Jbo/+ BMDM on oxysterol 
treatment in hypoxia (P <0.05) and a trend of lower Nos-2 was also 
observed in normoxic oxysterol treatment although the difference was not 
significant. Nos-2 is essential for pathogen clearance, and plays an 
immunoregulatory role by affecting differentiation of Thl cells and 
cytotoxic function of NK cells Nos-2'f' mice have been reported to be 
extremely susceptible to infections, bolstering the evidence for the role of 
Nos-2 in pathogen clearance. Lower NO might also make Jbo/+ BMDM 
prone to bacterial infection under high Ox-LDL and hypoxic conditions.
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Figure 1.2-Jbo/+ BMDM are LPS-hyper-responsive in normoxia but 
activated Jbo/+ BMDM have attenuated macrophage function in 
hypoxia
Jbo/+ BMDM are hyper-responsive to LPS in normoxia as is evident by 
higher levels o f pro-inflammatory Vegf, 11-6 expression. However, under 
hypoxic conditions, activated / 60/+BM D M  possess attenuated macrophage 
function with reduced Tnf-a and II-ip  levels. Oxysterol treated Jbo/+ 
BMDM are also hypo-responsive and have lower levels o f Nos-2. These 
properties o f Jbo/+ BMDM make them prone to inflammation in both 
normoxia and hypoxia.
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6.3.7- Resolution of inflammation in Jbo/+BMDM is impaired in 
hypoxic conditions
Hypoxia can either exacerbate inflammation or resolve inflammation as 
hypoxic macrophages express both pro-inflammatory Ml and an anti­
inflammatory M2 markers (Rahat et al, 2011). However, resolution of 
inflammation is dependent on phagocytic activity of macrophages as well as 
well-timed suppression of pro-inflammatory mediators. An abnormality in 
either process can result in chronic inflammation. Pro-inflammatory gene 
expression can delay resolution of inflammation if this expression is 
prolonged or at a relatively higher level.
Hypoxic conditions are prevalent in inflamed middle ear in Jbo/+ mice and 
results from this thesis indicate that under hypoxic conditions, Jbo/+ 
BMDM have dysregulated resolution of inflammation as is evident from 
higher level of pro-inflammatory gene expression levels of 11-6 (46% 
higher) and II-10 (30% higher) (P < 0.05). Higher levels of Il-lp, 11-6 can 
pre-dispose hypoxic Jbo/+ site to prolonged inflammation by prolonged 
release of acute phase proteins and downstream pro-inflammatory effectors 
and increasing inflammatory cell infiltration (Figure 6.3). Higher IL- 6  and 
IL-ip levels are associated with differentiation of a subset of T cells known 
as Thl7 cells which are associated with chronic inflammation and 
autoimmunity (Bettelli et al, 2006). This indicates that impairment of 
resolution in Jbo/+ BMDM under hypoxic conditions can exacerbate 
inflammation and drive it towards chronicity.
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Figure 1.3-Jbo/+ BMDM display impaired resolution of inflammation 
in hypoxia
LPS activation for 2 h in normoxia followed by LPS washout and 
subsequent hypoxic treatment for 24 h revealed that levels o f pro- 
inflammatory genes were higher in Jbo/+ than WT indicating a potential 
abrogated resolution o f inflammation under hypoxic conditions.
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6.3.8- Aberrant TGF-p signalling in Jbo/+ BMDM in normoxia and 
hypoxia- indications of involvement of Smad and non-Smad dependent 
pathways
6.3.8.1- Feg/*levels are differentially dysregulated with TGF-p 
treatment in normoxia and hypoxia
Angiogenesis is required for maintenance of any chronic inflammatory 
condition as VEGF acts through multiple signalling pathways to stimulate 
cell proliferation, cellular migration and recruitment (Teige et al, 2009; 
Walshe et al, 2009). Inflammatory cytokines often upregulate angiogenic 
mediators such as VEGF. Vascular changes have been linked to a number of 
chronic inflammatory diseases and increased Vegf levels have been 
observed in diseases such as RA, IBD and diabetic retinopathy (Angelo & 
Kurzrock, 2007). Vegf expression has been associated with increased 
recruitment of NLs, macrophages and increased mast cell activation 
(Angelo & Kurzrock, 2007; Canavese et al, 2010; Detmar et al, 1998).
Vegf expression pattern with TGF-P treatment was quite interesting as Vegf 
expression was upregulated by TGF-p treatment in normoxia and hypoxia. 
However, genotypic differences were observed only at 6  h time-point where 
Vegf expression was 30% lower in Jbo/+ BMDM than WT (P <0.05) in 
normoxia. Interestingly Vegf levels were comparable with further exposure 
to TGF-P and hypoxia. One possibility is that Vegf may be regulated by 2 
different mechanisms (via pathways other than Smad3 and Hif-la) in Jbo/+ 
BMDM in presence of TGF-P, which may be affected by Evi-1A2288T 
mutation.
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6.3.8.2- Jbo/+ BMDM has lower Pai-1 levels under TGF-p treatment in 
normoxia
Pai-1 levels were lower in Jbo/+ BMDM with 6  h TGF-P treatment in 
normoxia by 38% (P< 0.05). This is interesting as Pai-1 is a hypoxia 
responsive gene (Liao et al, 2007) as well as a Smad3 responsive gene 
(Dennler et al, 1998b; Stroschein et al, 1999). Pai-1 expression is induced 
by different signaling pathways as Pai-1 promoter has various cis-regulatory 
sites such as SP1 site, AP-1 sites, HRE sites and Smad binding sites which 
indicates complex transcriptional regulation of this gene (Liao et al, 2007; 
Nagamine, 2008). It is possible that the Evi-1A2288T mutation in Jbo/+ 
regulates Pai-1 gene expression through another novel pathway. In humans, 
polymorphisms in PAI-1 gene have been linked to higher PAI-1 levels and 
recurrent AOM (Emonts et al, 2007b). Higher PAI-1 levels due to PAI 
4G/4G genotype in humans and plasminogen deficient mice both display 
impaired wound healing rather than affect on OM susceptibility (Emonts et 
al, 2007b; Eriksson et al, 2006). Lower Pai-1 levels in Jbo/+ mice might not 
be the main reason behind OM but might predispose Jbo/+ mice to bacterial 
infection under hypoxic conditions.
6.3.8.3- Jbo/+ BMDM  has higher 11-6 levels under TGF-p treatment in 
hypoxia
Increased levels of 11-6 (214%, P < 0.05) under prolonged conditions of 
TGF-P and hypoxia in Jbo/+ BMDM can potentially predispose Jbo/+ 
BMDM to inflammation due to increased levels of acute-phase proteins and 
induce differentiation of pro-inflammatory Thl 7 cells (Figure 6.4).
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Figure 1.4-Jbo/+ BMDM displays dysregulated TGF-B signalling in 
normoxia and hypoxia
TGF-P signalling is dysregulated in Jbo/+ BMDM. Higher levels o f pro- 
inflammatory 11-6 in Jbo/+ BMDM may predispose them to inflammation 
under conditions o f hypoxia
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6.3.8.4- Jbo/+ BMDM are predisposed to inflammation at basal level
Comparative protein expression studies in this work revealed that Jbo/+ 
BMDM have upregulated levels of pro-inflammatory cytokines 11-23, C5a, 
Tnf-a, Trem-1, 11-17 as well as lymphocyte chemoattractants I-tac, 11-16 
under resting condition (Figure 6.5). These cytokines induce chemotaxis of 
pro-inflammatory Thl cells, eosinophil and monocytes. Jbo/+ BMDM also 
possessed higher level of B cell chemoattractant Cxcll3 and 
proinflammatory tissue inflammation associated cytokine 11-17. High levels 
of pro-inflammatory cytokines and low levels of anti-inflammatory 
cytokines 11-4, 11-2, II-Ira may potentially make Jbo/+ BMDM prone to 
inflammation and hyper-responsive to LPS in normoxic conditions. High 
Trem-1 levels may serve to amplify inflammatory responses in Jbo/+ 
BMDM.
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Figure 7.5-Differential cytokine expression in Jbo/+ indicates 
predisposition to inflammation at both basal level and after 48 h 
hypoxia and TGF-B treatment
At basal level Jbo/+ BMDM had upregulated levels o f pro-inflammatory 
cytokines as well as anti-inflammatory cytokines
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6.3.8.5- Jbo/+ BMDM are potentially pro-inflammatory, promoting 
T hl7 cell differentiation and dysregulated wound healing under 
conditions of prolonged hypoxia and TGF-p treatment
Ingestion of apoptotic of NLs is reported to stimulate the release of TGF-p 
which alternatively activates macrophages and primes them to resolve 
inflammation (Edwards et al, 2006; Martinez et al, 2009; Mosser & Zhang, 
2008a). To mimic resolving inflammation in Jbo/+ ears; TGF-p and 
hypoxia treatment of BMDM was performed.
Lower levels of key anti-inflammatory cytokines IL-lra, IL-10, IL-2, Ccl2, 
and Cell2 potentially predispose Jbo/+mice to impaired wound healing, 
spontaneous inflammation and infection susceptibility under conditions of 
prolonged hypoxia (48 H) in presence of TGF-p.
Jbo/+ BMDM also had higher levels pro-inflammatory 11-6, 11-23, Il-lp, 
Ccl5, 11-17, 11-16 and anaphylatoxin C5a in prolonged hypoxia (48 h) in 
presence of TGF-P treatment which would potentially result in increased 
levels of acute phase protein, increased respiratory burst, infiltration of NLs, 
eosinophils, monocytes, T cells as well as activation of macrophages, T 
cells, NLs and mast cells to release proinflammatory mediators.
Reduced levels of T cell and B cell growth factor 11-7, Mcsf, Ccl2, Cxcll3, 
Cell2 and Thl polarizing cytokine I-tac after treatment indicate a potential 
deficit in chemotaxis and differentiation of lymphocytes, macrophages, 
monocytes in prolonged hypoxic Jbo/+ BMDM in presence of TGF-p 
which can prove detrimental for resolution of inflammation.
Interestingly Jbo/+ BMDM released cytokines favourable for T hl7 
differentiation. T hl7 cells are a subset of T cells which are associated with 
chronic inflammation (Littman & Rudensky, 2010; Liu et al, 2011).
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Depending upon cytokines released in inflammatory microenvironment, 
CD4+ Th cells can differentiate into Thl, Th2, T hl7 or Tregs. Tregs and 
T hl7 cells have inverse roles in inflammation and their differentiation is 
dependent upon TGF-p and other cytokines. Tregs are immunosuppressive 
and are induced by activation of naive T cells by IL-10 or TGF-p (Foxp3+). 
Tregs are important ‘self check’ T cells which are critical to control 
excessive inflammation and cytokines released by Jbo/+ BMDM on 
prolonged TGF-p and hypoxia exposure describe an environment that 
potentially will inhibit Treg differentiation and facilitate Thl 7 
differentiation to result in chronic inflammation and PMN infiltration in the 
middle ear. However, 11-6 and IL-lp are reported to suppress Tregs 
differentiation and induce T hl7 differentiation.
T hl7 cells are associated with autoimmune diseases such as EAE, IBD, 
psoriasis and RA and are formed by differentiation of naive T cells by IL-6 , 
TGF-p and their maintenance and differentiation is supported by IL-17, IL- 
23 and IL-ip. 11-2 and 11-4 are known to decrease T h l7 differentiation. 
Higher levels of 11-6, 11-lp, 11-17 in Jbo/+ potentially may divert 
development of Foxp3+ Tregs towards T hl7 lineage under conditions of 
prolonged TGF-p and hypoxia. Higher levels of 11-23 and lower level of II- 
10, 11-2 and 11-4 can potentially maintain differentiation of T hl7 cells 
leading to chronic inflammation.
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6.4- Potential molecular pathways of disease development in 
Jbo/+ mice
Data in this thesis has revealed that dysregulation of HIF signalling pathway 
and TGF-P signalling pathway exists in Jbo/+ BMDM. Protein expression 
studies in Jbo/+ BMDM reveal that they are potentially pre-disposed to 
inflammation at basal level due to higher levels of pro-inflammatory and 
NF-kBtarget proteins such as 11-23,11-17, Tnf-a, I-tac, C5a, Trem-1 (Figure 
6.5). Gene expression studies in this thesis have also revealed that Jbo/+ 
BMDM are potentially hyper-responsive to LPS in normoxia with respect to 
11-6 and Vegf signaling. Vegf has been implicated in OM in Jbo/+ mice 
previously (Cheeseman et al, 2011). Jbo/+ BMDM also display pro- 
angiogenic property and impaired resolution of inflammation in hypoxia. 
However, the pathways behind OM susceptibility of Jbo/+ need to be 
elucidated further. In this thesis, I hypothesized that because Evi-1 gene or 
protein expression is comparable in the 2 genotypes, ZF2 A2288T mutation 
in ZF2 of Evi-1 potentially affects Evi-1 function as a transcription 
factor and co-repressor.
A characterized function of Evi-1 is as a co-repressor of Smad3 by direct
interaction via ZF1 and recruitment of CtBP (Izutsu et al, 2001; Kurokawa
et al, 1998b). I hypothesized that loss of function of Evi-1 due to Evi-1A2288T
mutation would result in increased activity of Smad3. Smad3 and other
Smad transcription factors have low affinity with DNA and must interact
with other transcription factors to form stable complexes with DNA (Mullen
et al, 2011). My hypothesis was that transcriptional activity of Smad3 would
be augmented under hypoxia as Smad3 is known to interact with H if-la in
hypoxia to co-activate expression of Vegf (Sanchez-Elsner et al, 2001). My
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hypothesis was validated as increased levels of Smad3 responsive and HIF 
responsive genes Vegf, Glut-1 was observed in Jbo/+ BMDM under 
conditions of prolonged hypoxia. Vegf induction was also higher in LPS 
activated and TGF-P and hypoxia treated BMDM. High levels of Smad3 
responsive Timp-1 protein, Il-lp protein after 48 h treatment also validate 
the above outlined hypothesis as they are both Smad3 and HIF responsive 
proteins (Aoki et al, 2006; Bosco et al, 2008; Rius et al, 2008; Verrecchia et 
al, 2001). Lower levels of Ccl2 and Cell2 (CCL2 structural and functional 
homologues in mice) after 48 h TGF-p and hypoxia treatment were also 
indicative of increased Smad3 transcriptional inhibitory activity under 
hypoxia due to potentially higher Smad3 levels (Feinberg et al, 2004). 
Interestingly, high levels of Smad2 responsive 11-6 gene were also observed 
in Jbo/+ BMDM on prolonged TGF- p and hypoxia treatment. The role of 
Evi-1 as a repressor of Smad2 has been previously also described (Alliston 
et al, 2005). Smad2 is reported to increase 11-6 expression in presence of 
TGF-P in DU145 cells (Park et al, 2003). Also, hypoxia is known to 
increase IL- 6  expression (Eickelberg et al, 1999; Junn et al, 2000; Li et al, 
2004). Thus in Junbo mice we may be observing an impaired inhibition of 
smad 2 by Evi-1 resulting in a more pro-inflammatory phenotype.
AJJRRTOther possible mechanisms via which Evi-1 exerts its affects could be
as follows. Evi-1 is also known to activate AP-1 activity and repress
RUNX1 activity via its second zinc finger domain (Senyuk et al, 2007;
Tanaka et al, 1994). AP-1 is a transcriptional factor which interacts with
both HIF and TGF-P signalling as well as other signalling pathways. Lower
levels of some AP-1 responsive genes such as Pai-1, Ccl2,11-4 (Johnston et
al, 2000; Schmidt-Weber et al, 2000; Wang et al, 1999) were seen in Jbo/+
BMDM with TGF-P treatment in hypoxia. AP-1 is also known to activate II-
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10 transcription in Th2 cell (Rooney et al, 1994). This means that Evi-1 is 
involved in number of pathways and that Evi-1 mutation in Jbo/+ 
might potentially dysregulate a number of pathways.
RUNX1 plays an essential role in differentiation and function of T cells. 
EVI-1 has been reported to interact with and inhibit RUNX1 activity via 
interaction with the second zinc finger domain (Senyuk et al, 2007). TGF-p 
is known to activate RUNX1 expression (Wildey & Howe, 2009). TGF-p 
has also been shown to upregulate expression of master Thl7 regulator 
RORyt and Foxp3 in T cells. Interactions between Runxl, RORyt and 
Foxp3 are known to regulate differentiation of Thl7 and Tregs where 
Runxl plays an important role in establishment of T cell lineage (Zhang et 
al, 2008; Zhou & Littman, 2009). Runxl interacts with Retinoic acid 
receptor related orphan receptor gamma (RORyt) to induce 11-17 expression 
(Zhang et al, 2008). Runxl can also interact with transcription factor Foxp3 
to induce Treg differentiation in presence of TGF-P (Zhang et al, 2008). In 
such a scenario, the microenvironment plays a crucial role in directing T 
h i7 or Treg differentiation. In presence of TGF-p CD4 + T cell express 
both RORyt and Foxp3 but Foxp3 antagonizes RORyt function and interacts 
with Runxl to enable Treg differentiation. However, in presence of pro- 
inflammatory cytokines sych as 11-6 or II-IP; Foxp3 function is inhibited 
and RORyt interacts with Runxl to induce Thl7 cell differentiation and 
upregulation of 11-17 (Adamson et al, 2009; Littman & Rudensky, 2010; 
Zhang et al, 2008; Zhou & Littman, 2009). Runxl is crucial for Thl7 cell 
development as transduction of Runxl induces Thl7 cell differentiation 
while siRNA against Runxl antagonizes Thl7 cell differentiation (Zhang et 
al, 2008).
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It is possible that increased activity of Runxl occurs in Jbo/+ BMDM due
A 7  7 # # 7 "’to Evi-1 encoded protein would result in activation of Runxl. HUM a 
is known to enhance degradation of FOXP3 in 293T cells (Human 
Embryonic Kidney 293 cells) (Dang et al, 2011). RUNX1 is also known to 
interact with SMAD3 (Jakubowiak et al, 2000). Results from this thesis 
reveal that prolonged hypoxia and TGF-p treatment resulted in upregulated 
11-6 expression. It is possible that under conditions of hypoxia, upregulated 
11-6, II-lp and Runxl activation, Thl7 differentiation is favoured resulting 
in chronic inflammation. Interestingly, data from this thesis also points that 
under prolonged hypoxia and TGF-P treatment, cytokines favourable for 
Thl7 differentiation are secreted. Interestingly, impaired repression of
A 7  7 # #  TRunxl by Evi-1 encoded protein may also contribute to lower Vegf
levels observed with TGF-P treatment in normoxia as Runxl is known to act 
as a repressor for Vegf (Ter Elst et al, 2011). Runxl is also known to 
downregulate 11-4 expression (Naoe et al, 2007). Interestingly lower levels 
of 11-4 were also observed in Jbo/+ BMDM along with higher levels of 11-17 
after 48 h TGF-P and hypoxia treatment.
Evi-1 is also known to repress PU.l function via ZF1 and by disrupting 
PU. 1 and c-Jun binding (Laricchia-Robbio et al, 2009). PU. 1 is reported to 
control lymphopoeisis and myelopoeisis and high PU.l level is known to 
favour NL and macrophage maturation. Impairment of ‘PU.l repressive’
A 7 7#J? Tactivity of Evi-1 would result in increased PU.l activation which can
potentially account for higher levels of II-ip (Marecki et al, 2001)and lower 
levels of 11-4 and 11-10 (Chang et al, 2005) as is observed in Jbo/+ BMDM 
after 48 h TGF-p and hypoxia treatment.
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Recently, it has also been reported that Evi-1 represses Phosphatase and 
tensin homologue on chromosome 10 (Pten) transcription via first zinc 
finger domain and recruiting PcG proteins (Yoshimi et al, 2011). Pten acts 
as a negative regulator of PI3k/Akt/mTOR pathway which Evi-1 activates 
via Pten repression (Yoshimi et al, 2011). Hypothetically, Evi-1 loss of 
function would result in Pten overexpression and repression of PI3k/AKt 
pathway as PI3k/Akt/mTOR pathway is activated by growth factors. As 
Pten is known to activate I-tac promoter (Rani et al, 2002) and 
downregulate II-ip expression (Wang et al, 2008; Yum et al, 2001), 
impaired Evi-1 repression of Pten may potentially explain decreased 
levels of I-tac and increased levels of II-lp after 48 h TGF-P and hypoxia 
treatment. PI3k/Akt signalling pathway is known to induce expression of M- 
csf, Trem-1, Tnf-a, Il-lra, 11-10 (Chen et al, 2008; Learn et al, 2001; Mandal 
et al, 2009; Pulendran, 2004). Abrogated PI3k/Akt signalling due to 
potential Pten overexpression due to impaired repression by Evi-1 
encoded protein could contribute to decreased levels of these cytokines 
observed after 48 h TGF-p and hypoxia treatment. However, it is important 
to note that Evi-1 represses Pten in only cells with high expression of Evi-1. 
Although BMDM express high levels of Evi-1 but low levels of Evi-1 gene 
are expressed and additional experiments would need to be performed to 
check if Pten repressive function of Evi- holds true for BMDM.
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Figure 7.6-Potential pathway for OM development in Jbo/+ and Jf/+ 
mice
This figure illustrates putative pathways that maybe involved in OM
pathogenesis in Jbo/+ and J//+ mice. Evi-1 is a co-repressor o f Smad3 and
Smad2 via Z F 1. E vi-1 also represses transcription o f transcription activator
PU .l and PI3K inhibitor Pten via ZF1. Evi-1 uses ZF2 to repress activity o f
R unxl and activates AP-1 activity. A2288T mutation in Evi-1 ZF2 coding
region does not affect its expression in genotypes but may affect its binding
and its function as a co-repressor or transcription activator. Similarly
F b x o ll is involved in stabilization o f p53 which is required for TGF-p
signalling via Smad2. Fbxoll expression level in both genotypes maybe
equal but the Fbxoll protein in Jf/+ is mutated and it is likely that the that
the function o f F bxoll is perturbed in Jf/+ mice. TGF-p triggers signalling
via TGF-pRs which leads to phosphorylation o f Smad2 and Smad3 and their
subsequent transport to the nucleus where they interact with co-factors to
modulate gene expression o f their down-stream targets. Hypoxia is a key
feature o f inflammation in middle ear o f Jbo/+ and Jf/+ mice. Hypoxia
leads to stabilization o f H if-la  which interacts with both Smad2 and Smad3
in hypoxia to modulate gene expression. Prior evidence and results from this
thesis indicate a dysregulation in HIF signalling as well as TGF-P signalling
in Jbo/+ and Jf/+ mice which points to a common pathway for OM
pathogenesis in both Jf/+ and Jbo/+ mice. However, the phenotypic
difference in OM and its severity between the two models may be due to
involvement o f other factors in Jbo/+ mice. TGF-P can also induce
signalling via other pathways such as PI3K, R unxl, AP-1 which are all
known to interact with Evi-1 and their activity maybe perturbed by Evi- 
jA228st mutatjon |n jJjq/a- mice.
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6.5- Future work
Further studies need to be performed in Jf/+ and Jbo/+ to elucidate OM 
pathogenesis.
Data from this thesis reveals that Jbo/+ BMDM are hyper-responsive to 
LPS and display attenuated resolution of inflammation in hypoxia. One of 
the first things to check next would be if clearance of apoptotic NLs is 
perturbed in Jbo/+ BMDM under hypoxia using a simple protocol described 
by (Michlewska et al, 2009). It is plausible that pathogen clearance by 
Jbo/+ BMDM also may also be affected under prolonged hypoxia as is 
indicated by reduced levels of Tnf-a and II-lp  levels in Jbo/+ BMDM after 
2 h LPS and hypoxia treatment. A bacterial challenge would be useful in 
confirming the finding. Comparison of cytokines after LPS activation and 
prolonged hypoxia between the genotypes using proteome profiler array 
would also indicate other cytokines whose expression is dysregulated 
between the genotypes and would confirm the RNA result.
To further elucidate the pathways that may be involved in OM due to
A 2 ORRTEvi-1 mutation in Jbo/+ mice, experiments with Smad3 and Runxl 
overexpression in transgenic mice can be performed. Co-
A H R R Timmunoprecepitation studies to study effect of Evi-1 mutation on the
interactions of encoded protein with Runxl, PU.l, Smad3, Smad2 and AP-1
would also shed more light to the pathways involved in OM development in
Jbo/+ mice. Another thing to check would be the levels of Pten expression
via RT-qPCR between WT and Jbo/+ BMDM which would indicate
whether Evi-1 repression of Pten is abrogated in Jbo/+ BMDM.
Studies performed in this thesis also provide a model which can be
replicated to study OM cellular processes in humans using peripheral
monocytes to further confirm the findings and, highlight the role of hypoxia
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in exacerbating inflammation in Jbo/+ BMDM. It would be interesting to 
observe if induction of arthritis (another inflammatory disease with 
dysregulated HIF signalling) shows that Jbo/+ BMDM are susceptible to a 
more aggressive disease.
Vegf, Glut-1, 11-6 were the key genes which were upregulated in Jbo/+ 
under hypoxia and it would be interesting to observe if their overexpression 
in mice results in a phenotype similar to OM in Jbo/+. 11-6 and I I - I f  were 
higher in Jbo/+ BMDM in resolution of inflammation study in hypoxia. 
Ultimately, the results from these studies and TGF-P studies can be 
potentially applied in a pharmacological and medical setting. At present OM 
is medically managed with antibiotics which are not very effective for OME 
and chronic OM (Browning et al, 2010; Griffin et al, 2006). Surgical 
intervention is the only way of treatment of chronic OM, in fact, each year 
30,000 surgical procedures are carried out in UK alone to treat OM (Sood & 
Waddell, 2007). Recently, Vegf receptor inhibitors have been reported to 
significantly reduce OM severity in Jbo/+ mice (Cheeseman et al, 2011). 
Vegf was reported to be upregulated in Jbo/+ under hypoxia and LPS 
activation in normoxia in this thesis. In such a scenario, it is important to 
check if addition of 1 1 -6  receptor inhibitor such as tocilizumab or II-lp 
inhibitor Canakinumab or exogenous II-ra (Anakira) and IL-10 can 
moderate OM severity in Jbo/+ as expression of these markers was 
dysregulated in data presented in this thesis.
Data from this thesis also strongly hints towards a predisposition of Jbo/+
BMDM in promoting differentiation of Thl7 cell lineage in hypoxia and in
presence of TGF-p. TGF-P is synthesized during apoptosis and potential
induction of pro-inflammatory Thl7 cells by Jbo/+ BMDM in hypoxia in
vivo might lead to chronic inflammation. Studies on Jbo /+ T cells would
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shed more light on interactions between innate and cell mediated immunity 
in development of chronic OM in Jbo /+ mice.
Last but not the least, it is important to repeat studies performed on Jbo/+ 
BMDM in Jf/+ BMDM for more time-points to further understand OM 
pathogenesis in Jf/+ mice.
6.7- Contribution to the field
• Previously it has been reported that inflamed middle ear in Jbo/+ is 
hypoxic by our group (Cheeseman et al, 2011). Data from this 
independently confirmed the finding.
• This thesis describes a successful model for studying in vitro cellular 
processes in OM in Jbo/+ and Jf/+ which can be applied to other 
mice models.
• Protein expression data reveals that Jbo/+ BMDM are pro- 
inflammatory at basal level with higher levels of inflammatory 
cytokines such as 11-23, Trem-1, and C5a.
A '?'7RRT• Evi-1 gene and protein expression is not affected due to Evi-1 
mutation in Jbo/+ BMDM rather the mutation is likely to be a loss 
of function mutation as its activity as a Smad3 co-repressor is 
perturbed.
• My results from this thesis indicate a pro-angiogenic nature of Jbo/+ 
BMDM in hypoxia despite attenuation of phagocytic function of 
Jbo/+ BMDM in hypoxia.
• Results indicate for the first time that Jbo/+ BMDM are hyper- 
responsive to LPS but possess impaired resolution of inflammation 
in hypoxia.
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• Data suggests a of a loss of function of Evi-1 and F bxoll in Jbo/+ 
and Jf/+ BMDM respectively via perturbations in HIF-TGF-(3 
signalling and TGF-P signalling pathways respectively.
• Data indicates a role of cytokines associated with Thl7 
differentiation in OM pathogenesis.
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